University of Kentucky

UKnowledge
Theses and Dissertations--Pharmacy

College of Pharmacy

2017

HALO- AND SOLVATO-FLUOROCHROMIC POLYMER
NANOASSEMBLIES FOR CANCER THERANOSTICS
Derek Alexander Reichel
University of Kentucky, derek.a.reichel@gmail.com
Digital Object Identifier: https://doi.org/10.13023/ETD.2017.273

Right click to open a feedback form in a new tab to let us know how this document benefits you.

Recommended Citation
Reichel, Derek Alexander, "HALO- AND SOLVATO-FLUOROCHROMIC POLYMER NANOASSEMBLIES FOR
CANCER THERANOSTICS" (2017). Theses and Dissertations--Pharmacy. 74.
https://uknowledge.uky.edu/pharmacy_etds/74

This Doctoral Dissertation is brought to you for free and open access by the College of Pharmacy at UKnowledge. It
has been accepted for inclusion in Theses and Dissertations--Pharmacy by an authorized administrator of
UKnowledge. For more information, please contact UKnowledge@lsv.uky.edu.

STUDENT AGREEMENT:
I represent that my thesis or dissertation and abstract are my original work. Proper attribution
has been given to all outside sources. I understand that I am solely responsible for obtaining
any needed copyright permissions. I have obtained needed written permission statement(s)
from the owner(s) of each third-party copyrighted matter to be included in my work, allowing
electronic distribution (if such use is not permitted by the fair use doctrine) which will be
submitted to UKnowledge as Additional File.
I hereby grant to The University of Kentucky and its agents the irrevocable, non-exclusive, and
royalty-free license to archive and make accessible my work in whole or in part in all forms of
media, now or hereafter known. I agree that the document mentioned above may be made
available immediately for worldwide access unless an embargo applies.
I retain all other ownership rights to the copyright of my work. I also retain the right to use in
future works (such as articles or books) all or part of my work. I understand that I am free to
register the copyright to my work.
REVIEW, APPROVAL AND ACCEPTANCE
The document mentioned above has been reviewed and accepted by the student’s advisor, on
behalf of the advisory committee, and by the Director of Graduate Studies (DGS), on behalf of
the program; we verify that this is the final, approved version of the student’s thesis including all
changes required by the advisory committee. The undersigned agree to abide by the statements
above.
Derek Alexander Reichel, Student
Dr. Younsoo Bae, Major Professor
Dr. David Feola, Director of Graduate Studies

HALO- AND SOLVATO-FLUOROCHROMIC POLYMER NANOASSEMBLIES
FOR CANCER THERANOSTICS

DISSERTATION

A dissertation submitted in partial fulfillment of the
requirements for the degree of Doctor of Philosophy in the
College of Pharmacy
at the University of Kentucky

By
Derek Alexander Reichel
Lexington, Kentucky
Director: Dr. Younsoo Bae, Associate Professor of Pharmaceutical Sciences
Lexington, Kentucky
2017
Copyright © Derek Reichel 2017

ABSTRACT OF DISSERTATION

HALO- AND SOLVATO-FLUOROCHROMIC POLYMER NANOASSEMBLIES
FOR CANCER THERANOSTICS
Theranostics is an emerging treatment approach that combines diagnostics with
therapy in order to personalize treatment regimens for individual patients and decrease
cancer mortality. Previously, nanoparticles entrapping conventional fluorescent dyes
were developed for cancer theranostics, but fluorescent nanoparticles did not allow
clinicians to significantly improve cancer treatments.
The use of fluorescent dyes that are sensitive to solvent acidity (halofluorochromism) and polarity (solvato-fluorochromism) may overcome the limitations of
fluorescent nanoparticles and improve cancer therapy by enabling researchers to detect
chemical properties within the nanoparticle core environment. The model halo- and
solvato-fluorochromic dye Nile blue was attached to the core of nanoscale drug delivery
systems called polymer nanoassemblies (PNAs), which were created by tethering
hydrophilic polymers and hydrophobic groups to a cationic polymer scaffold. The
fluorescence of empty PNAs increased by 100% at pH 5.0 compared to pH 7.4, and the
fluorescence of drug-loaded PNAs increased up to 300% compared to empty PNAs. A
comparison of the fluorochromic properties between PNAs with various core properties
indicated that both hydrophobic pendant groups and scaffold amines contributed to the
fluorochromism of PNAs.
The halo-fluorochromism of PNAs allowed investigators to minimize the
detection of fluorescence signals in healthy organs such as the liver. Fluorescence
imaging of halo-fluorochromic PNAs diffused into tissue mimics indicated that
fluorescence of PNAs in tissues increased by 100% at pH 7.0 compared to pH 7.4. In
addition, halo-fluorochromic PNAs identified the acidic perimeter surrounding metastatic
tumors in orthotopic metastatic tumor models. Computational simulations of metastatic
lesions verified that some halo-fluorochromic PNAs accumulate in the hypoxic/acidic
regions of metastatic tumors following intravenous administration. These simulations
also indicated that the accumulation of PNAs in the hypoxic regions of tumors doubles at
12 hours post-treatment compared to 1.8 hours post-treatment.

The solvato-fluorochromism of PNAs enabled the fluorescence-based
measurement of drug release from the nanoassembly core during dialysis-based drug
release measurements. Solvato-fluorochromic methods indicated faster drug release rates
than HPLC-based methods. Mechanistic modeling of drug release indicated that solvatofluorochromic methods were unaffected by released drugs that interfered with HPLCbased methods. However, mechanistic modeling also indicated that drug rebinding and
diffusion did not account for all of the differences between drug release rates determined
by solvato-fluorochromic- and HPLC-based methods. Based on this evidence, it was
hypothesized that solvato-fluorochromic drug release methods measure drug diffusion
from near the scaffold of PNAs in a small region of the nanoassembly core, and that this
process contributes to overall drug release but does not indicate apparent drug release
rates for PNAs.
In order to develop PNAs for potential clinical applications, ionizable amines
were removed from the polymer scaffold to increase drug loading and sustain the release
of model drugs carfilzomib and docetaxel. The removal of primary amines decreased
drug diffusivity in the core of PNAs (D from 3.9*10-18 cm2/s to 0.1*10-19 cm2/s) and
increased the drug release half-life (t1/2 from 4 to 26 hours). The controlled release of
carfilzomib from PNAs reduced drug metabolism by 60% for up to one hour and
sustained proteasome inhibition in cancer cells at 72 h post-treatment compared to free
drug.
Overall, this work provides insight into the design of theranostic nanoparticles
with beneficial properties for improving cancer treatment.
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Nanoparticle Core Environment, Tumor Metastasis
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CHAPTER ONE
FLUOROCHROMISM AND NANOTECHNOLOGY FOR IMPROVING CANCER
THERANOSTICS

1

1

FLUOROCHROMISM AND NANOTECHNOLOGY FOR IMPROVING

CANCER THERANOSTICS
1.1

Cancer Theranostics: Promise and Limitations
Theranostics is an emerging approach that combines therapy with diagnostics in

order to identify effective treatments, improve disease detection and reduce mortality (1).
In general, the use of theranostic methods enables clinicians to maximize the efficacy of
therapeutic agents by treating a disease with a conventional therapeutic agent while also
identifying patients who may respond poorly to that therapeutic regimen. For this subset
of patients, clinicians can select more aggressive therapeutic regimens or switch to
targeted therapeutic agents in order to improve patient outcomes (2). Theranostic
methods can also enable researchers to increase the sensitivity and accuracy of disease
detection in early stages (3). The biological and pharmacological indicators of many
diseases can be difficult to elucidate from traditional diagnostic methods such as medical
imaging (4). By measuring the physiological response of a disease in response to a
treatment, theranostic methods can allow clinicians to identify more effective treatment
approaches based on the biological properties of a disease state (5). Additionally,
theranostics may also enable clinicians to monitor disease progression and adjust
treatment over the course of a treatment regimen (6). Theranostics is an especially
promising approach for difficult-to-treat diseases with variable biological properties.
Theranostic methods combining medical imaging with drug delivery can enable
clinicians to overcome the limitations of biomarker-based theranostic methods by
indicating drug delivery to a targeted site (7). Biomarker-based theranostic methods allow
clinicians to detect genes or proteins that predict treatment efficacy in a patient (8, 9).
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Unfortunately, the identification of biomarkers that predict treatment responses in
patients and the development of clinical devices for biomarker detection remain difficult
(10, 11). Biomarker-based theranostic methods also fail to indicate the amount of drug
reaching solid tumors in patients. In contrast to biomarker-based theranostic methods,
medical imaging-guided theranostic methods often use FDA-approved drug delivery
systems that are modified with imaging agents. Clinicians can monitor the distribution of
these drug delivery systems after systemic administration (12, 13). By combining the in
vivo distribution and drug release profiles of these drug delivery systems, clinicians can
estimate drug delivery to diseased tissues and adjust treatments to maximize their
efficacy (14). Theranostic methods are expected to enable clinicians to measure the realtime ADME of anticancer drugs and to provide timely, personalized treatment regimens
that maximize anticancer drug accumulation in metastatic tumors (15-17).
Theranostic methods can also enable oncologists to detect small metastatic tumors
in patients. Cancer is the second leading cause of death in the United States, and more
than 90% of cancer-related deaths are attributed to metastasis (18). Metastasis is a disease
state in which cancer cells migrate from primary tumors to adjacent tissues through blood
vessels, lymphatic fluid or the peritoneal cavity (19). Cancer cells in metastatic tumors
grow in a heterogeneous tissue microenvironment, in which micrometastatic colonies of
cancer cells are surrounded by normal cells (20). The micrometastatic colonies within
parenchyma are often too small and too dispersed throughout organs for clinicians to
detect accurately. Theranostic methods allow clinicians to detect antigens or receptors on
metastatic cancer cells, rather than the tissue properties of metastatic tumors, and
accurately distinguish micrometastatic colonies from healthy tissues.
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Theranostic methods may allow clinicians to treat micrometastatic colonies while
they remain susceptible to treatment. Traditional primary tumor treatment methods such
as surgery, chemotherapy, radiotherapy, and heat ablation are often ineffective at treating
large metastatic tumors that can be detected with traditional methods (21-23). In contrast
to large metastatic tumors with an acidic extracellular microenvironment that can ionize
some anticancer drugs and prevent their diffusion through cell membranes, small
metastatic tumors remain susceptible to chemotherapy due to increased drug
accumulation in metastatic cancer cells (24-27). Theranostic methods can allow clinicians
to treat small metastatic tumors earlier in their development and to estimate drug
concentrations in tumor metastasis.
Although fluorescence imaging is an established diagnostic method with several
applications in theranostics, many fluorescent dyes can provide false signals unless they
are used carefully (28). The non-selective cellular accumulation of dyes and nanoparticles
has limited the applications of previous theranostic methods using fluorescence imaging.
Clinicians using fluorescent dyes for theranostics must also consider the signal-to-noise
ratios, quantum yields, and photo-bleaching of these dyes (29). Strategies for improving
theranostic methods using fluorescence imaging are needed to increase the accuracy of
metastatic tumor detection and improve the pharmacokinetic predictions for anticancer
drugs.
1.2

Halo- and Solvato-Fluorochromism for Theranostic Imaging
Fluorochromism is an optical property of fluorescent dyes in which fluorescence

excitation wavelengths, emission wavelengths and quantum yields change depending on
the solvent environment of the dye. The optical properties of fluorochromic dyes often
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change based on solvent pH (halo-fluorochromism) and polarity (solvatofluorochromism) (30). The halo- and solvato- fluorochromic properties of dyes are
controlled by the electronic mobility and conformation of dye molecules in the solvent
environment (31, 32). The halo-fluorochromism of dyes is also controlled by the
protonation state of ionizable groups such as amines or carboxylate anions that alter the
electronic mobility and conformation of dyes. Differences between the molecular
interactions among solvents and dye molecules such as solvent-induced dye conformation
changes, induced dipole interactions and hydrogen bonding contribute to the solvatofluorochromism of dyes (33). By measuring the halo- or solvato-fluorochromism of dyes
in solution, the chemical properties of their surrounding solvent environment can be
quantified (34, 35).
The halo- and solvato-fluorochromism of dyes has allowed investigators to
identify specific tissue regions in fluorescence images based on their chemical properties.
Halo-fluorochromic dyes with increased fluorescence below pH 5.0 allowed for the
identification of acidic lysosomes in cell images (36). In addition, solvato-fluorochromic
dyes with strong fluorescence in lipids enabled the detection of intracellular lipid droplets
in tissue samples (37). Solvato-fluorochromic dyes with increased fluorescence after
binding to DNA permitted researchers to identify cell nuclei in microscopic fluorescence
images (38). Fluorochromic dyes remaining in tumor tissue could be used by clinicians to
monitor the tumor microenvironment and indicate treatment efficacy, but small molecule
fluorochromic dyes often have poor retention in tissues. As a result, there is a critical
need to increase the accumulation and retention of fluorochromic dyes in tumor tissue in
order to investigate the tumor microenvironment.
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1.3

Polymer Nanoassemblies (PNAs) Entrapping Fluorochromic Dyes
Nanotechnology has allowed scientists to increase anticancer drug accumulation

in solid tumors with biocompatible nanomaterials that accumulate in the interstitial space
surrounding leaky tumor blood vessels (39). One type of biocompatible nanomaterial
with these properties is PNAs created from self-assembling or cross-linked copolymers,
such as polymer micelles, vesicles and polyionic complexes. The physicochemical
properties of PNAs, such as size, morphology and surface charge, can be controlled by
altering their chemical composition. Controlling the size (< 100 nm in diameter) and
surface charge (neutral or slightly anionic) of PNAs can increase their tumor
accumulation compared to other drug delivery systems and fine-tune the pharmacokinetic
profiles of entrapped drugs (40). PNAs often contain a hydrophobic core surrounded by a
hydrophilic shell. The hydrophobic core can entrap water-insoluble drugs and protect
drugs from metabolism, while the hydrophilic shell can prevent the non-specific binding
of PNAs to plasma proteins and also reduce the uptake of drug-loaded PNAs by the
mononuclear phagocyte system (41). The benefits of PNAs for anticancer drug delivery
have been validated in several clinical trials (42, 43).
PNAs can function as theranostic tools and allow oncologists to reduce cancer
mortality by combining anticancer drug delivery with fluorescence imaging capabilities.
Previous studies demonstrated that PNAs with beneficial physicochemical properties
allow clinicians to deliver many therapeutic, diagnostic and imaging molecules to tumors
separately or in combination (44-47). The chemical conjugation of fluorescent dyes to
PNAs prevents dyes from diffusing out of PNAs during imaging and allows researchers
to measure quantitative fluorescence signals. PNA-entrapped fluorescent dyes have
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reduced renal clearance compared to free dyes, because nanoassemblies cannot pass
through renal glomeruli and enter the urine (48). As a result, PNAs can increase the halflife of dyes in tumor tissue and extend the time window for successful fluorescence
detection of tumors from less than 5 minutes up to about two hours (49). PNAs can also
extend the imaging time window in healthy organs such as the liver and enable the
detection of metastatic tumors (50-52).
PNAs with fluorochromism can allow investigators to overcome the limitations of
previously developed fluorescent PNAs. Fluorochromic dyes entrapped in PNAs may
allow for the detection of the chemical properties within the nanoparticle core
environment without interference from the surrounding environment, because
fluorochromism occurs due to short-range molecular interactions (<0.1 nm distance) (53).
Figure 1.1A describes the synthesis of PNAs with fluorochromism.
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Figure 1.1. Graphical description of PNAs prepared through the unimolecular selfassembling of polymer conjugates (A). Fluorochromic PNAs for the real-time
determination of drug concentrations using solvato-fluorochromism (B) and the acidsensitive imaging of metastatic tumors using halo-fluorochromism (C).
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The solvato-fluorochromism of PNAs can allow researchers to measure drug
release from the nanoassembly core in real time (Figure 1.1B). The entrapment and
release of hydrophobic anticancer drugs from the PNA core may alter the hydrophobicity
within the nanoassembly core environment. Solvato-fluorochromism may allow
investigators to detect hydrophobicity changes of the PNA core environment in real time
indicating drug release. By combining fluorescence measurements of drug release with
the biodistribution of PNAs, the ADME of anticancer drugs in patients may be estimated
in real time (54).
The halo-fluorochromism of PNAs can allow researchers to improve the
sensitivity and accuracy of metastatic tumor detection by increasing the fluorescence
signals of PNAs accumulated in the acidic tumor microenvironment (Figure 1.1C). The
rapid glucose metabolism of cancer cells in tumors generates acidic by-products, such as
lactic acid, that are transported into the extracellular space of tumors (55). The
acidification of the extracellular tumor microenvironment, also known as the Warburg
effect, has been observed in tumors with various sizes, shapes, locations and biological
properties (56, 57). By detecting the acidity of the tumor microenvironment, clinicians
can select anticancer drugs that remain effective in the tumor microenvironment
conditions of patients (58, 59).
The fluorochromism of PNAs can also allow investigators to identify methods of
sustaining drug release and increasing the activity of anticancer drugs in cancer cells.
Sustained drug release from PNAs has improved cancer treatment efficacy by
maintaining effective drug concentrations in tumors, priming tumors for effective future
treatments and preventing cancer cells from developing resistance mechanisms (60-63).
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Unfortunately, the relationship between nanoassembly core environment properties and
drug release rates is difficult to determine (64). Solvato-fluorochromism may allow
researchers to identify specific chemical properties within the nanoassembly core
environment that control drug release profiles. By carefully considering the solvatofluorochromic characterization of the nanoassembly core environment, the therapeutic
properties of PNAs may be improved in order to enhance the clinical efficacy of drugloaded polymer nanoassemblies for cancer treatment.
Therefore, the overall goal of this research is to synthesize fluorochromic PNAs
and evaluate their potential for cancer theranostics. First, several fluorochromic PNAs are
synthesized and their fluorescence properties are characterized. Measurement conditions
for both halo- and solvato-fluorochromism are determined, and the necessary conditions
for separating halo- and solvato-fluorochromism in experimental measurements are
determined. Next, the diagnostic capabilities of fluorochromic PNAs for metastatic tumor
detection and drug release measurement are evaluated. Finally, the therapeutic potential
of PNAs to control drug release and sustain drug activity in cancer cells is determined.
The results from this work may indicate the potential of fluorochromism as a beneficial
approach for cancer theranostics.

**Portions of Chapter 1 were previously published in (65). Reproduced with permission
from Future Science Group: Therapeutic Delivery, Volume 6, Issue 10, 2015, Pages
1221-1237, Figure 1 and Introduction. Copyright 2015 is given to the publication in
which the material was originally published.
Copyright (C) Derek Reichel 2017
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CHAPTER TWO
SYNTHESIS AND CHARACTERIZATION OF POLYMER NANOASSEMBLIES
WITH FLUOROCHROMISM
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2

SYNTHESIS AND CHARACTERIZATION OF POLYMER

NANOASSEMBLIES WITH FLUOROCHROMISM
2.1

Introduction
The development of PNAs with fluorochromism may improve cancer theranostics

and decrease patient mortality, but fluorochromic dyes must be selected carefully to
maximize their potential for theranostics. The theranostic applications of nanoparticles
labelled with traditional fluorescent dyes are often limited by free dye impurities, which
increase fluorescence background signals and reduce the fluorescence signals of
nanoparticles in fluorescence images (66). Fluorescence signals from fluorochromic dyes
should enable researchers to reduce signals from free dye impurities and enhance signals
from entrapped dyes. The fluorochromism of dyes should also be detectable by
fluorescence imaging systems used in the clinic. The fluorescence properties of these
dyes should allow investigators to distinguish between the effects of halo- and solvatofluorochromism in fluorescence measurements. In order to account for signal fluctuations
due to concentration changes of PNAs, fluorochromic dyes should also allow for an
internal standard measurement condition (67). The fluorochromic properties of dyes must
be carefully considered in order to design PNAs that enable the monitoring of the
chemical properties within the nanoassembly core environment.
The chemical composition of the nanoassembly core could affect the
fluorochromic properties of the dyes and prevent the sensitive monitoring of the
nanoassembly core environment. For example, interactions between fluorochromic dyes
and the polymer scaffold in the PNA core could prevent dyes from sensing the
surrounding environment. Charged groups could also draw ionized or polar molecules
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into the nanoassembly core and decrease the hydrophobicity of the nanoassembly core
environment. In addition, hydrophobic groups within the nanoassembly core may also
interfere with the ionization of dyes necessary for halo-fluorochromism (68).
Hydrophobic groups in the nanoassembly core can also shield dyes from interactions with
other hydrophobic molecules in the nanoassembly core. Therefore, polymer
nanoassemblies with controlled core environments can allow investigators to elucidate
the effects of the nanoassembly core environment on the fluorochromism of dyes.
Nile Blue (NB) is a halo- and solvato-fluorochromic dye that emits strong
fluorescence in nonpolar and acidic solvents, but its fluorescence is quenched in water
(69). Fluorescence quenching of NB in water can minimize the background fluorescence
signals of potential free dye impurities. NB has fluorescence excitation and emission
wavelengths in the near-infrared light range, which is a commonly desired optical
property for biomedical imaging applications of fluorescent dyes (70). Despite the
beneficial optical properties of NB for biomedical imaging, free NB can be quickly
removed from the body quickly through renal clearance, which limits its imaging
applications (71). Because polymeric nanoparticles are typically larger than the pores on
renal glomeruli, NB conjugation to the core of PNAs can prevent the renal clearance of
dyes and enhance its capabilities for the theranostics of metastatic tumors.
PNAs with a controlled core environment can be developed by tethering
hydrophilic polymers and hydrophobic groups to a modifiable polymer scaffold. By
following this approach, simple, unimolecular nanoparticles with a hydrophobic core and
a hydrophilic shell can be created to entrap hydrophobic anticancer drugs. In addition,
fluorochromic dyes can be tethered to the polymer scaffold in the nanoassembly core.

13

Stable chemical bonds prevent fluorochromic dyes from diffusing out of the
nanoassembly core and reducing the fluorescence signals from PNAs. The unimolecular
design of PNAs prevents the nanoassembly core from dissociating at low concentrations
and exposing fluorochromic dyes to the surrounding aqueous environment. The chemical
conjugation of fluorochromic dyes to the polymer scaffold is expected to maintain an
ordered arrangement of dye molecules near the primary amines on the polymer scaffold.
The random distribution of functional groups onto the polymer scaffold following
conjugation reactions should keep the dyes in contact with pendant groups in the core of
the PNAs. Therefore, it is hypothesized that modulating the design parameters of PNAs
can control the fluorochromic properties of entrapped dyes.
The purposes of this study are to confirm the feasibility of monitoring the
nanoparticle core environment of PNAs with fluorochromism and to determine the
effects of PNA core environment properties on halo- and solvato-fluorochromism.
Polymer nanoassemblies were synthesized by tethering the hydrophilic polymer
poly(ethylene glycol) (PEG) and the hydrophobic pendant palmitate (PAL) group onto a
cationic polymer scaffold [poly(ethylene imine) (PEI) or poly(L-lysine) (PLL)] while
modifying the core of the nanoassemblies with the fluorochromic dye NB. In addition,
the remaining primary amines on PLL-based PNAs were end-capped by reacting the
PNAs with acetic anhydride (AA). The simple design of these PNAs allowed the effects
of PNA core environment properties on the optical properties of NB-conjugated PNAs to
be elucidated. Four types of PNAs were used in this study: PEG-PEI-NB (2PN), PEGPEI-PAL-NB (3PN), PEG-PLL-PAL-NB (3P’N) and PEG-PLL-PAL-NB-AA (3P’NAA).
2PN has ionizable groups in the core that can attract water and reduce NB fluorescence,
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while 3PN has a hydrophobic core to increase the entrapment of hydrophobic anticancer
drugs. 3P’N and 3P’NAA had fewer and no remaining amines in the nanoassembly core,
respectively. By comparing the fluorochromism of 2PN and 3PN, the effects of
hydrophobic groups on fluorochromism can be determined. In addition, by comparing the
fluorochromism of 3PN to 3P’N or 3P’NAA, the effects of scaffold amines on
fluorochromism can be investigated. The model anticancer drug carfilzomib (CFZ) was
selected for this study as a clinically relevant, non-fluorescent, poorly soluble (5-10 μM
in water) and lipophilic molecule (logP=4.2). Figure 2.1 contains the chemical structure
of CFZ. A further description of the clinical applications of CFZ for cancer treatment is
included in chapter 6.
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Figure 2.1. Chemical structure of carfilzomib.
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2.2

Materials and Methods

2.2.1

Materials
α-Succinimidyloxysuccinyl-ω-methoxy-poly(ethylene glycol) (NHS-activated

PEG, 5 kDa) was purchased from NanoCS (New York, NY). Branched PEI, PLL (15-30
kDa), chloroacetyl chloride, palmitoyl chloride and acetic anhydride were purchased
from Sigma Aldrich (St. Louis, MO). Acridine orange (AO), NB sulfate, HEPES buffer
(pH 8.0, 1 M), phosphate buffered saline (PBS, pH 7.4, 150 mM), acetone, DMF, DMSO,
ethanol, isopropanol (IPA), methanol, N-Methyl-2-pyrrolidone (NMP), pyridine,
tetrahydrofuran (THF), and dialysis membrane with molecular weight cut-off (MWCO)
of 8 and 100 kDa were purchased from Fisher Scientific (Waltham, MA). CFZ was
purchased from LC Laboratories (Woburn, MA).
2.2.2

Synthesis of Fluorochromic PNAs
PEI- and PLL-based PNAs were synthesized following the scheme in Figure 2.1.

Before the reactions, branched PEI was dialyzed for 24 hours in water using a 100 kDa
MWCO membrane in order to remove small impurities (72). PLL was also dialyzed for
24 hours in basic solution using a 6-8 kDa MWCO membrane in order to remove
bromide salts. All other reagents were used as provided. PEI (934.6 mg) was reacted with
NHS-activated PEG (10.0 g) in a mixed solution of DMSO and HEPES (1:1) at room
temperature for 2 days. The reaction product PEG-PEI (2P, 73.2% mass yield) was
purified by dialysis in water for 5 days using a 100 kDa MWCO membrane and then
collected after freeze drying. A portion of the product PEG-PEI (4.0 g) was reacted with
palmitoyl chloride (900 μl) in THF at 40 °C for 2 hours. Pyridine (1.8 ml) was added
after 30 minutes to neutralize hydrochloric acid by-products by forming THF-insoluble
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pyridinium salts. The reaction product PEG-PEI-PAL (3P, 85.7% mass yield) was
purified by ether precipitation and dialysis and then collected after freeze drying. 2PN
and 3PN were synthesized following a two-step coupling reaction scheme. First, 2P and
3P (2.0 g each) were reacted with chloroacetyl chloride (300 μl for 2P, and 200 μl for 3P)
in THF at 40 °C for 2 hours. Next, NB was dissolved in DMF at 10 mg/ml and added to
the reaction solution (685.4 mg for 2P, and 457.0 mg for 3P). The temperature was
increased to 60 °C and the reaction continued for 3 additional hours. Pyridine (300 μl for
2P, and 200 μl for 3P) was added 30 minutes after adding NB to neutralize hydrochloric
acid by-products. Reaction products 2PN (78.3% mass yield) and 3PN (87.0% mass
yield) were purified by dialysis in a mixed solution of methanol and water (9:1) for 3
days, followed by dialysis in pure water for an additional 3 days. The purified reaction
products were then collected after freeze drying. The removal of free dyes and other
impurities from 2PN and 3PN was confirmed by absence of small molecule peaks on Gel
Permeation Chromatography (GPC, Asahipak GF-7M column, 300 mm length, 7.5 mm
internal diameter, 7 μm particle size, 40 °C, peaks with >15 minute retention time, 200
nm, PBS at pH 7.4, 0.5 ml/min) and a NB peak on High Performance Liquid
Chromatography (HPLC, Agilent Eclipse XDB-C18 column, 150 mm length, 4.6 mm
internal diameter, 5 μm particle size, 40 °C, 5.85 min, 600 nm, gradient elution from 10%
ACN to 90% ACN, 1.0 ml/min). The chemical compositions of 2PN and 3PN were
determined by proton NMR spectroscopy (Varian 400 MHz, DMSO-d6) and described in
the results section (73). NB conjugation was confirmed by measuring the absorbance and
fluorescence of 2PN (Ex 640/Em 680) and 3PN (Ex 600/Em 630) with a microplate
reader (SpectraMax M5, Sunnyvale, CA). In addition, NB conjugation was further
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confirmed by comparing the molecular weight of PNAs to a calibration curve of PEG
standards with known molecular weights (74). By comparing the molecular weights of
2PN and 3PN with intermediates 2P and 3P, respectively, the mass substitution of NB
can be determined and the molar substitution of NB can be calculated.
PLL-based PNAs were also synthesized following Figure 2.2. PLL (183.6 mg)
was reacted with NHS-activated PEG (2.0 g) in a mixed solution of water, DMSO and
pyridine (2:1:1) at room temperature for 2 days. The reaction product PEG-PLL (2P’)
was purified by dialysis in water for 5 days using a 100 kDa MWCO membrane, and then
collected after freeze drying. PEG-PLL (1 g) was reacted with palmitoyl chloride (500 μl)
in THF at 40 °C for 2 hours. Pyridine (500 μl) was added after 30 minutes to neutralize
hydrochloric acid by-products. The reaction product PEG-PLL-PAL (3P’) was purified
by ether precipitation and dialysis, and then collected after freeze drying. 3P’N was
synthesized following a two-step coupling reaction scheme. First, a portion of 3P’ (200
mg) was reacted with chloroacetyl chloride (50 μl) in THF at 40 °C for 2 hours. Next, NB
(266.8 mg) was dissolved in DMF at 10 mg/ml and added to the reaction solution. The
temperature was increased to 60 °C and the reaction was continued for 3 additional hours.
Pyridine (50 μl) was added 30 minutes after adding NB to neutralize hydrochloric acid
by-products. The reaction product PEG-PLL-PAL-NB (3P’N) was purified by dialysis in
methanol for 14 days, followed by dialysis in pure water for an additional 3 days.
Purified 3P’N was collected after freeze drying. Some 3P’N (145 mg) was reacted with
acetic anhydride (50 μl) overnight in DMSO. The reaction product PEG-PLL-PAL-NBAA (3P’NAA) was purified by dialysis in pure water for 2 days and collected after freeze
drying. The removal of free dyes and other impurities from 3P’N and 3P’NAA was
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confirmed by GPC and HPLC as described for 2PN and 3PN. Chemical compositions of
3P’N and 3P’NAA were also determined by NMR spectroscopy and described in the
results section. NB conjugation was further confirmed by absorbance and fluorescence
spectroscopy.
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Figure 2.2. Synthesis protocols for PEI-based PNAs with an ionic (2PN) or mostly
hydrophobic core (3PN) and PLL-based PNAs with a reduced amine (3P’N) or negligible
amine (3P’NAA) content in the nanoassembly core.
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2.2.3

Physicochemical Characterization of Fluorochromic PNAs
The diameter and surface charge of PNAs were determined using dynamic light

scattering (DLS, Zeta-sizer Nano, Malvern, UK). Hydrodynamic diameters were
determined by measuring 173 degree back-scattered light from a He-Ne laser (4 mW, 633
nm), and calculated using the Stokes-Einstein equation. Diameters were determined from
number size distribution histograms. Zeta potentials were determined by measuring
scattered light while applying voltage (automatic voltage selection), and calculated from
light scattering data using the Smoluchowski equation. The molecular weight and
uniformity of PNAs were determined by GPC.
2.2.4

Evaluation of the Fluorochromic Properties of Nile Blue
NB was dissolved in various solvents used for biological assays and chemical

reactions: deionized water, methanol, ethanol, THF, IPA, DMF, acetone, DMSO,
pyridine, and NMP. Changes in light absorbance and fluorescence at various excitation
(Ex) and emission (Em) wavelengths were determined for NB in various solvents. NB
solutions (200 μl, 100 μg/ml) were added into clear glass vials for optical imaging. To
determine the fluorescent properties of NB, NB solutions were serially diluted (250, 125,
and 62.5 ng/ml) and imaged over a wide range of excitation and emission wavelengths
(500 nm Ex/620 nm Em, 605 nm Ex/660 nm Em, and 640 nm Ex/700 nm Em) using an
IVIS Spectrum imaging system (Caliper Life Sciences, Hopkinton, MA).
2.2.5 Quantification of the Fluorochromic Properties of Poly(ethylenimine)-based PNAs
The fluorochromic properties of PNAs were determined in response to both drug
loading and solution pH. In order to measure the effects of drug loading on
fluorochromism, PNAs were loaded with CFZ by mixing drug and PNA solutions in
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organic solvent and evaporating the solvent under reduced pressure. Drug-loaded PNAs
were then reconstituted in water and centrifuged to remove free drug and other insoluble
impurities. Drug loading of PNAs was verified by HPLC (Agilent Eclipse XDB-C18
column, 55:45 v/v acetonitrile/water with 0.1% formic acid mobile phase, 1 ml/min, 40
°C, 200 nm, 2.01 min retention time). The drug loading efficiency was defined as the
weight percent ratio of drug to total formulation.
PNAs (10 mg/ml) with and without CFZ were dispersed in 50 mM buffer
solutions at pH 7.4, 7.0, 6.0 and 5.0. Free dyes [NB (2 μg/ml) and AO (1 μg/ml)] were
also dissolved in buffer solutions with and without suspended CFZ (1 mg/ml). Each
solution (100 μl) was added to a 96 well plate and analyzed using fluorescence emission
spectroscopy at multiple excitation wavelengths to determine the optimal fluorescence
excitation and emission wavelength pairs. Two pairs were further imaged using a plate
reader (500 nm Ex/600 nm Em and 640 nm Ex/680 nm Em) and an IVIS (500 nm Ex/620
nm Em and 640 nm Ex/700 nm Em). Non-fluorescence of CFZ (1 mg/ml, ethanol) was
verified by measuring fluorescence emission spectra for several excitation values
between 400 and 700 nm.
2.2.6

Evaluation of the Fluorochromic Properties of Poly(L-Lysine)-Based PNAs
PLL-based PNAs (10 mg/ml) with and without CFZ were dispersed in 50 mM

buffer solutions at pH 7.4, 7.0, 6.0 and 5.0. Each solution (100 μl) was added to a 96 well
plate and analyzed using fluorescence emission spectroscopy at multiple excitation
wavelengths to determine optimal fluorescence excitation and emission pairs. These pairs
were further imaged using an IVIS (640 nm Ex/680 nm Em and 675 nm Ex/720 nm Em).
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2.2.7

Statistics
All values in figures are reported as mean±standard deviation for three

measurements unless otherwise reported. Groups of measurements were compared by a
one-way ANOVA with Bonferroni’s post-test correction, and pairs of measurements
were compared by a Student’s t test unless otherwise noted. Statistical significance in
each figure or table is indicated by * (p<0.05), ** (p<0.01) or *** (p<0.001).
2.3

Results

2.3.1

Synthesis of PNAs with a Hydrophobic, Ionic or Non-Ionic Core Environment
PEI-based PNAs were synthesized as described previously in Figure 2.2. Free NB

was difficult to purify from NB-conjugated PNA solutions using traditional dialysis
methods, because amphiphilic dye molecules bound to hydrophobic components of the
nanoassemblies. However, the complete removal of amphiphilic NB from PNA solutions
was achieved by dialysis using a 9:1 mixed solution of methanol and water. The absence
of free NB in PNA solutions was further confirmed by performing centrifugal filtration
with aliquots of the PNA solutions. The absorbance and fluorescence of each filtrate was
measured to detect free NB filtered from the samples. Similar absorbance and
fluorescence values between filtrates and deionized water indicated the complete removal
of free NB from the PNA solutions.
PLL-based PNAs were synthesized as described in Figure 2.2. The complete
removal of free NB from PNA solutions was achieved by dialysis using pure methanol.
The absence of free NB in PLL-based PNAs was confirmed by following the method
described in the previous paragraph. Because PLL-based PNAs were synthesized to
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evaluate the effects of polymer scaffold amine on fluorochromism of PNAs, the physical
properties of these PNAs were not analyzed in full detail.
PEG and PAL conjugation were further confirmed by NMR spectroscopy. Due to
overlapping DMSO and PEI peaks, the area of peaks on the PEI scaffold with shifts
between 2.4 and 2.6 ppm could not be accurately quantified. 2PN and 3PN had NMR
peaks corresponding to PEG (3.54 ppm, s, relative area 1.000) and PEI (2.32 ppm, s,
relative area 0.017; 2.44 ppm, s; 2.55 ppm, s; 2.60 ppm, s; 2.66 ppm, s, relative area
0.019). In addition, 3PN had NMR peaks corresponding to PAL (0.83 ppm, d, relative
area 0.022; 1.20 ppm, s, relative area 0.082). 3P’N and 3P’NAA had NMR peaks
corresponding to PEG (3.54 ppm, s, relative area 1.000), PLL (2.23 ppm, m, relative area
0.0013; 2.60 ppm, s, relative area 0.0005; 2.68 ppm, s, relative area 0.0008; 2.97 ppm, s,
relative area 0.0009; 3.24 ppm, s, relative area 0.0114; 3.68 ppm, s, relative area 0.027;
4.09 ppm, s, relative area 0.040; 7.78 ppm, s, relative area 0.009), and PAL (0.83 ppm, d,
relative area 0.002; 1.23 ppm, s, relative area 0.027; 1.46 ppm, s, relative area 0.009).
3P’NAA also had a peak corresponding to AA (1.78 ppm, s, relative area 0.024).
Based on a comparison of the NMR peak areas of each PNA component to the
polymer scaffold, the molar substitution percent of each component to the initial moles of
primary amines of the polymer scaffold (defined as the molar substitution) was
calculated. Based on the analysis of Qiu et al., a 2.5% coefficient of variation was
assumed for each measurement in order to account for error due to NMR accuracy (75).
The molar substitution of PEG on 2PN and 3PN was 10.0±0.3%, while the molar
substitution of PAL on 3PN was 55.0±1.4%. In addition, the molar substitution of PEG
on 3P’N and 3P’NAA was 25.0±0.6%, while the molar substitution of PAL on 3P’N and
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3P’NAA was 37.0±0.9%. The molar substitution of AA on 3P’NAA was 17.0±0.4%. In
addition, the molar substitution percent of each component relative to the remaining
moles of primary amines on the polymer scaffold before the reaction (defined as the
molar substitution yield) was calculated for AA. The molar substitution yield of AA on
3P’NAA was greater than 99%, indicating a complete substitution of the remaining
primary amines.
2.3.2

Diameters and Surface Charges of PNAs are not Controlled by the Nanoassembly

Core Environment
Diameter and zeta potential measurements of 2PN and 3PN confirmed that PNAs
were less than 40 nm in diameter and had a neutral surface charge (Table 2.1), which was
similar to the physical properties of unlabeled PNAs 2P and 3P, respectively (76). PNAs
have a smaller diameter (40 nm) than the pore size of the GPC resin (7 μm). Based on the
neutral surface charge of PNAs (ζ<±30 mV), PNAs could due to van der Waals
interactions (77). However, histograms from all DLS measurements were unimodal and
had narrow size distributions. In addition, 2PN and 3PN maintained consistent diameters
and at multiple concentrations, suggesting that PNAs remain unimolecular in solution at
the concentrations used in this study likely due to the PEG shell. These results indicate
that NB and palmitate substitution do not affect the diameter of PNAs and that the PEG
shell efficiently shielded the charge, dyes, and hydrophobic groups within the core.
Polydispersity measurements indicate that 3PN has a greater size distribution than 2PN,
but GPC measurements (Figure 2.3) suggest that both PNAs have narrow size ranges.
This observation suggests that weak interactions between PNAs and the GPC column
may limit the accuracy of size distribution measurements from GPC compared to DLS.
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Table 2.1. Physicochemical properties of 2PN and 3PN.
PNA

Diameter (nm)

Zeta Potential
(mV)

Polydispersity Index
(PDI) (unitless)

Drug Loading
Efficiency (%)

2PN

26.5±8.8

-0.6±0.4

0.32±0.04**

3.0±0.1**

3PN

34.3±3.5

-1.3±0.3

0.69±0.07**

8.7±0.4**

PNA

PEG (mol/mol primary
amine on scaffold) (%)

PAL (mol/mol primary
amine on scaffold) (%)

NB (mol/mol primary
amine on scaffold) (%)

2PN

10.0±0.3

---

50±1.0***

3PN
10.0±0.3
55.0±1.4
25±0.5***
Diameter, zeta potential, PDI and drug loading efficiency are reported as mean±SD
(n=3) for DLS or HPLC. PEG, PAL and NB substitution are reported as
measurement±SE from the measurement error for NMR or GPC (n=1). PAL was not
detectable on 2PN. Statistical significance is determined with a Student’s t test as
described in the methods section.
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Figure 2.3. Gel permeation chromatographs for 2PN (A) and 3PN (B). Chromatographs
were measured by UV-visible absorbance detector at 220 nm.
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GPC further indicated that PNAs were larger than their individual components
and free of impurities from each component. Based on molecular weight comparisons of
PNAs to PEG standards, the molecular weights of 2PN and 3PN were 165 and 176 kDa,
respectively. The molecular weights of intermediates 2P and 3P were also determined to
be 129 and 159 kDa, respectively. By comparing the molecular weights of each
component to the available primary amines on PEI, the substitution yield of each
component on PNA could be calculated and compared to the NMR quantification. For
2PN, approximately 10% of the binding sites were substituted with PEG. For 3PN,
approximately 10% and 55% of binding sites on PEI were substituted with PEG and
PAL, respectively. GPC also allowed the estimation of the molar substitution of NB to
2PN and 3PN. Due to the fluorochromic effects of NB, quantification of NB molar
substitution based on spectroscopic comparisons of free NB to NB-conjugated PNAs may
introduce measurement error and indicate false substitution values. Based on a
comparison of the molecular weights of 2PN and 3PN to 2P and 3P, respectively, 2PN
had 50% NB molar substitution while 3PN had 25% NB molar substitution. After
normalizing these measurements to the amount of remaining primary amines on 2PN and
3PN, 2PN had a 55% molar substitution yield of NB and 3PN had a 71% molar
substitution yield of NB. Although palmitate substitution decreased the available binding
sites for NB conjugation, the hydrophobic core environment increased the reaction yield
for the remaining binding sites. For 2PN and 3PN, substitution yields calculated by GPC
were in agreement with calculated NMR substitution yields.
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2.3.3

Solvato-Fluorochromic Properties of Nile Blue are Sensitive to Non-Polar

Solvent Environments
Figure 2.4 shows the optical properties of NB in various solvents. NB was blue in
water, methanol, ethanol, IPA, and acetone; purple in DMSO; pale pink in THF; and
bright pink in DMF, pyridine, and NMP (Figures 2.4A-B). There were no precipitates in
any of the samples. Similar to the color properties of NB, the fluorescence of NB
changed in a solvent-dependent manner based on excitation wavelength and decreased
linearly as dye concentration decreased. At 500 nm Ex, NB fluoresced strongly in DMF,
and weakly in acetone, pyridine and NMP (Figure 2.4C). At 605 nm Ex, NB fluoresced
strongly in ethanol, methanol and IPA and fluoresced weakly in DMSO (Figure 2.4D). At
640 nm Ex, NB fluoresced strongly in DMSO and weakly in ethanol, methanol and IPA
(Figure 2.4E). Importantly, the fluorescence of NB in water remained undetectable under
all conditions tested in this study (Figures 2.4C-E). It should be noted that weak
fluorescence of NB can be detected in water at high concentrations (>1 μg/ml), but the
fluorescence decreases at high concentrations due to dye aggregation. The fluorescence
properties of NB in cell media were similar to fluorescence of NB in water, suggesting
that interactions with small molecules in cell media do not prevent the fluorescence
quenching of NB. Similar to NB in various organic solvents (Figure 2.4A), NBconjugated PNAs in water had red-shifted fluorescence compared to free NB in water.
3PN with a hydrophobic core had stronger fluorescence than 2PN with a hydrophilic core
that can attract water and quench NB fluorescence. 2PN also showed a minor red shift
and fluoresced stronger than free NB. These results indicate that the hydrophobicity of
the NB solvent environment increases in order of water, 2PN core and 3PN core.
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Figure 2.4. Optical properties of Nile Blue in various solvents at high (A) and low
concentrations (B). Fluorescence was measured under three detection conditions (C, D,
and E) with varying excitation (Ex) and emission (Em) wavelengths at concentrations
from part (B).
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2.3.4

Halo-Fluorochromic Properties of Nile Blue are Sensitive to Acidic Solvent

Environments
Figure 2.5 shows the optical properties of PNAs and free dyes as measured by an
IVIS. AO, a common biological indicator for acidic lysosomes, was used as a control for
the fluorescence quenching effects of NB in water. At 500 nm excitation (Ex) and 620
nm emission (Em), the fluorescence intensity of AO increased below pH 6.0. At 640 nm
Ex/700 nm Em, the fluorescence intensity of NB increased below pH 6.0. The
fluorescence of AO and NB was minimally affected by suspended drug. It should be
noted that the maximum and minimum fluorescence intensity threshold values are
different in fluorescence images with and without drug. As a result, the fluorescence of
AO and NB appear to decrease in the presence of drug, but plate reader measurements
confirmed that the differences in fluorescence with and without drug were not statistically
significant. In contrast to free dyes, fluorochromic PNAs allowed for the simultaneous
detection of both pH and core hydrophobicity. These results suggest that the fluorescence
properties of NB in the core of PNAs behaved as an environmental sensor, but that
interactions with drug molecules did not interfere with the halo-fluorochromism of NB at
640 nm Ex and 700 nm Em. IVIS quantification indicates that pH-dependent differences
in the fluorescence of PNAs are significant enough to detect ex vivo. In order to
quantitatively evaluate the fluorochromism of PNAs, the fluorescence of PNAs was also
quantified using a plate reader.
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Figure 2.5. Fluorescence excitation (Ex) and emission (Em) wavelength-dependent
fluorochromic properties of free dyes (AO and NB) and PNAs with and without the model
drug carfilzomib. The relative fluorescence values for each image are on the right.
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2.3.5

Entrapment of Nile Blue in the Nanoassembly Core Enables the Fluorochromism

of Poly(ethylenimine)-Based PNAs
Figure 2.6 shows pH-dependent changes in the fluorescence of PNAs, as
quantified by a plate reader. These quantitative results confirmed the fluorescence
behavior of PNAs in Figure 2.5. Empty 2PN and 3PN had pH-insensitive fluorescence
properties at 500 nm Ex and 600 nm Em, but demonstrated pH-sensitive fluorescence
properties at 640 nm Ex and 680 nm Em. Specifically, empty 2PN demonstrated
decreased fluorescence as the pH decreased, but the fluorescence of empty 3PN increased
as the pH decreased. Drug-loaded PNAs exhibited increased fluorescence at 500 nm Ex
and 600 nm Em compared to empty PNAs. However, the fluorescence of drug-loaded
3PN decreased in acidic conditions, presumably due to changes in the molecular
conformation or ionization state of CFZ in the core of PNAs. CFZ ionization may also
draw water into the core of PNAs and decrease NB fluorescence. Both empty and drugloaded 2PN and 3PN showed pH-dependent differences in fluorescence at 640 nm Ex and
680 nm Em. 2PN demonstrated gradually decreased fluorescence as pH decreased, but
the fluorescence of 3PN increased as pH decreased. Drug-loaded PNAs had minimal
fluorescence changes compared to empty PNAs at 640 nm Ex and 680 nm Em. Based on
IVIS observations and plate reader quantification, 3PN was selected for further ex vivo
imaging studies in chapter 3.
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Figure 2.6. Quantification of the fluorochromic properties of 2PN and 3PN (10 mg/ml)
by fluorescence spectroscopy. The fluorescence of the PNAs was measured with and
without the model drug carfilzomib.
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2.3.6

Removal of Ionic Moieties from the Polymer Scaffold Reduces the

Fluorochromism of Poly(L-Lysine)-Based PNAs
Figure 2.7 shows the fluorescence properties of PNAs without scaffold amines.
Unfortunately, the fluorescence of 3P’N at concentrations up to 10 mg/ml could not be
quantified using an IVIS or a plate reader due to weak PNA fluorescence. This
observation indicates that the polymer scaffold affects the fluorescence properties of
fluorochromic dyes in the core of PNAs. As a result, the fluorochromism of 3P’N was not
investigated in detail. In contrast to 3P’N, the fluorescence of 3P’NAA could be detected
by an IVIS. However, the fluorescence of 3P’NAA could not be detected by a plate
reader due to a weak signal compared to 2PN or 3PN at a similar concentration. In
comparison to 2PN and 3PN that changed fluorescence intensities and wavelengths in
response to changes in pH and core hydrophobicity, 3P’NAA fluorescence was consistent
in response to changes in pH and drug loading. Figure 2.8 shows the quantification of
3P’NAA fluorescence. At 640 nm Ex and 680 nm Em, changes in fluorescence of
3P’NAA in response to drug loading or pH are not statistically significant. In addition, at
675 nm Ex and 725 nm Em, the fluorescence of drug-loaded 3P’NAA decreased at pH
6.0 compared to drug-loaded 3P’NAA at other pH values. There were no overall trends in
3P’NAA fluorescence in response to pH, but drug loading increased the fluorescence of
3P’NAA by 21% at 675 nm Ex and 725 nm Em compared to empty 3P’NAA. Because
the halo- and solvato-fluorochromism of 3P’NAA were minimal compared to 2PN and
3PN, the applications of 3P’NAA were not further considered.
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Figure 2.7. Fluorescence excitation (Ex) and emission (Em) wavelength-dependent
fluorescence properties of 3P’NAA (10 mg/ml) at various pH values with and without the
model drug carfilzomib.
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Figure 2.8. Quantification of the non-fluorochromic properties of 3P’NAA using IVIS.
3P’NAA was used at 10 mg/ml for all measurements. The Fluorescence of 3P’NAA was
measured with and without the model drug carfilzomib.
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2.4

Discussion

2.4.1

PNAs were Synthesized by Bioconjugation Chemistry
PNAs were synthesized by tethering polymers and pendant groups to a polymer

scaffold. In all of the studies throughout this dissertation, PNAs were synthesized in a
single batch in order to avoid any batch-to-batch variations in the molar substitution of
polymers or pendant groups. However, the future applications of PNAs would require the
synthesis of additional batches of PNAs with similar properties. In order to tether
polymers and pendant groups to the scaffold, NHS ester-activated PEG and acyl-chloride
activated palmitate molecules were reacted with primary amines on the polymer
scaffolds. The reaction of ester-activated carboxylic acids with primary amines is called
transesterification. Transesterification reactions are commonly used in bioconjugation
chemistry due to their versatility, reliability and biocompatibility (78). In addition, acid
chloride groups are highly reactive with primary amines such as functional groups on the
column. Therefore, the reactions used to produce PNAs are expected to be reliable and
reproducible for synthesizing additional batches of PNAs.
The synthesis of PNAs for clinical applications requires a significant scale-up of
the reaction, which could affect the molar substitution of polymers and pendant groups on
the scaffold. In addition, alternative reaction schemes may be needed to replace costly
reagents such as NHS-ester activated PEG that are used in this reaction. The scale-up of
each reaction in this process should be carefully considered in order to assure that
reaction yields are consistent. In addition, the variability in molar substitution of each
component must be considered in order to determine if the dispersity of PNAs is
acceptable for clinical applications. Although these considerations are beyond the scope
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of this work, they are necessary to consider when evaluating the potential clinical
applications of PNAs.
2.4.2

Effects of the PNA Core Environment on the Fluorochromism of Nile Blue
Fluorochromism is an optical property of dyes that change their fluorescence

spectra in response to environmental factors such as solvent polarity (solvatofluorochromism) or pH (halo-fluorochromism) (79). NB was selected as a model dye
with fluorochromism that can change the fluorescence properties of nanoparticles
depending on the amount of entrapped drug as well as the pH of the solvent environment.
Other solvato-fluorochromic dyes such as pyrene have been used to detect polarity
changes in the core environment of nanoparticles such as polymer micelles (80, 81). The
fluorochromic properties of pyrene change slightly when the dye is entrapped in the
nanoparticle core compared to water. By measuring the ratio of fluorescence peak
intensities of pyrene, polarity changes of the dye environment corresponding to micelle
entrapment can be detected. In contrast to the weak fluorochromism of pyrene, NB
changes fluorescence significantly in solvents with different polarities. Because of this
increased sensitivity, NB was able to detect polarity changes due to both the PNA core
environment and hydrophobic drug loading.
The structure and morphology of chemical groups in the core of fluorochromic
nanoparticles may contribute to fluorochromism of dyes. It can be assumed that pendant
groups are randomly attached to primary amines on the polymer scaffold, and that
hydrophilic polymers, hydrophobic groups and fluorochromic dyes are homogenously
distributed across the scaffold. The distance between primary amines on the polymer
scaffold prevents interactions between dye molecules that could affect fluorescence
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spectra. The unimolecular nature of PNAs allows them to attain similar conformations in
solution following reconstitution. Hydrophobic groups on PNAs are likely to enter the
core environment, while hydrophilic groups remain in the shell. The shell of PNAs is
likely composed entirely of PEG interacting with water molecules, because the high
molecular weight of PEG compared to other pendant groups (5000 Da vs. ~300 Da)
allow it to expand out of the core. The core of PNAs is mainly composed of NB,
hydrophobic groups and a polymer scaffold. In addition, the core of the PNAs may
contain end portions of PEG molecules that have refolded towards the core (82). By
keeping the dye molecules in the core, PNAs reduce NB interactions with water that
prevent the detection of NB fluorescence. In the core of 2PN, dye molecules can interact
with entrapped drug molecules, PEG or amines on the PEI scaffold. In the core of 3PN,
dye molecules can interact with entrapped drug molecules, PEG, palmitate or amines on
the PEI scaffold. For PEI-based PNAs, NB remains close to the polymer scaffold. In
contrast to NB in PEI-based PNAs, NB in PLL-based PNAs is attached to amines on the
lysine side chains. As a result, NB in PLL-based PNAs may be further from the polymer
scaffold. Therefore, the distance between dye molecules and the polymer scaffold may
contribute to the fluorochromism of dyes.
The hydrophobicity of the nanoassembly core environment controls both the drug
loading of PNAs and fluorochromic properties of dyes. The addition of PAL to the
polymer scaffold increases the drug loading of PNAs and the fluorescence intensity of
both drug-loaded and empty PNAs. In addition, PAL causes the fluorescence of PNAs in
acidic conditions to increase rather than decrease. A thorough comparison between 2PN
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and 3PN indicates that the design, synthesis and chemical properties of nanoparticles are
critical to the successful use of fluorochromic dyes for theranostics.
The removal of amines from the polymer scaffold of PNAs decreased the
fluorescence of NB and interfered with its fluorochromism. In comparison to 3PN with
strong fluorescence in water, the fluorescence of 3P’N was weak and could not be
detected by an IVIS or a plate reader. This result suggests that the PLL scaffold increases
the water content of the PNA core compared to PEI and decreases NB fluorescence. In
comparison to 3P’N, 3P’NAA had strong fluorescence but lacked fluorochromism. This
observation suggests that the interactions between NB and the polymer scaffold in the
core of PNAs contribute to fluorochromism. It should be noted that unexpected chemical
reactions between AA and tertiary amines on NB in the PNA core could also prevent dye
fluorochromism, but previous observations suggests that these reactions are not
thermodynamically favorable (83).
Halo-fluorochromic properties of molecules often depend on the ionization of
specific chemical moieties resulting in fluorescence spectra shifts (84). The pKa values of
these ionization processes can shift greatly depending on the solvent environment of the
molecule (85). The addition of hydrophobic groups to the core of PNAs changed the
halo-fluorochromic properties of 3PN compared to 2PN. While 2PN had decreased
fluorescence intensity in acidic conditions, 3PN had increased fluorescence intensity. The
interactions between NB and ionized moieties on PEI may cause this difference by
shifting NB fluorescence peak wavelengths. Both drug-loaded and empty PNAs have
similar fluorescence trends in response to acidity. This indicates that drug loading in the
core of PNAs does not prevent NB from detecting changes in solvent acidity, and
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suggests that PNAs have separable solvato- and halo-fluorochromic properties. However,
the loading of ionizable drugs could affect the halo-fluorochromic properties of the
PNAs. Therefore, the use of these PNAs should be avoided for drugs with pKa values
between 6.0 and 7.4.
The ionization of model drugs in the core of PNAs may contribute to the solvatofluorochromism of PNAs. Although empty 3PN demonstrated no halo-fluorochromism at
500 nm Ex and 620 nm Em, carfilzomib-loaded 3PN had decreased fluorescence at pH
6.0 and 5.0 compared to pH 7.4. The PubChem (NIH) and DrugBank (University of
Alberta) databases report that the pKa of carfilzomib is 3.5; however, a literature analysis
of the ionization behavior of N-substituted morpholine groups suggests that the pKa of
carfilzomib is between 5.0 and 5.2 (86). Additionally, a European Medicines Agency
report reports the pKa of carfilzomib to be 5.14 (87). Ionized carfilzomib in the 3PN core
could decrease the fluorescence of 3PN and lower excitation wavelengths by decreasing
the hydrophobicity within the nanoparticle core compared to unionized carfilzomib.
However, additional work is needed to determine an accurate pKa value of carfilzomib in
solution and in the nanoassembly core.
Identifying experimental conditions to separate the effects of halo- and solvatofluorochromism in fluorescence measurements is necessary to evaluate the potential
applications of fluorochromism for cancer theranostics. These results show that the
fluorescence of 2PN and 3PN at low excitation and emission wavelengths is dependent
on drug loading but not solvent acidity. This suggests that specific fluorescence
excitation and emission conditions can detect drug loading and ignore solvent acidity. At
high excitation and emission wavelengths, the fluorescence of 2PN and 3PN are
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dependent on both drug loading and solvent acidity. Therefore, in order to measure the
effects of solvent acidity in fluorescence measurements, empty PNAs can be used. It
should be noted that the drug loading effects on fluorescence that are solely attributed to
solvato-fluorochromism could be partially attributed to halo-fluorochromism if
hydrophobic drug molecules alter the protonation behavior of NB. By measuring the
activity of the nanoassembly core environment before and after drug loading and
comparing activity changes to the halo-fluorochromic properties of PNAs, the specific
effects of drug loading on both halo- and solvato-fluorochromism could be determined.
2.4.3

Benefits of Solvato-Fluorochromism for Cancer Theranostics
Solvato-fluorochromism is critical to the design of nanoparticles for the detection

of metastatic tumors. Non-fluorochromic dyes entrapped in nanoparticles allowed
investigators to detect solid tumors, because the accumulation of dye-containing
nanoparticles in solid tumors increased the fluorescence signals from solid tumors and
overcame the background signals from free dyes and circulating nanoparticles (88).
However, metastatic tumors are not expected to accumulate significant amounts of dyecontaining nanoparticles compared to solid tumors, and free dyes or circulating
nanoparticles could interfere with fluorescence imaging (89). The results in this study
show that NB-conjugated PNAs fluoresce stronger than free NB in water due to solvatofluorochromism. Because of this result, any potential fluorescence from free NB will not
contribute significantly to overall fluorescence signals. Therefore, the development of
nanoparticles that can minimize the fluorescence signals from free dyes and circulating
nanoparticles, while also enhancing nanoparticle fluorescence in tumor tissue, may allow
for the detection of metastatic tumors without interference from free dyes.
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Solvato-fluorochromism can overcome the limitations of other fluorescence
methods for detecting drug loading in nanoparticles. For example, florescence resonance
energy transfer (FRET) has measured hydrophobic drug loading in nanoparticles in real
time (90). FRET detection of drug loading requires specific energetic interactions
between drugs and dyes in the nanoassembly core, which limits the potential
combinations of drugs and dyes that can be used in these systems (91). Because the
solvato-fluorochromic properties of dyes do not require hydrophobic drugs to have
specific optical properties, fluorochromic PNAs have the potential to measure drug
loading and release for various applications (92). However, the use of solvatofluorochromic dyes to measure drug release has some limitations. First, drugs that absorb
and fluoresce light at the same wavelengths as fluorochromic PNAs may interfere with
fluorescence measurements. Therefore, the scope of this approach must be narrowed to
hydrophobic drugs without absorbance in the visible range of light (400-700 nm).
Although this limits the potential applications of fluorochromism, many hydrophobic
anticancer drugs do not absorb or fluoresce light in the visible range. Second,
hydrophobic anticancer drugs that contain some hydrophilic moieties such as amines or
carboxylate anions may draw water into the nanoparticle core and reduce the
fluorescence signals of PNAs. Therefore, the chemical properties of hydrophobic drugs
should be carefully considered to avoid drawing additional water into the PNA core.
Although further feasibility tests are necessary in vivo, these results suggest that in situ
determination of drug concentrations in metastatic tumors or other targeted sites might be
possible by using fluorochromic nanoparticles. In combination with measurements of
drug metabolism and clearance, this system has the potential to determine the ADME of a
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drug in real time. Towards this goal, a method of normalizing fluorochromic signals with
respect to drug carrier concentration is needed.
2.4.4

Benefits of Halo-Fluorochromism for Cancer Theranostics
Fluorochromic dyes are often used to identify biological molecules in imaging

assays. For example, acridine orange (AO) is a widely used dye to detect nucleic acids,
because its Ex and Em maximum wavelengths change upon binding to DNA or RNA
(93). In acidic conditions, AO also has a blue shift in excitation wavelength (94). Despite
its imaging potential, AO cannot differentiate between metastatic tumors and normal
tissue. NB has several advantages over fluorochromic dyes such as AO, such as the
potential for dye conjugation to the core of PNAs and the enhanced halo-fluorochromism
of NB following conjugation. These unique optical properties of NB allowed NBconjugated PNAs to provide real-time information on the amount of drugs remaining in
the particles and solution acidity.
PNAs entrapping fluorochromic dyes can improve the detection of metastatic
tumors compared to traditional biomarker-based methods. Biomarker detection using
dye-labelled antibodies or aptamers can be selective for cancer cells, but antibodies or
aptamers may have a limited time window for imaging due to dye photobleaching (95).
The photostability of NB has been reported in the literature (96), and the photostability of
NB during conditions used for fluorescence detection are experimentally confirmed in
chapter 4. In contrast to antibodies or aptamers with a limited time windows for imaging,
nanoparticles circulating throughout the body for a prolonged period of time can extend
the time window for clinicians to observe metastatic tumors (97). Therefore, PNAs may
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be a beneficial tool for the sensitive detection of metastatic tumors during surgery or
other treatments.
Although the tissue pH of solid tumors has been measured, the detection of
metastatic tumor tissue pH remains elusive. One of the obstacles to measuring metastatic
tumor tissue pH is the rapid clearance and inconsistent optical properties of reporter
molecules within the tumor tissue. In contrast to small molecules, dye-conjugated PNAs
can accumulate in tumors and remain in tumor tissue for an extended period of time (98,
99). Although PNAs could detect acidic conditions in vitro, further optimization of tissue
pH detection conditions such as fluorescence signal normalization at multiple emission
wavelengths may be needed to accurately quantify the tissue pH of the acidic tumor
microenvironment.
2.5

Conclusions
In this study, polymer nanoassemblies were synthesized by tethering hydrophilic

polymer chains (PEG) onto cationic polymer scaffolds (PEI or PLL), followed by
conjugation of fluorochromic molecules (NB), lipophilic chains (PAL) and amine endcapping groups (AA) to the core of the nanoassemblies. NB was selected as a model
fluorochromic dye because of its increased fluorescence in the PNA core compared to
free dyes in solution and its potential for both halo- and solvato-fluorochromism. In
comparison to 2PN with a hydrophilic core that quenched NB fluorescence, 3PN with a
hydrophobic core showed strong fluorescence in acidic conditions or in the presence of
the model hydrophobic anticancer drug (CFZ). In contrast to 3PN, 3P’N had weak
fluorescence that could not be quantified, while 3P’NAA had fluorescence but lacked
fluorochromism. These results suggest that interactions between dyes, hydrophobic drugs
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and the polymer scaffold contribute to the fluorochromism of PNAs. The findings in this
study suggest that further experiments with PNAs may validate their potential as
diagnostic tools with the capability to deliver chemotherapeutic drugs to tumors.

**Portions of Chapter 2 were previously published in (65). Reproduced with permission
from Future Science Group: Therapeutic Delivery, Volume 6, Issue 10, 2015, Pages
1221-1237, Figures 2-6, Methods, Results, Discussion and Conclusion. Copyright 2015 is
given to the publication in which the material was originally published.
Copyright (C) Derek Reichel 2017
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3

DISTRIBUTION OF HALO-FLUOROCHROMIC POLYMER

NANOASSEMBLIES IN NORMAL ORGANS AND SOLID TUMORS FOR THE
DETECTION OF METASTATIC CANCER
3.1

Introduction
Colorectal cancer (CRC) is the second most common cause of gender non-

specific cancer deaths for adults in the United States, but its treatment is commonly
hindered by the lack of effective methods for the early and accurate detection of
metastatic CRC (MCRC) (100). Although primary CRC tumors can kill patients by
interfering with normal colon functions, metastasis accounts for 90% of CRC-related
deaths (101). The primary site of CRC metastasis is the liver; however, liver metastatic
CRC has the second shortest median survival time of all metastatic CRC (102).
Unfortunately, clinically available detection methods cannot effectively distinguish small
MCRC tumors infiltrating into the liver from healthy tissue with high accuracy. In
comparison to primary CRC tumors that can be treated with surgery or chemotherapy,
MCRC tumors are difficult to treat because they are surrounded by healthy cells (103). In
addition, MCRC tumors often become resistant to chemotherapy unless they are treated
early in their development because they contain heterogeneous cell sub-populations with
high mutation rates (104). As MCRC tumors grow and expand, the delivery of ionizable
drugs into MCRC tumors becomes poor due to the dense acidic tissue microenvironment
decreasing the diffusion of ionized anticancer drugs through cancer cell membranes (58,
59, 105). Small metastatic tumors may remain susceptible to clinically available
micrometastatic tumor treatment methods such as neoadjuvant chemotherapy (106, 107).
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Therefore, there is a need to detect small, underdeveloped MCRC tumors accurately
before they grow too large to be treated effectively with surgery and chemotherapy.
Medical imaging has been used in the clinic for the non-invasive detection of
solid tumors and tumor metastasis, but traditional imaging methods have failed to
improve the treatment of MCRC because they cannot detect small metastatic tumors.
Traditional medical imaging methods for tumor detection include magnetic resonance
imaging (MRI), computerized tomography (CT), and intraoperative fluorescence imaging
(108). MRI and CT identify structural abnormalities in normal tissue caused by tumors,
but these methods may fail to detect small metastatic tumors that are smaller than the size
detection limit. In order to decrease this size detection limit and detect small metastatic
tumors, contrast agents have been developed to enhance MRI or CT signals in tumor
tissues compared to normal tissue. Unfortunately, many contrast agents still fail to allow
clinicians to detect small metastatic tumors that make little to no changes to tissue
structure (109). Imaging artifacts also contribute to high false positive rates in MRI and
CT. In contrast to MRI and CT, fluorescence imaging holds promise for the highresolution imaging of tumors (110). Unfortunately, most fluorescent dyes do not
selectively accumulate in cancer cells (111). In addition, many fluorescent dyes have
poor diagnostic properties such as low signal-to-noise ratios, high background signals,
short half-life in tumor tissue, and rapid clearance from the blood (112). Delivery systems
that can improve the diagnostic properties of fluorescent dyes hold promise to increase
the sensitivity of fluorescence imaging for the detection of primary tumors and tumor
metastasis (113).
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Nanoparticles entrapping fluorescent dyes may improve the diagnostic properties
of fluorescent dyes and allow clinicians to detect CRC, but the effects of nanoparticle
distribution on CRC detection are poorly understood. The accumulation of nanoparticles
in the fenestrated vasculature surrounding primary tumors enhances fluorescence signals,
but significant hepatic vasculature can also increase fluorescence signals in the liver
(114). Distinguishing between fluorescence signals from primary tumors and healthy
organs complicates tumor detection using fluorescence imaging. In addition, uneven
diffusion of nanoparticles throughout tumor tissue due to heterogeneous sub-populations
of cells with various cell densities and biological origins may cause clinicians to
misidentify the size and shape of tumors (115). Heterogeneous sub-populations of cells
create dense collagen meshes near tumor blood vessels with pore sizes of 50-100 nm
(116, 117). Fluorescence signals from metastatic tumors may also be obscured by strong
background fluorescence from the healthy tissue surrounding tumors. Nanoparticles
entrapping halo-fluorochromic dyes can address these imaging limitations and detect
small metastatic tumors by combining the indirect detection of abnormal tumor tissue
with the direct monitoring of fluorescent dyes within tumors.
Based on this background, it is hypothesized that PNAs accumulate in the
extracellular space of solid tumors and in the acidic interstitium between MCRC tumors
and healthy cells in liver tissue (Figure 3.1). In order to test this hypothesis, the
macroscopic and microscopic distributions of PNAs in tumor tissue were evaluated, and
the distributions were compared to computational simulations of PNAs in metastatic
tumors. Initially, the diffusion and opsonization of PNAs were evaluated using PNAs
entrapping non-halo-fluorochromic dyes (IR820 and Alexa Fluor® 546). In addition,

52

cellular uptake was evaluated using halo-fluorochromic PNAs with various core
environments. Patient-derived xenograft (PDX) models of primary CRC tumors and
orthotopic liver MCRC tumor models were selected for this study. PDX tumor models
reproduce the heterogeneity and microenvironment of tumors observed in the clinic
(118), while orthotopic liver MCRC tumor models mimic metastatic tumors surrounded
by healthy tissue in normal organs (119, 120). Orthotopic MCRC tumors also retain
heterogeneous sub-populations of cancerous and healthy cells. Liver MCRC tumors were
selected for this study because the liver is the primary site of CRC metastasis in patients
(121). In addition, collaborators used a computational simulation based on a reactiondiffusion system to model PNA distribution in a metastatic lesion. Modeling results were
compared to fluorescence images of PNA accumulation in metastatic tumors. Key
simulation parameters such as blood vessel density and tumor cell state (proliferating,
hypoxic, necrotic) were calibrated from orthotopic liver MCRC tumor models (122-124).
These simulations provide a quantitative method to evaluate the potential of halofluorochromic PNAs for the early and accurate detection of metastatic tumors. By
comparing the diffusion, cellular uptake, and aggregation of PNAs to the macroscopic
and microscopic distribution of PNAs in solid CRC and liver MCRC tumors, the
mechanism by which halo-fluorochromic PNAs detect MCRC tumors can be elucidated.
Computational simulations can further validate the potential of halo-fluorochromic PNAs
for the early and accurate detection of tumor metastasis. Results from this study will aid
the development of halo-fluorochromic PNAs and other types of nanoparticles as useful
tools for the early and accurate detection of MCRC tumors.
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Figure 3.1. Graphical description of the halo-fluorochromic detection of acidic
microenvironments (top), macroscopic and microscopic imaging of halo-fluorochromic
PNAs in primary tumors or live MCRC tumors (middle), and computational simulations
of PNAs in metastatic tumors (bottom). Simulations model a metastatic lesion (bottom
left) containing blood vessels (black) and tumor with proliferating (red), hypoxic (blue)
or necrotic (brown) regions. The model then predicts PNA distribution (bottom right,
red)over time and quantifies PNA accumulation in each region.
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3.2

Materials and Methods

3.2.1

Materials and Cells
α-Succinimidyloxysuccinyl-ω-methoxy-poly(ethylene glycol) (5 kDa, NHS-

activated PEG) was purchased from NOF America (White Plains, NY). Acetic anhydride,
agarose, HEPES sodium salt, IR-820 sodium salt, NHS-activated Alexa Fluor® 546 dye
(Alexa 546), palmitoyl chloride, poly(L-lysine hydrobromide) (30-70 kDa, PLL) and
sucrose were purchased from Sigma Aldrich (St. Louis, MO). The chemical structure of
IR-820 sodium salt is in figure 3.1. Diethyl ether, DMSO, THF, methanol, nuclear
staining dye Hoechst 33342, pyridine, chamber slides, dialysis membrane with 3.5 or 100
kDa MWCO, phosphate buffer solutions (50 mM, pH 7.4, 7.0 and 6.0) and preparative
size exclusion columns (PD Minitrap, G-25, 3.5 ml) were purchased from Fisher
Scientific (Waltham, MA). Aqueous ultramount permanent mounting medium was
purchased from Dako (Carpinteria, CA). Optimal cutting temperature compound (OCT)
was purchased from Andwin Scientific (Schaumburg, IL). Paraformaldehyde solution
(4%) was purchased from Polysciences (Warrington, PA). Mouse EpCAM antibodies
were purchased from LSBio (Seattle, WA), while mouse CD31 and donkey anti-mouse
NL637-labelled IgG antibodies (secondary antibody) were purchased from R&D Systems
(Minneapolis, MN). McCoy’s 5A (M5A) media, phosphate buffered saline (PBS) and
0.05% trypsin/EDTA were purchased from GE Healthcare (Logan, UT). Fetal bovine
serum (FBS) was purchased from Atlanta Biologicals (Flowery Branch, GA). Human
CRC cell-lines (HT29 and HCT116) were purchased from the American Type Culture
Collection (ATCC, Manassas, VA). Cells were cultured in M5A supplemented with 10%
FBS in a humidified environment with 5% CO2 at 37 °C.
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Figure 3.2. Chemical structure of IR-820 sodium salt.
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3.2.2

Synthesis of Non-Halo-Fluorochromic PNAs
PNAs were synthesized following Figure 3.3. The synthesis protocol and

characterization of halo-fluorochromic PNAs is described in chapter 2. Non-halofluorochromic PNAs are denoted as PEG-PLL-PAL-AA-IR-820 (3P’IR820) and PEGPLL-PAL-Alexa Fluor® 546 (3P’A546). Briefly, PLL (334.4 mg) was reacted with
NHS-activated PEG (2.0 g) in 2:1:1 water:DMSO:pyridine at room temperature for 3
days. PEG-PLL was purified by dialysis in water and collected after freeze drying. A
portion of the PEG-PLL (1.0 g) was reacted with palmitoyl chloride (299 μl) at 40 °C in
THF for 2 h. Pyridine (100 μl) was added to the reaction solution after 15 minutes to
scavenge hydrochloric acid by-products. The product PEG-PLL-PAL was purified by
ether precipitation and dialysis in water, and then collected after freeze drying. A portion
of PEG-PLL-PAL (100.0 mg) was reacted with Alexa 546 (673.0 μg) at room
temperature in DMSO overnight. The product 3P’A546 was purified using preparative
size exclusion columns and collected after freeze drying. Another portion of the PEGPLL-PAL (200.0 mg) was reacted with IR-820 (542.4 mg) in methanol at 40 °C
overnight. Pyridine (300 μl) was added to the reaction solution after 1 hour to scavenge
hydrochloric acid by-products. The product PEG-PLL-PAL-IR-820 was purified by
dialysis in water and collected after freeze drying. PEG-PLL-PAL-IR-820 (180.0 mg)
was subsequently reacted with acetic anhydride (54.3 μl) at room temperature in DMSO
to end-cap remaining primary amines on PLL. The final product 3P’IR820 was purified
by dialysis in water and collected after freeze drying.

57

Figure 3.3. Synthesis protocol for halo-fluorochromic and non-halo-fluorochromic
PNAs.
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3.2.3

Physical and Optical Characterization of Non-Halo-Fluorochromic PNAs
Chemical compositions of non-halo-fluorochromic PNAs were determined by

proton NMR spectroscopy (Varian 400 MHz, d6-DMSO, referenced to TMS). In order to
determine the dye conjugation of PNAs, the absorbance of dye-conjugated PNAs was
compared to free dye standards using a plate reader (SpectraMax M5, Sunnyvale, CA).
The size distribution and uniformity of PNAs were determined by GPC (Asahipak GF7M, PBS, 0.5 ml/min, 40 °C, calibrated using PEG standards). The diameter and surface
charge of PNAs were determined by DLS (Zetasizer Nano ZS, Malvern, UK). The
insensitivity of 3P’IR820 fluorescence to changes in drug loading and solvent pH was
confirmed by measuring the fluorescence of PNAs (1 mg/ml) with and without
carfilzomib loading at pH 7.4, 7.0, 6.0 and 5.0 using an IVIS (Ex 745 nm/Em 840 nm).
3.2.4

Diffusion and Flux of PNAs in Tissue Mimics
Agarose gels were prepared to mimic the pH and density of healthy and tumor

tissues. These gels allowed for the direct measurement of PNA diffusion under controlled
conditions (125). Briefly, agarose (0.5% or 1% w/v) was added to buffers (pH 7.4, 7.0
and 6.0) and heated to prepare suspensions. Low gel density (0.5% w/v) creates pores
mimicking extracellular space between healthy cells (200 to 500 nm), while high gel
density (1.0% w/v) provides pores corresponding to the keratin mesh surrounding tumors
(50 to 100 nm) (117). The acidity of gels represents healthy tissue (pH 7.4), tumor
periphery (pH 7.0) and the tumor core (pH 6.0) (126). Agarose suspensions were then
pipetted into 96 well plates (100 μl per well) and cooled at room temperature to create
gels. Stock solutions of 3P’IR820 (1 mg/ml) and 3PN (10 mg/ml) were prepared in water.
3P’IR820 solution (100 μl) was added to wells and allowed to diffuse into gels for 0.1,
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0.5, 1, 3, 6 or 24 h at 37 °C. The solutions were removed from the wells and the
absorbances of these gels were measured at 820 nm. The background signals of untreated
wells were subtracted from the measurements and the corrected signal was normalized to
absorbance of 100 μl of 3P’IR820 solution. In an attempt to mimic interarterial pressure
forcing PNAs into liver stroma, diffusion experiments were repeated under an additional
16 kPa (120 mm Hg) external pressure. The normalized absorbance changes of gels over
time were fit to a linear regression. Flux values were calculated by dividing the slope
values from the linear regressions by the well surface area and multiplying by the initial
PNA concentration. In order to evaluate the effects of tissue diffusion on halofluorochromic imaging, 3PN (100 μl, 10 mg/ml) was added to wells and allowed to
diffuse into gels for 24 h at 37 °C. PNA solutions were removed from the wells and gels
were imaged using an IVIS (Ex 640 nm/Em 700 nm).
3.2.5

Opsonization and Aggregation of PNAs
PNAs were exposed to anionic, cationic, physiological and serum-containing

conditions that were previously reported in the literature to induce nanoparticle
aggregation (127-130). Stock solutions of magnesium sulfate (Anionic, 1 M), calcium
chloride (Cationic, 30 mM), McCoy’s 5A media (Physiological), and McCoy’s 5A media
containing FBS (Serum-Containing, 50% v/v) were prepared. 3P’IR820 was dispersed in
anionic, cationic, physiological and serum-containing solutions at 2 mg/ml and stored at
37 °C for 24 hours. Absorbance changes indicating potential aggregation were measured
at 0, 1, 3, 6 and 24 h. Absorbance values above 0.3 (650 nm) indicating 50% turbidity
were defined as the aggregation threshold for PNAs. The diameter of PNAs in each
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solution was also measured after 24 h using DLS and compared to initial diameter of
PNAs in deionized water.
3.2.6

Uptake of PNAs and Small Molecules in Cells
HT29 cells were seeded in chamber slides at 15,000 cells per well. After

overnight incubation of the chamber slides, the cells were treated with 2PN, 3PN or
Mitotracker Green (MG) (1 mg/ml 2PN and 3PN, 200 nM MG) for 0.5, 1, 3, and 6 h.
Cells were then placed on a heated stage maintained at 37 °C and imaged using a
fluorescence microscope (Zeiss Axiovert 200M, Thornwood, NY). 2PN and 3PN were
imaged using a Texas red filter (Ex 568 nm/Broad Spectum Em), while MG was imaged
using a FITC filter (Ex 488 nm/Broad Spectrum Em). The background fluorescence of
2PN, 3PN and MG was equalized in order to normalize the fluorescence signals over
time for each treatment. The average intracellular and extracellular fluorescence for 2PN, 3PN- and MG-treated samples were calculated for each timepoint using ImageJ (NIH,
Bethesda, MD). The fluorescence measurements were then converted to relative
concentrations using a calibration curve of known concentration standards. The ratio of
intracellular to extracellular PNA concentrations was defined as the uptake quotient (Q)
in equation 3.1. Q is unitless.
𝐶𝐶

𝑄𝑄 = 𝐶𝐶 𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼

(3.1)

𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸

To compare cellular uptake between PNAs, the cell experiments were repeated
with 2PN and 3PN, but fluorescence images of cells were taken every 10 seconds for 0.5
h following treatment. Kinetic parameters of cellular uptake were determined using a
mathematical model based on previous reports (131). Briefly, a chamber with PNA
concentration C1 and volume V1 was assumed to contain cells with intercellular PNA
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concentration C2, volume V2 and surface area α2. In this derivation, the volume of cell
media was assumed to be significantly greater than the volume of cytosol, and the surface
ratio to volume ratio of cells was assumed to remain constant during measurements.
Mass transfer equations describing PNA movement into (r12) and out of cells (r21)
through the cell membrane can be written following equations 3.2 and 3.3, respectively.
𝐶𝐶

𝑟𝑟12 = 𝑘𝑘12 (𝐶𝐶1 − 𝐾𝐾 2 )

(3.2)

𝐸𝐸𝐸𝐸

𝐶𝐶

𝑟𝑟21 = 𝑘𝑘21 (𝐾𝐾 2 − 𝐶𝐶1 )

(3.3)

𝐸𝐸𝐸𝐸

In equations 3.2 and 3.3, r12 and r21 have units of moles of PNA per square meter
of cell surface area per minute, k12 and k21 have units of meters per minute, C1 has units of
moles of PNA per cubic meter of cell media and C2 has units of moles of PNA per cubic
meter of cytosol. In addition, KEQ is defined as a unitless cellular partition coefficient
(C1eq/C2eq) that relates the media PNA concentration to the cytosol PNA concentration at
equilibrium.
Equations 3.2 and 3.3 were combined into equation 3.4, which describes the
overall kinetic transfer of PNAs into and out of cells.
𝐶𝐶

𝑟𝑟𝐴𝐴 = −𝐾𝐾𝑀𝑀 �𝐾𝐾 2 − 𝐶𝐶1 �

(3.4)

𝐸𝐸𝐸𝐸

In equation 3.4, rA has units of moles of PNA per square meter of cell surface area
per minute. KM is defined as an overall mass transfer coefficient accounting for both
physical and biological processes contributing to nanoparticle uptake by cells. Similar to
each rate constant, KM has units of meters per minute.
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In addition to a kinetic equation describing uptake of PNAs, a mole balance
describing changes in PNA concentrations in cells can be written as described in equation
3.5.
𝑑𝑑𝑑𝑑2
𝑑𝑑𝑑𝑑

= 𝑛𝑛12 − 𝑛𝑛21

(3.5)

In equation 3.5, n12, n21, and dN2/dt have units of moles of PNA per minute. By
assuming that the volume of cell media remains constant and that PNAs accumulate in
cells only through mass transfer processes, we can convert equation 3.5 into terms of
concentration using equations 3.6 and 3.7.
𝑑𝑑𝑑𝑑2
𝑑𝑑𝑑𝑑

= 𝑉𝑉2 ∗

𝑑𝑑𝑑𝑑2

(3.6)

𝑑𝑑𝑑𝑑

𝑛𝑛12 − 𝑛𝑛21 = 𝛼𝛼 ∗ 𝑟𝑟𝐴𝐴

(3.7)

In equations 3.6 and 3.7, V2 has units of cubic meters and α has units of square
meters. Equations 3.6 and 3.7 were substituted into equation 3.5 to yield equation 3.8.
𝑉𝑉2 ∗

𝑑𝑑𝑑𝑑2

𝑉𝑉2 ∗

𝑑𝑑𝑑𝑑2

𝑑𝑑𝑑𝑑

= 𝛼𝛼 ∗ 𝑟𝑟𝐴𝐴

(3.8)

Equation 3.4 was substituted into equation 3.8 to yield equation 3.9.
𝑑𝑑𝑑𝑑

𝐶𝐶

= −𝛼𝛼 ∗ 𝐾𝐾𝑀𝑀 �𝐾𝐾 2 − 𝐶𝐶1 �
𝐸𝐸𝐸𝐸

(3.9)

If extracellular PNA concentrations remain constant during uptake and M remains
constant with respect to PNA concentrations, C1 is simplified to the initial extracellular
PNA concentration C10 and equation 3.9 can be simplified to equation 3.10.
𝑉𝑉2 ∗

𝑑𝑑𝑑𝑑2
𝑑𝑑𝑑𝑑

𝐶𝐶

= −𝐾𝐾𝑀𝑀 ∗ 𝛼𝛼2 ∗ (𝐾𝐾 2 − 𝐶𝐶10 )
𝐸𝐸𝐸𝐸

(3.10)

Equation 3.10 can be rearranged to yield equation 3.11, which was solved for C2
to yield equation 3.12, using the initial condition of no PNAs in the cytosol or on the cell
membrane before treatment.
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𝑑𝑑𝑑𝑑2
𝑑𝑑𝑑𝑑

𝐶𝐶2

𝐶𝐶10

=

−𝐾𝐾𝑀𝑀 ∗𝛼𝛼2
𝐾𝐾𝐸𝐸𝐸𝐸 ∗𝑉𝑉2

∗ (𝐶𝐶2 − 𝐾𝐾𝐸𝐸𝐸𝐸 ∗ 𝐶𝐶10 )

= 𝐾𝐾𝐸𝐸𝐸𝐸 ∗ (1 − 𝑒𝑒

−𝐾𝐾𝑀𝑀 ∗𝛼𝛼2
∗𝑡𝑡
𝐾𝐾𝐸𝐸𝐸𝐸 ∗𝑉𝑉2

)

(3.11)

(3.12)

As described earlier and repeated below in equation 3.13, KEQ was defined as the
cellular partition coefficient. In addition, k was defined as the cellular uptake rate
constant in equation 3.14. KEQ is unitless, while k has units of inverse minutes. In
addition, because extracellular PNA concentrations are assumed to remain constant, the
left side of equation 3.12 is equal to the uptake quotient. These parameters are
substituted into equation 3.12 and simplified to yield equation 3.15. The uptake
coefficient-time profiles were fit to equation 3.7 using Prism 5.0 (Graphpad, La Jolla,
CA). Because the concentration ratios are determined in equation 3.15 rather than the
molar ratios, the phase volumes are not necessary to calculate uptake kinetics.

𝑘𝑘 =

𝐸𝐸𝐸𝐸

𝐶𝐶1

(3.13)

−𝐾𝐾𝑀𝑀 ∗𝛼𝛼2

(3.14)

𝐾𝐾𝐸𝐸𝐸𝐸 =

𝐸𝐸𝐸𝐸

𝐶𝐶1

𝐾𝐾𝐸𝐸𝐸𝐸 ∗𝑉𝑉2

𝑄𝑄 = 𝐾𝐾𝐸𝐸𝐸𝐸 ∗ (1 − 𝑒𝑒 𝑘𝑘∗𝑡𝑡 )

(3.15)

In order to compare the rate of cellular uptake between different PNAs, t95 was
defined as the time for the uptake quotient (Q) to reach 95 percent of the cellular partition
coefficient (KEQ) (equation 3.16). The t95 value has units of minutes.

3.2.7

𝑡𝑡95 =

ln(20)

(3.16)

𝑘𝑘

Ex Vivo Imaging of Patient-Derived Xenograft Tumors from Mice using Non-

Halo-Fluorochromic PNAs
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NOD-scid gamma mice between 6 to 8 weeks old were purchased from the
Jackson Laboratory (Bar Harbor, ME). All animal experiments were performed in
accordance with the Institutional Animal Care and Use Committee (IACUC) and with
approval from the Institutional Review Board of the University of Kentucky. A patient
primary CRC tumor sample (F0) was collected, divided and implanted into a mouse
flank. When these tumors (F1) grew to 1 cm3, the tumors were resected and divided into
2 mm3 sections. The divided tumors were then implanted into mice (F2) for experiments.
Mice bearing F2 tumors were dosed with 3P’A546 by tail vein injection (10 mg/kg). As a
negative control, mice were also dosed with PBS. Mice were euthanized 1, 4, 8 and 24
hours post-injection and lung, liver, kidney, spleen and PDX tumors were collected. The
fluorescence of 3P’A546 in normal organs and tumors were quantified by IVIS. Density
maps of PNA fluorescence in tissues were prepared using Living Image 3.1 (Caliper Life
Sciences, Hopkinson, MA) and represented as a color gradient centered at the maximum
fluorescence intensity. Additionally, tumor tissue samples were fixed in 4%
paraformaldehyde containing 10% sucrose at 4°C, embedded in OCT on dry ice,
sectioned at 10 μm thickness, and then dried overnight in the dark. Tumor tissue samples
were then washed in PBS at room temperature, stained with Hoechst 33342 (500 ng/ml,
PBS) and mounted in aqueous permanent mounting medium overnight. Additionally,
tumor tissue samples were also treated with either EpCAM or CD31 primary antibodies
to identify CRC cells or blood vessels, respectively. Primary antibody-treated samples
were then treated with dye-labelled secondary antibodies for fluorescence imaging.
Stained tissue slides were imaged by confocal microscopy at 20x magnification
(Olympus FV1000, Tokyo, Japan).
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3.2.8

Ex Vivo Imaging of Livers from Mice with Liver Metastatic Colorectal Cancer

using Non-Halo-Fluorochromic and Halo-Fluorochromic PNAs
Male athymic NCr nude mice between 6 to 8 weeks old were purchased from
Taconic (Hudson, NY). Orthotopic liver MCRC tumors were established in these mice.
Briefly, mice were injected with HCT 116 cells expressing green fluorescent protein
(GFP) into the spleen capsule and allowed to develop MCRC tumors for 6 weeks. The
establishment of liver MCRC tumors was confirmed by measuring the fluorescence of
GFP corresponding to cancer cells in liver tissue. In order to maximize the fluorescence
signals from normal organs without saturating the IVIS fluorescence detector, tumor-free
mice were injected with 3P’A546 through the tail vein at varying doses (0, 5, 10 and 20
mg/kg). Twelve hours after injection, mice were euthanized to collect organs for imaging
by IVIS (Ex 535 nm/Em 580 nm). Based on the measured fluorescence intensities of
livers from tumor-free mice, mice bearing liver MCRC tumors were injected with
3P’A546 (10 mg/kg) through the tail vein and euthanized after 12 h. Mice bearing MCRC
tumors were also injected with either 3PN (10 mg/kg) or PBS through the tail vein and
euthanized after 6 h. The liver, kidney and lungs were collected from these mice for
macroscopic imaging as described above. For microscopic imaging, liver tissue and liver
MCRC tumor samples were collected from mice treated with 3P’A546 and fixed as
described in the previous section. Tissue samples were stained with Hoechst 33342 (500
ng/ml, PBS) to visualize cell nuclei, and then stained with CD31 primary antibodies to
identify blood vessels. Primary antibody-treated tissue samples were then stained with
dye-labelled secondary antibodies for fluorescence imaging. Stained tissue slides were
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imaged by confocal microscopy at 20x magnification as described in the previous
section.
3.2.9

Quantification of Fluorescence Signals in Microscopic Fluorescence Images of

Metastatic Tumors
Fluorescence signals corresponding to cell nuclei (DAPI), tumor vasculature
(CD31) and PNAs were quantified from microscopic liver MCRC images. First, the
fluorescence signals from merged images were split by channel to isolate nuclei,
vasculature and PNA signals. To account for differences in fluorescence signal strength
between dyes, dye-labelled antibodies and PNAs, the fluorescence signals from each
channel were normalized by converting the fluorescence intensities to binary signals
using ImageJ. Next, regions of interest (80x80 μm) corresponding to metastatic tumor
foci were selected and the total fluorescence per unit area was quantified in these regions.
Fluorescence values per unit area were used to estimate cancer cell and vasculature
density in metastatic tumors for computational simulations.
3.2.10 Computational Simulations of PNA Distribution in Metastatic Tumors
A computational model was used by Frieboes et al. to describe PNA distribution
in MCRC tumors as a function of the surrounding tissue vascularization. Frieboes
describes the model in detail in previous publications (124, 132-136). Briefly, the model
represents viable, hypoxic, and necrotic tissue regions of a tumor in a two dimensional
Cartesian coordinate system, and it simulates a small lesion (initial diameter ~50 μm) in
the center of a pre-existing vascular capillary grid from healthy tissue. Mass conservation
equations describe tissue growth (proliferation as a function of cells cycling) and tissue
death via necrosis as a function of hypoxia. Hypoxia induces the release of tumor
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angiogenic factors such as Vascular Endothelial Growth Factor (VEGF), which causes
neovascularization to supply the tumor with sufficient nutrients for growth. The tumor
growth equations are combined with the diffusion of PNAs, oxygen, and cell nutrients to
a reaction-diffusion equation. The rate constants for proliferation and death depend on the
availability of oxygen, nutrients, and drug, and are thus spatio-temporally heterogeneous.
The tumor growth component of the computational model is based on (137).
Briefly, the tumor tissue and its boundary are denoted by Ω and Σ, respectively. The
tissue typically has a proliferating region ΩP (100-200 μm thickness) in which cells have
sufficient oxygen and nutrients, a hypoxic region ΩH in which oxygen and nutrients are
sufficient for survival but not for proliferation, and a necrotic region ΩN in which oxygen
and nutrients are insufficient for survival. The non-dimensionalized tumor growth
velocity is implemented via a generalized Darcy’s law in equation 3.17 (137).
𝒗𝒗𝐶𝐶 = −𝜇𝜇∇𝑃𝑃 + χ𝐸𝐸 ∇𝐸𝐸

(3.17)

In equation 3.17, μ is cell-mobility representing the net effects of cell-cell and
cell-matrix adhesion, P is oncotic pressure, χE is haptotaxis, and E is extra-cellular matrix
(ECM) density. Definitions for χE and E are in (137). By assuming that the cell density is
constant in the proliferating region, the overall tumor growth can be associated with the
rate of volume change in equation 3.18.
∇ · 𝒗𝒗𝐶𝐶 = 𝜆𝜆𝑃𝑃

(3.18)

In equation 3.18, λP is the non-dimensional net proliferation rate as further
detailed below.
The angiogenesis component of the model simulates the lesion by (138) and is
based on previous work (136, 139). As a tumor grows in the dynamic, vascularized tissue
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environment, tumor cells have varying access to molecules diffusing from the
vasculature, depending on the tissue pressure and the distance from the nearest blood
vessels.
The diffusive transport of oxygen σ through tumor tissue is simulated from the
extravasation location of molecules from the tumor blood vessels. Oxygen is supplied
from the neo- and pre-existing vessels with extravasation rates λevσ = λneo σ and λev σ = λpre σ,
respectively, diffuses with a diffusion coefficient Dσ, is taken up by both normal cells
(with a rate λtissue σ) and tumor cells (λtumor σ in the proliferating region and qs in the
hypoxic region), and decays (with a rate λN σ) in the necrotic region. Oxygen is consumed
in tumor tissue (with a rate λP) depending on the tumor region. Assuming steady-state
conditions, the formulation is in equation 3.19 and 3.20, which was derived based on
previous reports (133, 135, 137).
0 = ∇ · (𝐷𝐷𝜎𝜎 ∇𝜎𝜎) + 𝜆𝜆𝜎𝜎𝑒𝑒𝑒𝑒 (𝒙𝒙, 𝑡𝑡, 𝟏𝟏𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣 , 𝑝𝑝𝑖𝑖 , 𝜎𝜎, ℎ) − 𝜆𝜆𝜎𝜎 (𝜎𝜎)𝜎𝜎

𝜆𝜆𝜎𝜎𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡 outside Ω
𝜆𝜆𝜎𝜎
in Ω𝑃𝑃
𝜆𝜆𝑃𝑃 = � 𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡
𝑞𝑞𝜎𝜎 (𝜎𝜎)
in Ω𝐻𝐻
𝜎𝜎
𝜆𝜆𝑁𝑁
in Ω𝑁𝑁

(3.19)

(3.20)

In equation 3.19, x is position in space, t is time, 1vessel is the characteristic
function for the vessels (equals 1 at vessel locations and 0 otherwise), pi is the interstitial
pressure, and h is the hematocrit in the vessel network which is related to oxygen
extravasation (following reference (137)). The extravasation of oxygen is modulated by
the extravascular interstitial pressure pi scaled by the effective pressure pe, with kpi being
the weight of the convective transport component of molecules (133). This process is
described in equation 3.21.
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𝜎𝜎

𝑝𝑝

ℎ

� 𝑚𝑚𝑚𝑚𝑚𝑚 � + �1 − 𝑘𝑘𝑝𝑝 𝑖𝑖 � (1 − 𝜎𝜎)(3.21)
𝜆𝜆𝜎𝜎𝑒𝑒𝑒𝑒 = 𝜆𝜆�𝑒𝑒𝑒𝑒 𝟏𝟏𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣 (𝐱𝐱, t) � � − ℎ
𝑖𝑖
𝑝𝑝𝑒𝑒

𝐻𝐻𝐷𝐷

�𝐷𝐷 and ℎ�𝑚𝑚𝑚𝑚𝑚𝑚 represent the normal and minimum
In equation 3.21, the constants 𝐻𝐻

blood hematocrit levels required for oxygen extravasation, respectively, and 𝜆𝜆̅𝜎𝜎𝑒𝑒𝑒𝑒 is the
constant transfer rate from both pre-existing and tumor-induced blood vessels. The
oxygen transport parameters are calibrated so that the growth rate of an avascular
spheroid matches the experimentally observed rates (134).
The acidity of the tumor microenvironment is modeled as a first order

approximation that is proportional to the release of tumor angiogenic factors (TAF) from
hypoxic cells within the tumor. The maximum TAF value represents a pH of 5, and the
absence of TAF represents physiological conditions (pH 7.4). TAFs are produced by
hypoxic tumor cells at rate 𝜆𝜆̅𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝 , diffuse into the tissue with a constant diffusion

coefficient 𝐷𝐷𝑇𝑇 , are taken up by endothelial cells with a rate 𝜆𝜆̅𝑇𝑇𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏 , and decay

exponentially with a rate 𝜆𝜆̅𝑇𝑇𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑 [33]. This process is described in equation 3.22.
0 = ∇ ∙ (𝐷𝐷𝑇𝑇 ∇𝑇𝑇) + 𝜆𝜆𝑇𝑇̅𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝 (1 − 𝑇𝑇)𝟏𝟏Ω𝐻𝐻 + 𝜆𝜆̅𝑇𝑇𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑 𝑇𝑇

−𝜆𝜆̅𝑇𝑇𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏 𝟏𝟏𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣

(3.22)

The transport of PNAs s through tumor tissue, like oxygen, is also simulated from
the location of extravasation from the vessels. PNAs are simulated to be injected
systemically, flowing from the lower left to upper right of the vascularized tumor system.
s

PNAs are taken up both by both normal and tumor cells with a rate λ uptake . The
formulation is described in equation 3.23.
𝑠𝑠
𝑠𝑠
0 = ∇ ∙ (𝐷𝐷𝑠𝑠 ∇s) + 𝜆𝜆𝑒𝑒𝑒𝑒
(𝒙𝒙, 𝑡𝑡, 𝟏𝟏𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣 , 𝑝𝑝𝑖𝑖 , 𝑠𝑠) − 𝜆𝜆̅𝑢𝑢𝑢𝑢𝑢𝑢𝑢𝑢𝑢𝑢𝑢𝑢
(3.22)
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s

Assuming a constant transfer rate λ ev from both pre-existing and tumor-induced
vessels, the PNA extravasation is described in equation 3.23.
𝑠𝑠

𝑝𝑝
𝐶𝐶
𝑠𝑠
𝑠𝑠
𝜆𝜆𝑒𝑒𝑒𝑒
= 𝜆𝜆̅𝑒𝑒𝑒𝑒
𝟏𝟏𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣 (x, t)(1 − 𝑘𝑘𝑝𝑝𝑖𝑖 𝑝𝑝 𝑖𝑖 )(𝐶𝐶𝑡𝑡̅ 𝑠𝑠 − s)
𝑒𝑒

(3.23)

In this equation, the diffusion in tumor tissue is assumed to be modulated by the
interstitial pressure (133). The diffusivity is assumed to be similar to previous diffusion
measurements for nanoparticles (140).The initial PNA concentration in the vasculature is
𝐶𝐶̅ 𝑠𝑠 , with an extravasation described in equation 3.24.
𝐶𝐶𝑡𝑡𝑠𝑠 = 𝐶𝐶̅ 𝑠𝑠 𝑒𝑒 −𝑡𝑡/𝜏𝜏

(3.24)

Equation 3.24 assumes first order kinetics, i.e., the extravasation is concentration
dependent. The PNA half-life (dependent on τ) is assumed to be proportional to the
clearance rate of drug released from them, as previously measured (134).
The model parameters associated with oxygen uptake and transfer rates were
determined from the literature (141). In addition, the diffusivity, mass transfer rate and
clearance of PNAs were estimated based on previous experiments (123, 142). The tumor
proliferation rate, necrosis threshold and hypoxia threshold were calibrated based on
growth profiles of liver MCRC tumors.
3.2.11 Statistics
All values in figures are reported as mean±standard deviation for three
measurements unless otherwise noted. Groups of multiple measurements were compared
by one-way ANOVA with Bonferroni’s post-test correction, while pairs of measurements
were compared by Student’s t test unless described otherwise. Statistical significance in
figures and tables is represented with * (p<0.05), ** (p<0.01) or *** (p<0.001).
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3.3

Results

3.3.1

Fluorochromism Does Not Affect the Physicochemical Properties of PNAs
The synthesis and characterization of 2PN and 3PN was described in chapter 2.

Proton NMR indicated attachment of PEG (3.51 ppm, s, relative area 1.000), PAL (0.83
ppm, d, relative area 0.002; 1.23 ppm, s, relative area 0.027; 1.46 ppm, s, relative area
0.009) and AA (1.78 ppm, s, relative area 0.024) to PLL (2.23 ppm, m, relative area
0.0013; 2.60 ppm, s, relative area 0.0005; 2.68 ppm, s, relative area 0.0008; 2.97 ppm, s,
relative area 0.0009; 3.24 ppm, s, relative area 0.0114; 3.68 ppm, s, relative area 0.027;
4.09 ppm, s, relative area 0.040; 7.78 ppm, s, relative area 0.009). The size and chemical
purity of 3P’A546 and 3P’IR820 were confirmed by GPC in Figure 3.4. 3P’A546 and
3P’IR820 had 1% molar substitution of Alexa Fluor® 546 and 5% molar substitution of
IR820, respectively. Table 3.1 summarizes the diameters, surface charges and chemical
properties of non-halo-fluorochromic PNAs. Figure 3.5 shows the fluorescence of
3P’IR820 at various pH values and with and without drug loading in order to confirm
non-halo-fluorochromism. Changes in pH did not consistently alter the fluorescence of
3P’IR820, but the fluorescence of drug-loaded 3P’IR820 slightly decreased at pH 7.0 and
6.0 compared to pH 7.4. Drug loading increased the fluorescence of PNAs by about 30%
compared to empty PNAs.
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Figure 3.4. Gel permeation chromatographs of 3P’A546 (A) and 3P’IR820 (B).
Chromatographs were measured by UV-visible absorbance detector at 546 nm (A) or 820
nm (B).
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Table 3.1. Physicochemical properties of 3P’A546 and 3P’IR820. Characterization
information for 2PN and 3PN are in Table 2.1 of Chapter 2.
Polydispersity Index
PNA
Diameter (nm)
Zeta potential (mV)
(PDI) (unitless)
3P’A546
23.2±1.0**
-0.8±0.4
0.31±0.02
3P’IR820
18.8±0.3**
0.3±0.7
0.29±0.02
PEG Substitution
PAL Substitution
Dye Substitution
PNA
(mol/mol primary
(mol/mol primary
(mol/mol primary
amine on scaffold) (%) amine on scaffold) (%) amine on scaffold) (%)
3P’A546
24.0±0.6
37.0±0.9
1.0±0.1***
3P’IR820
24.0±0.6
37.0±0.9
5.0±0.1***
Diameter, zeta potential PDI and dye substitution are reported as mean±SD (n=3). PEG
and PAL substitution are reported as measurement±SE for NMR measurement (n=1).
Statistical significance is determined with a Student’s t test as described in the methods
section.
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Figure 3.5. Fluorescence properties of 3P’IR820 measured by IVIS (A). The fluorescence
of empty (B) and drug-loaded 3P’IR820 (C) were quantified from IVIS images.
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3.3.2

PNAs Diffuse into Gels Mimicking Tissue Conditions and Fluoresce in Acidic

Environments
Figure 3.6 describes the flux of 3P’IR820 into agarose gel tissue mimics with and
without 120 mmHg additional external pressure. The calculated flux for PNAs in each gel
density, pH, and pressure condition are located in Table 3.2. The flux of 3P’IR820
decreased by about 40 % in high density gels (1.0%) compared to low density gels
(0.5%). Decreases in gel pH did not consistently affect the flux of PNAs, but the flux of
PNAs was greater for pressurized 1% gels at pH 7.0 compared to pH 7.4 or 6.0. External
pressure decreased the flux of 3P’IR820 slightly, possibly due to the compression of the
gel disrupting pores near the top of the gel. To determine the effects of diffusion on the
halo-fluorochromic imaging of PNAs, gels were treated with 3PN for 24 h. Figure 3.7
shows the fluorescence of halo-fluorochromic 3PN after diffusion into tissue mimics.
Fluorescence images confirm PNA diffusion and distribution in the gel mimics. For each
gel density, the fluorescence increased in order of pH 6.0>7.0>7.4. The fluorescence of
PNAs in 0.5% gels was slightly greater than the fluorescence in 1.0% gels at varying pH
values, except pH 6.0 where 3PN showed greater fluorescence in 1.0% gel than 0.5% gel.
The fluorescence of halo-fluorochromic PNAs in 1.0% gel at pH 6.0 is greater than
expected, based on fluorescence trends due to changes in pH and gel density.
Imperfections on the surfaces of gel surfaces in the pH 6.0 gels with 1.0% gel density,
perhaps due to air bubbles at the surface of the gels after solidification, may increase the
observed fluorescence signal of PNAs in acidic gels, due to reflections of fluorescence
signals during imaging amplifying signals. However, the exact mechanism of increased
fluorescence at low pH and high gel density is unknown. Future studies are needed to
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elucidate the effects of gel density and acidity on fluorescence signals of dyes diffused
into agarose in gels. In addition, the halo-fluorochromism of PNAs appears to be greater
in gels than in solution, as measured in chapter 2. Differences in the observed
fluorescence behavior of 3PN may be due to the exclusion of the pH 5.0 measurement,
which had much greater fluorescence than the other pH values in solution. As a result, the
fluorescence of 3PN in gels can more accurately elucidate subtle differences in
fluorescence signals due to increased acidity.
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Figure 3.6. Diffusion of PNAs into gels mimicking tissue conditions. The pressurized
condition is 120 mm Hg as described in the methods section.
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Table 3.2. Calculated flux values for PNAs in gels with and without additional external
pressure.
Flux (kg/(s*cm2))*1010
Additional
Pressure
Gel %***
pH 7.4
pH 7.0
pH 6.0
(mm Hg)
0
0.5
9.76 (9.01-10.47) 10.55 (9.05-12.06) 10.08 (9.01-11.15)
(Atmospheric)
1.0
7.63 (6.95-8.30)
7.12 (6.31-7.94)
5.97 (5.11-6.83)
Additional
Pressure
Gel %***
pH 7.4**
pH 7.0**
pH 6.0**
(mm Hg)
120
0.5
8.23 (7.05-9.41) 9.31 (8.36-10.25)
7.73 (6.14-9.32)
(Pressurized)
1.0
4.35 (3.45-5.24)
7.18 (6.27-8.09)
4.66 (3.81-5.51)
Flux values are reported as mean with 95% CI in parenthesis. Statistical significance is
determined for gel density and pH at each pressure by two-way ANOVA with
Bonferroni’s post-test correction.
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Figure 3.7. Fluorescence of 3PN that has diffused into gels for 24 hours (A).
Fluorescence signal was quantified by IVIS (B).
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3.3.3

Ionic and Serum-Containing Conditions Do Not Induce the Opsonization or

Aggregation of PNAs
Figure 3.8A describes the changes in the absorbance of PNA solutions for up to
24 h in aggregating conditions. The absorbance of PNAs decreased after 1 hour but
slightly increased up to 24 h in cationic, physiological and serum-containing conditions.
However, the absorbance of PNAs in anionic solutions slightly decreased for 24 h after
treatment. No precipitation was observed in the samples over 24 h. Because the
absorbance of PNAs in solution was below 0.3 for all time points (black dotted line),
PNAs did not aggregate. Figure 3.8B shows the diameters of PNAs in aggregating
conditions after 24 h. Changes in PNA diameters are not statistically significant. These
results confirm that PNAs do not significantly opsonize for up to 24 h in aggregating
conditions.
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Figure 3.8. Absorbance (A) and diameter (B) changes of PNAs stored in aggregating
conditions for 24 hours.
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3.3.4

Most Nanoassemblies Remain in the Cell Media During In Vitro Cellular Uptake

Measurements
Figures 3.9A-C describe the uptake of 2PN, 3PN and MG in HT29 cells from 0.56 h post-treatment. Uptake quotients of 2PN, 3PN and MG were calculated from
fluorescence images (Table 3.3). Because uptake quotients (Q) are defined as the ratio of
intracellular to extracellular PNA concentrations, a low Q value (<1) indicates a high
concentration of PNAs in the extracellular space relative to cells, while a high Q value
(>1) indicates a high concentration of PNAs in cells relative to the extracellular space.
Low values of Q for PNA uptake up to 6 h post-treatment indicate that most PNAs
remain in the cell media rather than accumulating inside of cancer cells. In contrast to
PNA uptake quotients, MG uptake quotients increased up to 6 h post-treatment. The high
values of MG uptake quotients suggest that MG accumulates inside of cancer cells.
Figure 3.9D shows the changes in uptake quotient over time for 2PN, 3PN and MG.
Time-dependent differences in uptake quotient for 2PN or 3PN were not statistically
significant, but time-dependent differences for MG were significant. Treatmentdependent differences between uptake quotients of PNAs and MG are not statistically
significant at 0.5 h post-treatment, but they were statistically significant between 1-6 h
post-treatment. In addition, Figure 3.9E shows uptake quotients over time of 2PN and
3PN from 0 to 0.5 h post-treatment. Kinetic parameters from a mathematical model of
nanoparticle uptake in Figure 3.8E are in Table 3.4. 3PN had a larger cellular partition
coefficient (KEQ) and a larger rate constant (k) than 2PN; however, both 2PN and 3PN
had low cellular uptake quotients (Q) compared to small molecules. Cellular partition
coefficients of 2PN and 3PN indicate that the intracellular concentrations of 2PN and
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3PN are 25% and 40% of their extracellular concentrations, respectively. Small t95 values
for both 2PN and 3PN suggest that PNAs are taken up in cells by active processes such as
endocytosis, but that processes such as exocytosis may remove PNAs from the cytosol
and maintain low cellular partition coefficients over time. Rheiner et al. previously
confirmed that cellular uptake of PNAs was performed by endocytosis (76). All PNAs
showed low cellular uptake under in vitro conditions based on concentration ratios. Based
on estimations of molar ratios of PNA uptake accounting for intracellular volume,
extracellular volume and measured cellular partition coefficients (KEQ) of cells in
chamber slides, molar ratios of PNA uptake in cells on chamber slides were less than
0.01. A further analysis of PNA uptake in metastatic tumors or solid tumors is in the
discussion section.
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Figure 3.9. Microscopic fluorescence imaging of 2PN (A), 3PN (B) and MG (C) uptake
into HT29 cells. Uptake of PNAs and MG were compared up to 6 h of treatment (D).
Uptake of 2PN and 3PN was compared up to 0.5 h of treatment (E).
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Table 3.3. Uptake quotients of cells treated with 2PN, 3PN and MG.
Time (h)
Treatment
0.5
1
3
6
2PN
0.37±0.11
0.22±0.12
0.26±0.10
0.27±0.08
3PN
0.33±0.10
0.39±0.11
0.38±0.11
0.40±0.07
MG
0.11±0.12
1.33±0.14***
2.37±0.31***
12.26±1.92***
Uptake quotients are reported as mean±SD (n=3). Differences in uptake quotients
between treatments at each timepoint were compared by a one-way ANOVA with
Bonferroni’s post-test correction. Statistical significance is reported as described in the
methods section.
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Table 3.4. Kinetic parameters of PNA uptake from a first order association model.
PNA
KEQ (unitless)
k (min-1)
t95 (min)
2PN
0.26 (0.25-0.26)*** 0.23 (0.20-0.25)*** 13.2 (11.8-15.0)***
3PN
0.41 (0.40-0.41)*** 0.46 (0.44-0.47)***
6.6 (6.4-6.8)***
Kinetic parameters are reported as mean with 95% CI in parentheses. Differences in
kinetic parameters between each model were compared by an extra sum of squares F
test. Statistical significance is reported as described in the methods section.
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3.3.5

PNAs Accumulate Throughout Cancer Cells in Solid Tumors
Figure 3.10 shows fluorescence imaging of tumors, livers, spleens, kidneys and

lungs from mice bearing PDX tumors. Weak fluorescence signals can be observed in
PDX tumors at 1 hour post-injection, but the signal increases up to 24 hours postinjection. In contrast to PDX tumors, the fluorescence signals in normal organs are
minimal. Figure 3.11A shows microscopic fluorescence imaging of PDX tumors from
mice treated with 3P’A546. Weak fluorescence can be observed at 4 hours post-injection,
but the fluorescence signal increases up to 24 hours post-injection. The fluorescence of
PNAs is near the fluorescence of nuclei in all images, suggesting that PNAs accumulate
in PDX tumor cells. Differences between the measured cellular uptake in Figures 3.9 and
3.11A may be due to biological differences between cancer cells and patient-derived
tumor cells, extracellular PNA concentrations, exposure times or removal of extracellular
PNA signal due to sample preparation. Figure 3.11B shows microscopic fluorescence
imaging of PNAs and EpCAM antibodies, which indicates the colocalization of PNAs
with cancer cells. The fluorescence of PNAs remains near the fluorescence of EpCAM,
suggesting that PNAs accumulate in EpCAM-expressing CRC cells rather than other
tumor-associated cells such as macrophages. Figure 3.11C show microscopic
fluorescence imaging of PNAs and CD31 antibodies, which indicates the colocalization
of PNAs and blood vessels in tumors. Fluorescence of PNAs does not colocalize with
CD31 fluorescence, suggesting that PNAs diffuse out of blood vessels and enter the
interstitium of tumors. Figure 3.12 shows digitally zoomed versions of the microscopic
fluorescence images in Figure 3.11.
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Figure 3.10. Macroscopic fluorescence imaging of PDX tumors and organs from mice
treated with 3P’A546 (10 mg/kg).
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Figure 3.11. Microscopic fluorescence imaging (20x) of PNA uptake in PDX tumors over
24 hours (A). Fluorescence images at 8 hours were also taken with EpCAM (B) or CD31
(C) staining. In all images, blue is the cell nucleus, red is PNAs and green is EpCAM or
CD31. The arrows in (C) indicate blood vessels.
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Figure 3.12. Digitally zoomed microscopic fluorescence imaging (80x) of PDX tumors. In
all images, blue is the cell nucleus, red is PNAs and green is either EpCAM or CD31.
The arrows in (B) and (C) indicate cancer cells and blood vessels, respectively.
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3.3.6

Halo-Fluorochromic PNAs Enable the Detection of Liver Metastasis and the

Reduction of Background Signals from Healthy Tissue
Figure 3.13 shows a fluorescence signal optimization of 3P’A546 in liver. The
fluorescence of the liver increased with increasing doses of PNAs, but the fluorescence
signal was not evenly distributed throughout the liver receiving the 20 mg/kg dose. Based
on these measurements, a dose of 10 mg/kg was selected to maintain a consistent PNA
concentration throughout liver tissue. Figure 3.14A shows the fluorescence of liver,
kidney and lungs from mice bearing liver MCRC tumors that were treated with 3P’A546.
The presence and location of metastatic tumors in the livers of these mice was confirmed
by brightfield and GFP imaging of the liver. PNAs fluoresce throughout the liver, kidney
and lungs. In addition, fluorescence is observed in both healthy tissue and MCRC tumors
in the liver. Figure 3.14B shows the fluorescence of liver from either healthy mice or
mice with liver MCRC tumors that were treated with halo-fluorochromic 3PN. The GFP
signal in liver confirms that MCRC tumors were successfully established in mice. No
fluorescence signal is observed in healthy mice treated with 3PN, suggesting that halofluorochromism of PNAs reduces fluorescence signals from PNAs in in healthy tissue. In
mice bearing liver MCRC tumors, the halo-fluorochromic signal from 3PN colocalizes
with GFP, but there are differences between the shapes of each signal. Figure 3.15 shows
microscopic fluorescence images of the boundary between the healthy liver and
metastatic tumors from mice treated with either PBS or 3P’A546. The fluorescence of
3P’A546 is stronger in liver tissue than in metastatic tumors. Figure 3.16 shows
microscopic imaging of healthy liver and MCRC tumor tissues from mice treated with
either PBS or 3P’A546. Hoechst staining indicates that nuclei are less dense in healthy
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liver tissue compared to MCRC tumors. In addition, the nuclei in liver tissue are larger
than the nuclei in metastatic tumors. CD31 staining indicates that the number of blood
vessels per unit area is greater in liver tissue than in MCRC tumors, and that the
distribution of blood vessels in the healthy liver is more homogeneous than in metastatic
tumors. Differences in blood vessel density suggest that MCRC tumors are less perfused
with blood than healthy liver tissue. Weak fluorescence signal corresponding to 3P’A546
throughout liver tissue suggests that PNAs accumulate throughout liver tissue. Figure
3.17 shows digitally zoomed microscopic imaging of PNAs in healthy liver and liver
MCRC tumors. Although most PNAs are evenly distributed throughout tissue samples,
some PNAs fluoresce in small circles near outside edges of CD31 fluorescence. The
exact cause of these spots is unknown. It should be noted that these small circles are
difficult to observe in large microscopic images and do not significantly contribute to
overall fluorescence signals in liver tissue. In addition, weak fluorescence of 3P’A546 is
observed in the space near blood vessels surrounding colonies of cancer cells in
metastatic tumors, but the fluorescence signal decreases near center of metastatic cancer
cell colonies. The fluorescence signal of 3P’A546 in microscopic images is weaker than
the fluorescence signal from macroscopic images, suggesting that the fixing and staining
methods used to prepare tissue samples may extract extracellular PNAs from tissue
samples and decrease fluorescence signals.
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Figure 3.13. Macroscopic fluorescence imaging of liver, spleen, kidney and lung from
mice treated with 3P’A546 at various doses.
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Figure 3.14. Macroscopic fluorescence imaging of non-halo-fluorochromic and halofluorochromic PNAs (10 mg/kg for each) in healthy liver and liver metastatic tumors.
Fluorescence images of liver, kidney and lung tissue from mice bearing orthotopic liver
MCRC tumors treated with 3P’A546 (A). Fluorescence imaging of liver from healthy
mice or mice bearing orthotopic liver MCRC tumors treated with 3PN (B).
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Figure 3.15. Microscopic fluorescence imaging (20x) of 3P’A546 at the boundary of
healthy liver and metastatic tumors (10 mg/kg). In all images, blue is the cell nucleus, red
is PNAs and green is CD31.
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Figure 3.16. Microscopic fluorescence imaging (20x) of 3P’A546 in healthy liver or
metastatic tumors (10 mg/kg). In all images, blue is the cell nucleus, red is PNAs and
green is CD31.
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Figure 3.17. Digitally zoomed microscopic fluorescence imaging of healthy liver and
metastatic tumors. Blue corresponds to nucleus, green corresponds to CD31 and red
corresponds to 3P’A546.
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3.3.7

Computational Simulations of PNA Accumulation in Metastatic Tumors
Figure 3.18 shows the distribution and accumulation of PNAs in metastatic CRC

tumors after systemic, intravenous bolus injection simulated by Frieboes et al. for low,
medium and high tissue vascularization densities. Physical parameters for PNAs and
biological parameters for tumors are in Table 3.5. The computational model is based on
previous results (122), and it builds on computational modeling of a reaction-diffusioncontrolled reactor simulating a metastatic tumor (123, 124, 132). PNA concentrations in
the blood, indicated by the tumor blood vessels, decrease over time as PNAs are cleared
from the plasma. Most PNAs remain in the extracellular matrix surrounding the lesion
and the tumor tissue adjacent to it. As the vascular density increases, the PNAs
accumulate at higher concentrations in the periphery of the metastatic tumors. The figure
also indicates that PNA accumulation near the metastatic tumors is projected to decline to
about half of its initial value 12 h post-treatment. In order to quantify PNA accumulation
in various regions of the metastatic lesion, the uptake profiles of PNAs were also
simulated.
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Table 3.5. Parameters for the computational model of PNA distribution in metastatic
tumors.
Parameter
Value
Reference
-1
CRC Tumor proliferation rate
1 day
Measured (134)
CRC in liver tumor necrosis threshold
0.515
Calibrated
CRC in liver tumor hypoxic threshold
0.575
Calibrated
Oxygen diffusivity
1 (*)
(136)
Oxygen transfer rate from vasculature
5 (*)
(136)
Oxygen uptake rate by proliferating tumor cells
1.5 (*)
(136)
Oxygen uptake rate by hypoxic tumor cells
1.3 (*)
(136)
Oxygen uptake rate by tumor microenvironment
0.12 (*)
(136)
Oxygen decay rate
0.35 (*)
(136)
PNA diffusivity
0.3 (*)
Estimated (140)
PNA transfer rate from vasculature
5 (*)
Estimated (140)
PNA uptake rate by tumor cells
1.5 (*)
Estimated (140)
PNA plasma clearance half life
14.4 h
Estimated (142)
The parameters denoted with (*) were rescaled by the characteristic length (1 cm), the
characteristic time (1 s) or oxygen diffusivity (1*10-5 cm2/s) as described in previous
work (143).
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Figure 3.18. Computational simulations of PNA distribution in metastatic tumors. Images
on the left represent metastatic tumors with tumor vessels (brown), proliferating (red),
hypoxic (blue) and necrotic region (brown). Images in center and right represent PNA
distribution in the tumors on the left of each row.
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Figure 3.19 describes PNA accumulation based on vasculature surface area (µm2,
based on vessel length x circumference) for up to 60 h following treatment. One day (24
h) after treatment, the total PNA concentration has decreased by 75%, 80%, and 90% for
the low, medium and high vascularization cases compared to the initial total PNA
concentration, which reflects increasing PNA washout with a higher number of blood
vessels. The total PNA concentration has the largest peak for the case of medium
vascularization (0.20), while the peak concentration is reached in the hypoxic tissue for
the high vascularization case (0.057). Figure 3.20 quantifies the simulated PNA
accumulation per vasculature surface area at 1.8 and 12 h post-treatment as a function of
the degree of vascularization and the tumor region (proliferating, hypoxic, necrotic, and
blood vessels). At 1.8 h post-treatment, the PNA concentration is 10x, 7.8x, and 7.5x
higher in the proliferating regions than in the hypoxic regions for the low, medium, and
high vascularization conditions, respectively. By 12 h, these concentrations become
more comparable (1.8x, 2x, and 1.2x, respectively), with PNA accumulation decreasing
by 75% in the proliferating regions, by 50% in the tumor blood vessels, while also
increasing by 100% in the hypoxic tissue regardless of vascular density. In all cases, the
accumulation of PNAs in the necrotic regions of tumors is negligible. These
computational modeling results suggest that although a higher number of PNAs is
projected to be initially taken up by the proliferating regions, accumulation in the hypoxic
(and more acidic) tissue of the lesion is expected to increase and remain steady for
several hours. Further, this accumulation is projected to be mostly independent of the
degree of vascularization of the tissue surrounding the lesion.
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Figure 3.19. Distribution-time profiles of PNAs in simulated metastatic tumors with low,
medium and high vascularization.
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Figure 3.20. Distribution Profiles of PNAs in simulated metastatic tumors at 1.8 and 12
hours post-treatment.
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3.4

Discussion

3.4.1

PNAs Sustain Fluorescent Dye Concentrations in Tumors
The successful treatment of CRC depends on the effective detection of small

MCRC tumors. Traditional CRC detection methods cannot identify small MCRC tumors
that rarely affect the structure and morphology of the surrounding tissues (144). As a
result, MCRC tumors cannot be easily detected until they become too large to effectively
treat with chemotherapy due to acquired drug resistance (145). Fluorescent dyes are often
used to identify small tumors by visualizing cancer cells, but their clinical applications
have been limited by low signal-to-noise ratios and short half-lives in vivo (146). In order
to overcome these limitations, small molecule fluorescent dyes are often entrapped in
nanoparticles. In previous studies, nanoparticles entrapping fluorescent dyes increased
the strength and duration of fluorescence signals from solid tumors, which allowed for
the fluorescence imaging-guided detection of tumors (46).
Despite their benefits for fluorescence imaging, fluorescent nanoparticles can
hinder the detection of metastatic tumors by increasing background signals in healthy
organs, such as the liver, lung, spleen, or kidney (147, 148). In order to reduce
background fluorescence signals and identify MCRC tumors more accurately and earlier
in their development, PNAs entrapping halo-fluorochromic dyes were developed.
Although halo-fluorochromic PNAs detected liver MCRC tumors in preliminary studies,
their fluorescence signals did not perfectly correspond to liver MCRC tumors. Halofluorochromic PNAs could emit fluorescence only in some sections of acidic tumor
tissue, due to the altered distribution patterns of PNAs in MCRC tumors compared to the
liver (149). Therefore, it was hypothesized that halo-fluorochromic PNAs accumulate in
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the acidic interstitium between MCRC tumors and healthy liver tissue. To test this
hypothesis, the effects of physical and biological factors related to MCRC tumor
detection, such as tissue diffusion, cell interactions, and opsonization, were elucidated.
The effects of these factors were observed in fluorescence images of PNA distribution in
solid tumors, healthy liver tissue and liver MCRC tumors. In addition, fluorescence
images were compared to computational simulations of PNAs in metastatic lesions.
3.4.2

Physicochemical Properties of PNAs Predict Their In Vivo Distribution Profiles
Although PNAs accumulated throughout liver tissue with MCRC tumors, the

diffusion rate of PNAs into tissue was difficult to measure accurately due to fluctuations
in tissue density, interstitial space volume, and tissue pH. To accurately measure tissue
diffusion rates for PNAs, agarose gel tissue mimics with controllable mass transport
properties such as density and pH were prepared. As described in the methods section,
the gel densities in this study mimic the extracellular space between healthy cells (0.5%
w/v) and the keratin mesh surrounding tumors (1.0% w/v). In addition, the pH of gels
was selected to mimic healthy tissue (pH 7.4) and acidic tumor tissue (pH 7.0 and 6.0).
These gels simulate a variety of conditions representative of healthy and tumor tissues.
Mass transport properties of agarose gels have been well studied for physical separation
methods such as electrophoresis and gel blotting. Unlike ionizable molecules that alter
their diffusion rates into agarose gels as a function of pH, PNAs lacking surface charge
had consistent flux into agarose gels between pH 7.4 and 6. Although there were small
pH-dependent variations in flux, these variations did not represent an overall trend. High
gel density reduced PNA flux by about 40% compared to low gel density. Although the
pores in both gels are large enough (50 to 500 nm) for 30 nm PNAs to enter, smaller
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pores may increase the interactions between pore walls and PNAs and slow long-range
diffusion. Therefore, although gel pores should allow PNAs to freely diffuse into tissue
mimics, the experimental data demonstrate a clear correlation between tissue density and
PNA transport.
Despite these findings, it should be acknowledged that gel mimics have physical
and chemical limitations in accurately reproducing tissue conditions. For example, gel
mimics lack lipids and proteins that can affect pore structure and PNA interactions during
diffusion (150). In addition, tumors have high interstitial tissue pressure due to disrupted
lymphatic drainage that can further influence PNA transport into MCRC tumors (151).
Previous studies show that high intratumoral pressure limits the diffusion of small
molecules and nanoparticles into solid tumors (152, 153). A simple pressurized system
was developed to attempt to investigate the effects of pressure on diffusion; however,
because the system pressurized gels from all sides, rather than creating a pressure
gradient through the gel, the system was unlikely to accurately mimic in vivo pressure
conditions. In addition, this system did not account for blood flow, which can increase
nanoparticle transport out of the blood vessels and into interstitial space surrounding
tumors (154, 155). Regardless, pressurized conditions increased short-term entry of
PNAs into tissue mimics (<0.5 h) but failed to further enhance PNA diffusion (> 0.5 h).
This increase may be due to the deformation of gels near the surface increasing the entry
of PNAs into the surface. Future work is needed to develop a robust system that
accurately mimics the flow conditions in tumor vasculature and the pressure conditions in
solid tumors in order to further investigate nanoparticle transport into gel mimics.
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The diffusion of molecules into gel mimics is expected to follow Fick’s second
law of diffusion. Mathematically, this indicates that the concentration-time data should fit
to an unsteady state first order diffusion equation with a constant concentration and a zero
concentration boundary condition. The analytical solution of this equation indicates that
concentration-distance profiles at each timepoint follow an error function distribution,
and total mass-time profiles in gels would follow an exponential function. Preliminary
diffusion experiments using the small molecule NB followed this expected behavior;
however, mass-time plots from 3P’IR820 yielded linear equations with respect to time.
As a result, the flux of PNAs into gels could be determined by the slope of a linear
regression of the mass-time profiles. This unexpected result indicates that there are
fundamental differences between small molecule and nanoparticle diffusion into gels, and
that an unsteady state first order diffusion model may not be appropriate to model
nanoparticle diffusion in gel mimics. Small molecules have small hydrodynamic
diameters (< 1 nm) compared to PNAs (~30 nm), so small molecules can diffuse
unimpeded through gel pores (50-500 nm) compared to small molecules (156).
Interactions between PNAs and the walls of pores in tissue mimics may change their
diffusion behavior from expected profiles (157). In addition, non-linearity of PNA
absorbance due to the heterogeneous distribution of PNAs in gels could increase the
absorbance of PNAs diffused into gels at later timepoints and artificially increase
measured flux rates. Therefore, the physical properties of PNAs and other nanoparticles
related to pore interactions should be carefully considered in addition to their diffusivity
in solution in order to increase the in vivo diffusion of nanoparticles.
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The opsonization and aggregation of nanoparticles can reduce their tumor
accumulation, decrease their half-life in blood and increase the interactions between
PNAs and immune cells (158, 159). PNAs showed negligible opsonization and
aggregation in vitro, which indicates that the PEG shell shields dyes from
macromolecules in solution and allows dyes to detect the tumor microenvironment.
However, fluorescence imaging of halo-fluorochromic PNAs shows that the PEG shell
does not prevent the diffusion of small acidic molecules into the PNA core allowing the
detection of the acidic environment. Taken together, these results suggest that PNAs with
minimal opsonization allow fluorescent dyes to remain in the blood and detect acidic
tumors or tumor metastasis.
The accumulation of halo-fluorochromic PNAs in the cytosol or in the endosomes
of cancer cells can prevent the detection of the acidic extracellular tumor
microenvironment. In vitro cellular uptake measurements indicated that only a small
fraction of PNAs by mole or mass entered cells, but these conditions had fewer cells and
greater extracellular volume than solid tumors. The molar ratio of PNA uptake in cells of
tumors at equilibrium is calculated following equation 3.25.
𝐸𝐸𝐸𝐸

𝑁𝑁𝑖𝑖𝑖𝑖𝑖𝑖
𝐸𝐸𝐸𝐸

𝑁𝑁𝑒𝑒𝑒𝑒𝑒𝑒

= 𝐾𝐾𝐸𝐸𝐸𝐸 ∗

𝑉𝑉𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐 ∗𝑁𝑁𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐 ∗𝜌𝜌𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡 ∗𝑉𝑉𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡
𝑉𝑉𝑒𝑒𝑒𝑒𝑒𝑒 ∗𝑉𝑉𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡

(3.25)

In equation 3.25, KEQ and Vext are unitless, Vcell has units of cm3 per cell, Ncell has
units of cells per g of tumor tissue, ρtumor has units of g per cm3, and Vtumor has units of
cm3. If the spatial properties of tumors are assumed to be independent of volume, then the
results are independent of Vtumor. Experimental measurements by Park et al. indicated that
solid xenograft tumors have a density (ρtumor) of 0.79 g/cm3 (160). Solid tumors are often
assumed to contain 109 cells per gram of tumor tissue (Ncell), but it should be noted that
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this value has been challenged for some types of tumors (161). In addition, Vestvik et al.
estimated the extracellular fluid volume ratio (Vext) of human melanoma xenograft tumors
to be between 7.1 to 27.1% based on the cell type (162). Table 3.6 contains calculated
molar ratios of 2PN and 3PN uptake for solid tumors with the extracellular fluid volume
ratios 7.1, 17.1 and 21.7%. After accounting for the decreased extracellular space and
increased cell density in tumors, the estimated in vivo molar ratio of PNAs in cells is
greater than the in vitro measured ratio. In order for this calculation to be valid, it is
assumed that the biological factors affecting KEQ, such as a constant surface area-tovolume ratio of cancer cells and the homogeneous distribution of PNAs in the interstitial
fluid surrounding cancer cells, remain consistent from in vitro conditions to in vivo
conditions. The decreased surface area-to-volume ratios of cancer cells and the
heterogeneous distribution of PNAs in solid tumors may significantly reduce the
measured equilibrium constant in vivo.
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Table 3.6. Calculated molar ratios of PNA uptake using the spatial properties of solid
tumors.
Extracellular Fluid Volume Ratio (%)
PNA
7.1
17.1
27.1
2PN
5,800 (5,600-6,000) 2,400 (2,300-2,500) 1,500 (1,400-1,600)
3PN
9,100 (8,900-9,300) 3,800 (3,700-3,900) 2,400 (2,300-2,500)
Calculated molar ratios are reported as mean with 95% CI in parentheses. The
confidence intervals contain errors that were propagated from the equilibrium constant
in equation 3.25. Because these values are calculated estimations and not measured
values, they were not compared statistically.
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The accumulation of halo-fluorochromic PNAs in acidic endosomes or lysosomes
could interfere with the detection of the acidic tumor microenvironment. Fluorescence
signals of halo-fluorochromic PNAs were not observed in healthy tissue, suggesting that
fluorescence signals from PNAs in endosomes or lysosomes of healthy cells is not
sufficient to detect halo-fluorochromic PNAs. Videos of live cell uptake of 3PN showed
small circular spots traveling through cells, suggesting that some PNAs were present in
endosomes. However, these endosomes quickly disappeared, suggesting that 3PN can
escape endosomes and enter the cytosol. Fluorescence imaging of cells stained with
lysosome-sensitive dyes indicated that PNAs with a hydrophobic core environment
escaped endosomes and entered the cytosol (76). However, it should be noted that some
PNAs (~10% of intracellular fluorescence) remained in endosomes, and the fluorescence
of PNAs in endosomes or lysosomes may contribute to the overall fluorescence signals of
halo-fluorochromic PNAs in tumors.
It is often assumed that nanoparticle uptake by cells depends on interactions
between the nanoparticle shell and the surface of the cell membrane. Intracellular uptake
of PNAs reached equilibrium within 0.5 h of initial treatment, but small molecules that
diffuse through the cell membrane accumulate in cells up to 24 hours post-treatment.
Surprisingly, hydrophobic core modifications slightly increased the uptake of PNAs
despite the PEG shell, suggesting that the core of PNAs can weakly interact with the cell
membrane through hydrophobic interactions and slightly increase cellular uptake.
Differences in cellular uptake mechanisms between samples can contribute to
differences in uptake behavior. First, MG and PNAs had distinct cellular uptake profiles
up to 6 hours post-treatment. Although PNAs remained outside of cells and quickly
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reached equilibrium with the surrounding environment, MG continued to accumulate
inside cells up to 6 h post-treatment. MG is a cell membrane-permeable dye that initially
accumulates in mitochondria of cells due to mitochondrial membrane potential (163).
Due to its lipophilicity at physiological pH, MG can enter cells by diffusion through the
cell membrane. Because PNAs are large and contain a hydrophilic shell, they are unlikely
to diffuse through the cell membrane. Previous studies indicate that PNAs enter cells
through energetic processes such as endocytosis (76). However, differences in
equilibrium constants and rate constants were observed between the uptake of 2PN and
3PN, which should contain similar hydrophilic shells due to PEG substitution.
Differences between the diameters of 2PN (~25 nm) and 3PN (~35 nm) could slightly
increase the uptake of 3PN compared to 2PN. In addition, increased adsorption of 3PN to
the cellular membrane could contribute to increased apparent uptake. Simulated
illumination methods such as the ApoTome were considered for more sensitive imaging
of the cell membrane, but poor spatial resolution of cells imaged by these methods
compared to confocal microscopy limited their application for cell membrane imaging
(164). In future studies, confocal microscopy of single live cells treated with PNAs could
elucidate the differences in spatial distribution between 2PN and 3PN and indicate if
differences in cellular uptake are due to extracellular membrane accumulation or
intracellular cytosol accumulation.
3.4.3

Computational Simulations of PNA Accumulation in Metastatic Tumors

Overcome the Limitations of Microscopic Fluorescence Imaging
Clinicians typically use microscopic fluorescence images of patient tissues from
biopsy samples to identify tumors and determine effective treatment regimens.
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Macroscopic fluorescence imaging indicated that PNAs accumulate in PDX tumors and
liver bearing MCRC tumors, but microscopic fluorescence images had decreased
fluorescence compared to macroscopic images. Macroscopic fluorescence images of
normal organs and tumors are taken immediately after collection, but microscopic images
require significant sample preparation prior to imaging. For example, tissue samples in
this study were washed, stained, treated and fixed to microscope slides prior to imaging.
Tissue washing may extract water-soluble PNAs from the extracellular space and
decrease fluorescence signals, but the cell membrane may prevent the extraction of PNAs
from the cytosol (165). Therefore, microscopic fluorescence imaging may underestimate
extracellular PNA concentrations in tissues. It should be noted that differences in
detection method sensitivity could also contribute to changes in fluorescence signals
between macroscopic and microscopic images. Specifically, increased sensitivity of the
IVIS compared to the fluorescence microscope could increase fluorescence signals in
macroscopic images compared to microscopic images. However, the fluorescence of NBlabelled PNAs was stronger under a fluorescence microscope than under an IVIS, and
decreased concentrations of 3PN had to be used in cellular uptake experiments compared
to the IVIS characterization experiments in chapter 2. In order to investigate changes in
extracellular PNA concentrations following tissue sample preparation, computational
simulations of metastatic tumors were used to predict PNA accumulation in these tumors.
Computational simulations of PNA distribution in metastatic tumors were used to
quantitatively assess the potential for the early and accurate detection of tumor
metastasis. These simulations indicate that PNAs are expected to readily accumulate near
the perimeter and within tumor metastases. This accumulation is projected to remain
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steady within hypoxic (more acidic) tumor regions. This is consistent with the
experimental results showing that PNAs near the perimeter of tumors can increase
fluorescence and help identify the acidic environment of metastatic tumors. In the
simulation, the uptake rate of PNAs by cancer cells was assumed to be equal to the
uptake rate of oxygen. This assumes the highest expected value for the uptake of
nanoparticles without receptor-targeting ligands. Decreased uptake parameters of PNAs
would increase extracellular concentrations of PNAs and increase the predicted
accumulation of PNAs in the hypoxic and necrotic regions of metastatic lesions. In the
future, the computational simulations could be improved by calculating uptake
parameters for PNAs in proliferating, hypoxic or necrotic regions of metastatic tumors
and determining the effects of extracellular pH, oxygen concentrations and angiogenesis
on PNA uptake parameters.
3.4.4

Mechanism for the Halo-Fluorochromic Detection of Liver Metastatic Tumors
Determining a mechanism for the halo-fluorochromic detection of liver MCRC

holds promise to improve the future detection of small MCRC tumor foci. The results
from this study suggest that PNAs diffuse throughout healthy and tumor tissue, and that
some PNAs remain outside of cancer cells. Macroscopic imaging implies that halofluorochromic PNAs accumulate in acidic MCRC tumor tissue and fluoresce in the
interstitial space between liver cells and tumors. However, microscopic imaging showed
only small amounts of PNAs accumulating in interstitial space, probably because PNAs
outside of cells were extracted during sample preparation for microscopic imaging.
Nevertheless, non-halo-fluorochromic PNAs accumulated throughout liver tissue and
failed to identify MCRC tumors, while halo-fluorochromic PNAs fluoresce strongly in
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acidic microenvironments and identify MCRC tumors. Although some PNAs are taken
up by Kupffer cells in the liver, their influence on overall images would be relatively
small. Future studies should focus on determining the minimum size of MCRC tumor
foci that halo-fluorochromic PNAs can detect effectively.
3.5

Conclusions
Halo-fluorochromic PNAs were developed as a tool for the early and accurate

detection of liver MCRC tumors by imaging the periphery of acidic tumor tissues while
minimizing signals from liver stroma. PNAs entrapping halo-fluorochromic dyes showed
low opsonization, cellular uptake, and tissue diffusion, which allowed PNAs to enter the
extracellular space of the liver. Macroscopic and microscopic imaging of PDX tumors
showed that PNAs accumulate throughout primary tumors. Non-halo-fluorochromic
PNAs diffuse through the healthy liver and hinder the detection of liver MCRC tumors,
but halo-fluorochromic PNAs emit fluorescence mainly near acidic tumors and reduce
background fluorescence signals from healthy liver. Computational simulations were
used to evaluate halo-fluorochromic PNA detection of small metastatic CRC tumors early
in development that cannot be detected by traditional imaging methods. These results
suggest that halo-fluorochromic PNAs may detect MCRC tumors more effectively than
small molecule dyes or nanoparticles modified with traditional dyes.
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CHAPTER FOUR
SOLVATO-FLUOROCHROMIC METHODS AS AN APPROACH TO OVERCOME
THE LIMITATIONS OF CHROMATOGRAPHY-BASED METHODS FOR
DIALYSIS-BASED DRUG RELEASE MEASUREMENTS
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4

SOLVATO-FLUOROCHROMIC METHODS AS AN APPROACH TO

OVERCOME THE LIMITATIONS OF CHROMATOGRAPHY-BASED METHODS
FOR DIALYSIS-BASED DRUG RELEASE MEASUREMENTS
4.1

Introduction
PNAs can serve as nanoscale carriers delivering anticancer drugs to solid tumors,

and they can increase drug accumulation in tumor cells by fine-tuning drug release rates
within the interstitial and intercellular spaces of tumors (134, 142, 166-172). Drug release
rates from PNAs have been controlled by modulating their polymer composition, particle
stability, and chemical interactions with drug molecules (173-175). The antitumor
activity of PNAs was expected to change as a function of their drug release rates (176183). However, in vivo drug release rates from PNAs were difficult to predict from in
vitro measurements because of complicated interactions between nanoassemblies and
released drugs in vitro (184, 185).
Dialysis-based methods are often used to determine in vitro drug release rates for
PNAs and other nanoparticle drug carriers (186-191). Under typical experimental
conditions, drug-loaded nanoparticles are added into a dialysis cassette to release drugs
over time, and released drugs diffuse through the dialysis membrane into a large volume
of buffer solution (dialysis sink). Analytical methods such as HPLC or light spectroscopy
are then used to quantify the drug remaining inside the dialysis solution and predict drug
release patterns. However, these analytical methods cannot distinguish between released
drugs from the nanoparticle carrier and entrapped drugs within the dialysis cassette. To
address this issue, investigators have modified traditional dialysis methods for measuring
nanoparticle drug release to use tangential flow, ultrafiltration, electrodialysis, surfactants
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or organic solvents. These modifications attempt to either facilitate released drug
diffusion through the dialysis membrane into the dialysis sink or to sequester released
drugs within the dialysis cassette and improve sink conditions (192-198). In addition,
computational modeling has corrected for in vitro interactions between PNAs and
released drugs in the dialysis cassette (199, 200).
Despite these efforts, the accuracy of drug release rates predicted by both
traditional and modified dialysis methods remains questionable. Drug release profiles
from dialysis-based methods are often fit to simple exponential models, which predict
drug release rates based on four main assumptions: 1) all drug in the dialysis cassette is
encapsulated in nanoparticles, 2) nanoparticles and dialysis membranes do not interact
with released drug, 3) released drug is quickly removed from the dialysis cassette, and 4)
released drug in the dialysis cassette does not affect the release rate of drug-loaded
nanoparticles. Unfortunately, environmental factors such as molecular interactions and
complicated mass transfer effects can invalidate some, if not all, of these assumptions.
Drug binding to nanoparticles after release from the hydrophobic core can cause
unrealistically slow drug release rates (64). In addition, drug adsorption to dialysis
membranes can alter measured drug release rates. The adsorption of released drugs in the
dialysis solution to the dialysis membrane can remove released drugs from the dialysis
solution and increase the accuracy of chromatography-based drug release measurements,
but rapid drug adsorption to the dialysis membranes followed by slow desorption of drug
into the dialysis solution could also cause unrealistically slow drug release profiles (177,
184). The slow diffusion of hydrophobic drugs out of the dialysis cassette can also
increase the residence time of released drugs inside the cassette. As a result, a measured
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in vitro drug release rate is often different from its corresponding in vivo release rate.
Computational models cannot easily compensate for these modeling errors unless the
specific contributions from encapsulated drug, bound drug, and released drug inside a
dialysis cassette to the overall drug release rate can be measured. The isolation of these
various drug species during drug release measurements from nanoparticle drug carriers
remains challenging. Therefore, there is a critical need to develop a novel method to
measure drug release profiles of nanoparticles and predict drug release rates in a facile
and accurate manner.
Based on this background, this study developed and evaluated a novel method to
determine drug release rates from PNAs and potentially other types of nanoparticles with
improved convenience and accuracy compared to traditional chromatography-based
methods. This method employs solvato-fluorochromism (SFC), which was shown in
chapter 2 and in the literature to be useful for analyzing the hydrophobicity of the PNA
core and determining drug entrapment (201). Because the fluorescence of NB is
quenched in water, potential interactions between free NB and released drug in solution
should not interfere with fluorescence measurements. In addition, because SFC occurs
over a short distance, NB in the core of PNAs should not interact with released drug.
Therefore, in comparison to chromatographic methods that cannot distinguish various
drug species in dialysis cassettes, SFC-based methods are expected to elucidate molecular
interactions specifically between nanoparticles and drugs entrapped in the nanoparticle
core.
In this study, HPLC- and SFC-based methods were compared to determine drug
release rates from NB-conjugated PNAs in dialysis cassettes with varying core conditions
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that modulate drug entrapment and release (Figure 4.1). NB-conjugated PNAs with an
ionic or hydrophobic core were synthesized as described in chapter 2 and reported in the
literature (201). Carfilzomib (CFZ) and docetaxel (DOC) were used as clinically relevant
model anticancer drugs with well-studied physicochemical and biological properties. To
evaluate drug diffusion effects on drug release measurements, hydrophobic excipients
(palmitate and deoxycholate) were added to PNAs to force entrapped drugs into the
center of the nanoparticle core. Mathematical modeling was also used to elucidate the
effects of drug binding and diffusion on each measurement method. Therefore, the goal
of this study was to compare HPLC- and SFC-based methods for measuring drug release
from dialysis cassettes and to evaluate the potential of the SFC method for the
determination of drug release rates from nanoparticles.
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Figure 4.1. Graphical description of solvato-fluorochromism (A) as a fluorescence-based
drug release measurement method to overcome the limitations of HPLC-based drug
release methods (B) and measure drug release (C).
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4.2

Materials and Methods

4.2.1

Materials
2PN and 3PN PNAs were prepared as described in chapter 2. Palmitic acid (PAL)

and deoxycholic acid (DOCA) were purchased from Sigma Aldrich (St. Louis, MO).
Dimethyl sulfoxide (DMSO), phosphate buffered saline (PBS), McCoy’s 5A cell media,
ethanol, and dialysis cassettes with a 10 kDa MWCO were purchased from Fisher
Scientific (Waltham, MA). CFZ and DOC were purchased from LC Laboratories
(Woburn, MA).
4.2.2

Drug Loading of Unstabilized and Excipient-Stabilized PNAs
Stock solutions of PNAs (2PN and 3PN, 100 mg/ml), drugs (CFZ and DOC, 1

mg/ml), and excipients (PAL and DOCA, 100 mg/ml) were prepared in ethanol. PNA
(100 μl) and drug solutions (1 ml) were mixed in a round bottom flask and evaporated at
reduced pressure to create a thin film. These thin films were reconstituted in water and
centrifuged at 1000 RPM for 1 minute to remove free drug, excess excipients, and other
insoluble impurities. Drug-loaded PNAs in the supernatant were collected after freeze
drying and stored at -20 °C. In addition, excipient-stabilized PNAs were prepared by
adding excipient (20 μl), PNA (100 μl) and drug solutions (1 ml) into a round bottom
flask and repeating this procedure. Drug concentrations in drug-loaded PNA solutions
were determined by HPLC (Agilent Eclipse XDB-C18 column, 40 °C, 1 ml/min mobile
phase) for CFZ (55:45 ACN/water with 0.1% formic acid, 200 nm, 2.01 min elution) and
DOC (65:35 ACN/water with 0.1% formic acid, 230 nm, 2.65 min elution). Drug peaks
in each sample were compared to calibration curves of known concentration drug
standards. The drug loading efficiency and encapsulation efficiency were defined as the
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weight ratio of drug to drug-loaded PNAs and the weight ratio of drug in PNAs to total
drug added, respectively. In addition, the molar drug loading efficiency was calculated as
the molar ratio of drug to drug-loaded PNAs.
4.2.3

HPLC-Based and Solvato-Fluorochromic Drug Release Measurements
Drug-loaded PNAs were dispersed at 10 mg/ml in PBS, and the solutions (1 ml)

were dialyzed into 1 l of PBS at 37 °C. Aliquots (100 μl) from within the dialysis
cassettes were removed after 0, 1, 3, 6, 24 and 48 hours, and drug concentrations were
quantified by HPLC as described in the previous section. For the SFC method, drugloaded PNAs were dispersed at 10 mg/ml in PBS, and the solutions (1 ml) were dialyzed
into 1 l of PBS at 37 °C. Aliquots (100 μl) from within the dialysis cassettes were
removed after 0, 1, 3, 6, 24 and 48 hours, and drug concentrations were quantified as
described below. In order to optimize the SFC method for measuring drug release
profiles, fluorescence emission spectra of drug-loaded and empty PNAs were initially
measured using several excitation wavelengths. From these spectra, excitation conditions
for fluorescence spectra for 2PN (610 nm) and 3PN (580 nm) were selected for
measurement using a plate reader (Spectramax M5, Sunnyvale, CA). These fluorescence
spectra identified optimal excitation and emission wavelengths for analyzing 2PN (Ex
610 nm/Em 670 nm) and 3PN (Ex 580 nm/Em 630 nm) drug release profiles.
Fluorescence measurements were converted to normalized drug concentrations. Briefly,
the fluorescence of empty PNAs was subtracted from the fluorescence of each SFC
measurement, and the fluorescence was normalized to the initial fluorescence of each
drug-loaded PNA. Drug release profiles from dialysis-based and SFC-based methods
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were fitted to first order release kinetics models using Prism 5 (Graphpad, La Jolla, CA).
Equation 4.1 below describes a first order kinetic model for drug release.
𝐶𝐶

𝐶𝐶0

= 100 ∗ 𝑒𝑒 −𝑘𝑘∗𝑡𝑡

(4.1)

In equation 4.1, C/C0 is the percent drug concentration in samples at time t
relative to the initial drug concentration, and k is the rate constant. The time t has units of
hours, while the rate constant has units of inverse hours. C/C0 is unitless. The drug
release half-life t1/2 was defined in equation 4.2 as the time for drug in samples to reach
50% of the initial concentration.
𝑡𝑡1/2 =

ln(2)

(4.2)

𝑘𝑘

The drug release half-life has units of hours.
4.2.4

Free and Spiked Drug Release Measurements using HPLC-based and Solvato-

Fluorochromic Methods
The release of free CFZ (1 or 0.5 mg/ml CFZ), free CFZ (1 mg/ml) spiked into
2PN solution (10 or 5 mg/ml) and drug-loaded 2PN (10 or 5 mg/ml) was measured using
both the HPLC and the SFC method. Briefly, CFZ was dissolved in DMSO at 100 mg/ml
to prepare a stock solution. For free drug release experiments, either 10 or 5 μl of drug
solution was added to 990 or 995 μl of PBS, respectively. For spiked drug release
experiments, 10 μl of drug solution was added to 990 μl of 2PN solution (5 or 10 mg/ml
in PBS). CFZ-loaded 2PN was also dispersed in PBS at 5 or 10 mg/ml for drug-loaded
PNA release experiments. Each colloidal solution (1 ml) was dialyzed into 1 l of PBS at
37 °C under sink conditions. Drugs remaining in PNAs were quantified using both the
HPLC-based and SFC methods. As a negative control for the effects of organic solvents
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on the SFC method, SFC measurements were repeated while adding blank DMSO (10 μl)
to 990 μl 2PN solution (5 or 10 mg/ml PBS).
4.2.5

Mechanistic Modeling of Drug Release from PNAs
A mechanistic model of drug release kinetics from PNAs was derived to account

for weak drug binding to the shell of PNAs and drug diffusion through the dialysis
membrane. The mechanistic model was based on previous studies of drug release kinetics
from polymer micelles (184). Mass balances were written for released drug (MR) and
total drug remaining (MT) in dialysis cassettes in equations 4.3 and 4.4. Encapsulated
drug in the core of PNAs was defined as ME, while drug that is weakly bound to PNAs
and released drug in the dialysis solution were defined as MR,P and MR,W, respectively.
𝑀𝑀𝑅𝑅 = 𝑀𝑀𝑅𝑅,𝑃𝑃 + 𝑀𝑀𝑅𝑅,𝑊𝑊

(4.3)

𝑀𝑀𝑇𝑇 = 𝑀𝑀𝐸𝐸 + 𝑀𝑀𝑅𝑅,𝑃𝑃 + 𝑀𝑀𝑅𝑅,𝑊𝑊

(4.4)

In equations 4.3 and 4.4, all mass values have units of micrograms.
Equation 4.4 was divided by the total volume of the dialysis cassette (VT) in order
to convert total mass to total concentration. Equation 4.5 describes total drug
concentration in terms of volume.
𝐶𝐶𝑇𝑇 =

𝑀𝑀𝑅𝑅,𝑊𝑊 +𝑀𝑀𝐸𝐸 +𝑀𝑀𝑅𝑅,𝑃𝑃

(4.5)

𝑉𝑉𝑇𝑇

In equation 4.5, VT has units of milliliters, while CT has units of micrograms per
milliliter in the dialysis cassette. The total volume is assumed to be equal to the volume
of the solution (VW) plus the volume of the PNAs (VP).
In order to convert equation 4.5 into concentration terms for each species, the
mass of each species is converted to the product of its concentration and its species
volume in equation 4.6.
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𝐶𝐶𝑇𝑇 =

�𝐶𝐶𝑅𝑅,𝑊𝑊 ∗𝑉𝑉𝑊𝑊 �+(𝐶𝐶𝐸𝐸 ∗𝑉𝑉𝑃𝑃 )+(𝐶𝐶𝑅𝑅,𝑃𝑃 ∗𝑉𝑉𝑃𝑃 )
𝑉𝑉𝑇𝑇

(4.6)

In equation 4.6, all concentration values have units of micrograms per milliliter,
and all volumes have units of milliliters of volume per species.
Constants a and b are defined as unitless volume ratios of solution and PNAs in
equations 4.7 and 4.8. These values are substituted into equation 4.6 to yield equation 4.9.
𝑎𝑎 =

𝑉𝑉𝑊𝑊

(4.7)

𝑉𝑉𝑇𝑇

𝑉𝑉

𝑏𝑏 = 𝑉𝑉𝑃𝑃

(4.8)

𝑇𝑇

𝐶𝐶𝑇𝑇 = 𝑎𝑎𝐶𝐶𝑅𝑅,𝑊𝑊 + 𝑏𝑏𝐶𝐶𝐸𝐸 + 𝑏𝑏𝐶𝐶𝑅𝑅,𝑃𝑃

(4.9)

Using an estimated 2PN density (1.1 g/ml) and measured dialysis cassette
volume, the calculated values of a for 2PN at 5 and 10 mg/ml were 0.996 and 0.992,
respectively. In addition, the calculated values of b for 5 and 10 mg/ml PNA
concentrations are 0.004 and 0.008, respectively.
Mass balances were written for encapsulated drug, total released drug and drug in
the dialysis sink (MS) in equations 4.10, 4.11 and 4.12.
𝑑𝑑𝑀𝑀𝐸𝐸
𝑑𝑑𝑑𝑑

𝑑𝑑𝑀𝑀𝑅𝑅
𝑑𝑑𝑑𝑑

𝑑𝑑𝑀𝑀𝑆𝑆
𝑑𝑑𝑑𝑑

= −𝑘𝑘𝐶𝐶 𝑀𝑀𝐸𝐸 + 𝑘𝑘𝑅𝑅 𝑀𝑀𝑅𝑅,𝑃𝑃

(4.10)

= 𝑘𝑘𝐷𝐷 𝑀𝑀𝑅𝑅,𝑊𝑊 − 𝑘𝑘𝐷𝐷 𝑀𝑀𝑆𝑆

(4.12)

= 𝑘𝑘𝐶𝐶 𝑀𝑀𝐸𝐸 − 𝑘𝑘𝑅𝑅 𝑀𝑀𝑅𝑅,𝑃𝑃 − 𝑘𝑘𝐷𝐷 𝑀𝑀𝑅𝑅,𝑊𝑊 + 𝑘𝑘𝐷𝐷 𝑀𝑀𝑆𝑆

(4.11)

Mass balances were converted to concentration in equations 4.13, 4.14 and 4.15
by assuming that species volumes remain constant over time, and by substituting mass for
volume times the concentration.
𝑉𝑉𝑃𝑃

𝑉𝑉𝑇𝑇

𝑑𝑑𝐶𝐶𝐸𝐸
𝑑𝑑𝑑𝑑

𝑑𝑑𝐶𝐶𝑅𝑅
𝑑𝑑𝑑𝑑

= −𝑘𝑘𝐶𝐶 𝑉𝑉𝑃𝑃 𝐶𝐶𝐸𝐸 + 𝑘𝑘𝑅𝑅 𝑉𝑉𝑃𝑃 𝐶𝐶𝑅𝑅,𝑃𝑃

= 𝑘𝑘𝐶𝐶 𝑉𝑉𝑃𝑃 𝐶𝐶𝐸𝐸 −𝑘𝑘𝑅𝑅 𝑉𝑉𝑃𝑃 𝐶𝐶𝑅𝑅,𝑃𝑃 −𝑘𝑘𝐷𝐷 𝑉𝑉𝑊𝑊 𝐶𝐶𝑅𝑅,𝑆𝑆 + 𝑘𝑘𝐷𝐷 𝑉𝑉𝑆𝑆 𝐶𝐶𝑆𝑆
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(4.13)
(4.14)

𝑉𝑉𝑆𝑆

𝑑𝑑𝐶𝐶𝑆𝑆
𝑑𝑑𝑑𝑑

= 𝑘𝑘𝐷𝐷 𝑉𝑉𝑊𝑊 𝐶𝐶𝑅𝑅,𝑊𝑊 − 𝑘𝑘𝐷𝐷 𝑉𝑉𝑆𝑆 𝐶𝐶𝑆𝑆

(4.15)

In equations 4.14 and 4.15, VS is the volume of the dialysis sink (1000 ml).
Differential rate equations 4.13, 4.14 and 4.15 were rearranged into equations
4.16, 4.17 and 4.18, respectively. In equation 4.18, 0.001 is calculated volume ratio of the
dialysis cassette (1 ml) to the dialysis sink (1 L).
𝑑𝑑𝐶𝐶𝐸𝐸
𝑑𝑑𝑑𝑑

𝑑𝑑𝐶𝐶𝑅𝑅
𝑑𝑑𝑑𝑑

𝑑𝑑𝐶𝐶𝑆𝑆
𝑑𝑑𝑑𝑑

= −𝑘𝑘𝐶𝐶 𝐶𝐶𝐸𝐸 +𝑘𝑘𝑅𝑅 𝐶𝐶𝑅𝑅,𝑃𝑃

(4.16)

= 𝑏𝑏(𝑘𝑘𝐶𝐶 𝐶𝐶𝐸𝐸 − 𝑘𝑘𝑅𝑅 𝐶𝐶𝑅𝑅,𝑃𝑃 ) − 𝑘𝑘𝐷𝐷 (𝑎𝑎𝐶𝐶𝑅𝑅,𝑊𝑊 − 𝐶𝐶𝑆𝑆 )

= 0.001 ∗ 𝑘𝑘𝐷𝐷 �𝑎𝑎 ∗ 𝐶𝐶𝑅𝑅,𝑊𝑊 − 𝐶𝐶𝑆𝑆 �

(4.17)
(4.18)

The unitless ratio of weakly bound drug to released drug in solution is defined as
the PNA-water partition coefficient (KP) in equation 4.19. Mass balances can be written
for released drug in equation 4.20 and converted to concentration in equation 4.21.
𝐶𝐶

𝐾𝐾𝑃𝑃 = 𝐶𝐶 𝑅𝑅,𝑃𝑃

(4.19)

𝑉𝑉𝑇𝑇 𝐶𝐶𝑅𝑅 = 𝑉𝑉𝑃𝑃 𝐶𝐶𝑅𝑅,𝑃𝑃 + 𝑉𝑉𝑊𝑊 𝐶𝐶𝑅𝑅,𝑊𝑊

(4.21)

𝑅𝑅,𝑊𝑊

𝑀𝑀𝑅𝑅 = 𝑀𝑀𝑅𝑅,𝑃𝑃 + 𝑀𝑀𝑅𝑅,𝑊𝑊

(4.20)

By solving equation 4.21 for CR,P or CR,W and substituting in Kp for CR,W or CR,P,
respectively, the concentration of each species of released drug can be described in terms
of total released drug as in equations 4.22 and 4.23.
𝐶𝐶

𝑅𝑅
𝐶𝐶𝑅𝑅,𝑊𝑊 = 𝑎𝑎+𝑏𝑏𝐾𝐾

𝐾𝐾 ∗𝐶𝐶

(4.22)

𝑃𝑃

𝑃𝑃 𝑅𝑅
𝐶𝐶𝑅𝑅,𝑃𝑃 = 𝑎𝑎+𝑏𝑏𝐾𝐾

(4.23)

𝑃𝑃

Equations 4.22 and 4.23 are substituted into equations 4.16, 4.17 and 4.18 to yield
equations 4.24, 4.25 and 4.26, respectively. In addition, equations 4.22 and 4.23 were
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substituted into equation 4.9, and the equation was rewritten as 4.27. Drug release
profiles were simultaneously fitted to equations 4.24, 4.25, 4.26 and 4.27 using a
weighting factor of 2 to determine kC, kR, KP and kD using Scientist 3.0 (Micromath, St.
Louis, MO).
𝑑𝑑𝐶𝐶𝐸𝐸
𝑑𝑑𝑑𝑑

𝑑𝑑𝐶𝐶𝑅𝑅
𝑑𝑑𝑑𝑑

𝑑𝑑𝐶𝐶𝑆𝑆
𝑑𝑑𝑑𝑑

𝐾𝐾 ∗𝐶𝐶

𝑃𝑃 𝑅𝑅
= −𝑘𝑘𝐶𝐶 𝐶𝐶𝐸𝐸 +𝑘𝑘𝑅𝑅 𝑎𝑎+𝑏𝑏𝐾𝐾

= 𝑏𝑏(𝑘𝑘𝐶𝐶 𝐶𝐶𝐸𝐸 −

𝑃𝑃

𝑘𝑘𝑅𝑅 ∗𝐾𝐾𝑃𝑃 ∗𝐶𝐶𝑅𝑅
𝑎𝑎+𝑏𝑏𝐾𝐾𝑃𝑃
𝑎𝑎∗𝐶𝐶

(4.24)
𝑎𝑎∗𝐶𝐶

) − 𝑘𝑘𝐷𝐷 (𝑎𝑎+𝑏𝑏𝐾𝐾𝑅𝑅 − 𝐶𝐶𝑆𝑆 )
𝑃𝑃

= 0.001 ∗ 𝑘𝑘𝐷𝐷 �𝑎𝑎+𝑏𝑏𝐾𝐾𝑅𝑅 − 𝐶𝐶𝑆𝑆 �

𝐶𝐶𝑇𝑇 = 𝐶𝐶𝑅𝑅 + 𝑏𝑏𝐶𝐶𝐸𝐸

𝑃𝑃

(4.25)
(4.26)
(4.27)

For spiked drug release experiments, all drug in the dialysis cassette is initially
assumed to be released. In contrast, all drug in the dialysis cassette is initially assumed to
be encapsulated in drug-loaded PNA introduced in release experiments.
4.2.6

Chemical Stability and Photostability of Nile Blue
NB was dissolved at 50 μg/ml in McCoy’s 5A cell media and added into a quartz

cuvette. The NB-containing cuvette was stored in the dark at 37 °C while gently mixing.
The absorbance spectrum of NB in the cuvette was measured from 450 nm to 750 nm at
0, 1, 2 and 5 days post-storage. In addition, NB was dissolved at 100 μg/ml in deionized
water and added into a 96 well plate. The fluorescence of NB (Ex 632 nm/Em 680 nm) in
the plate was measured 10 times over a period of 10 minutes.
4.2.7

Statistics
All values in figures are reported as mean±standard deviation of three

measurements. Groups of measurements are compared by one-way ANOVA with
Bonferroni’s post-test correction, and pairs of measurements are compared by a Student’s
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t test unless otherwise noted. Statistical significance in tables and figures is indicated by *
(p<0.05), ** (p<0.01) or *** (p<0.001).
4.3

Results

4.3.1

Hydrophobicity of the PNA Core Environment Controls Drug Loading
Drug loading and encapsulation efficiencies of PNAs are described in Table 4.1.

Both 2PN and 3PN successfully entrapped CFZ and DOC. 3PN had a higher drug loading
efficiency than 2PN for both drugs, possibly due to favorable interactions between the
model drugs and PAL in the PNA core. The drug loading and encapsulation efficiency of
both DOC-loaded 2PN and 3PN increased in order of no excipient, PAL, and DOCA.
Because CFZ-loaded 3PN already had high drug loading and encapsulation efficiencies,
hydrophobic excipients were not added to PNAs.
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Table 4.1. Drug loading of 2PN and 3PN with and without stabilizing excipients.
Drug
Molar Drug
Encapsulation
Loading
Loading Efficiency
Efficiency
PNA
Excipient
Drug
Efficiency
(mol Drug/
(w/w %)
(w/w %)
mol PNA)
2PN
None
CFZ
3.0±0.1***
11.5±0.4
30.5±0.9
3PN
None
CFZ
8.7±0.4***
21.3±1.0
94.7±3.8
Drug
Molar Drug
Encapsulation
Loading
Loading Efficiency
Efficiency
PNA*** Excipient*** Drug
Efficiency
(mol Drug/
(w/w %)
(w/w %)
mol PNA)
2PN
None
DOC
1.5±0.1
3.1±0.2
15.1±0.1
2PN
PAL
DOC
2.3±0.1
5.0±0.2
23.0±0.2
2PN
DOCA
DOC
4.6±0.1
10.0±0.2
47.9±0.5
3PN
None
DOC
3.4±0.1
7.4±0.2
34.7±0.4
3PN
PAL
DOC
4.1±0.1
8.9±0.2
42.9±0.1
3PN
DOCA
DOC
6.6±0.1
14.3±0.2
71.0±0.8
Drug loading efficiency, molar drug loading efficiency and encapsulation efficiency are
reported as mean±SD (n=3). Statistical significance is determined by either a Student’s ttest (CFZ-loaded PNAs) or a two-way ANOVA with Bonferroni’s post-test correction
(DOC-loaded PNAs) for each group as described in the methods section. For the twoway ANOVA, statistical significance is indicated on each parameter.
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4.3.2

HPLC-Based Methods Indicate a Longer Drug Release Half-Life Than Solvato-

Fluorochromic Methods
Drug release profiles of DOC and CFZ from 2PN and 3PN were measured using
both HPLC-based and SFC methods (Figures 4.2 and 4.3). Because CFZ and DOC were
non-fluorescent up to 10 mg/ml, fluorescence of the model drugs did not interfere with
the observed SFC spectra of PNAs. Figure 4.2 shows drug release profiles for DOCloaded 2PN and 3PN, in which HPLC signals from the dialysis method and SFC signals
decreased as DOC escaped the dialysis cassettes. CFZ-loaded PNAs showed similar drug
release trends (Figure 4.3). Table 4.2 summarizes the kinetic parameters of 2PN and 3PN
determined by both HPLC-based and SFC methods. For each drug-loaded PNA, the
HPLC-based method indicated a longer drug release half-life than the SFC method. It
should be noted that the specific excitation and emission wavelengths used for SFC
measurements did not affect the mean values of SFC kinetic parameters, but the weak
fluorescence signals from sub-optimal measurement conditions significantly increased
measurement variability.
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Figure 4.2. Docetaxel release measurements from 2PN (A/B) and 3PN (C/D) using
HPLC- and SFC-based methods (A/C). SFC spectra of 2PN (B) and 3PN (D).
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Figure 4.3. Carfilzomib release measurements from 2PN (A/B) and 3PN (C/D) using
HPLC- and SFC-based methods (A/C). SFC spectra of 2PN (B) and 3PN (D).
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Table 4.2. Parameters from a first order kinetic model of drug release for 2PN and 3PN
from HPLC- and SFC-based methods.
PNA Drug Method
t1/2 (h)
k (h-1)
kSFC/kHPLC
HPLC
4.89 (4.22-5.82)
0.14 (0.12-0.16)
2PN CFZ
2.64 (1.79-3.49)
SFC
1.89 (1.74-2.07)
0.37 (0.34-0.40)
HPLC
4.66 (3.91-5.76)
0.15 (0.12-0.18)
3PN CFZ
1.73 (0.88-2.59)
SFC
2.68 (2.32-3.18)
0.26 (0.22-0.30)
HPLC
2.25 (2.05-2.49)
0.31 (0.28-0.34)
2PN DOC
1.39 (1.02-1.75)
SFC
1.62 (1.54-1.72)
0.43 (0.40-0.45)
HPLC
5.14 (4.64-5.76)
0.13 (0.12-0.15)
3PN DOC
1.92 (1.27-2.58)
SFC
2.75 (2.49-3.08)
0.25 (0.23-0.28)
Kinetic parameters are reported as mean with 95% CI in parenthesis. The error for
kSFC/kHPLC is propagated from individual rate measurements. The 95% CI of the drug
release rate ratio is compared to 1 to evaluate if drug release rates are statistically
similar.

135

4.3.3

Drug Binding to PNAs Reduces the Accuracy of HPLC-Based Measurements but

Minimally Affects Solvato-Fluorochromic Measurements
Figure 4.4 shows free CFZ, spiked CFZ, and CFZ-loaded 2PN release profiles.
Drug release rates increased in order of drug-loaded 2PN, spiked drug, and free drug for
high and low PNA concentrations. The free CFZ release half-life was greater than 10
minutes, suggesting that the diffusion rate of free drug through dialysis membrane could
affect the measured drug release rate. Spiked drug release measurements showed a longer
drug release half-life than free drug release measurements at high and low concentrations,
indicating that the PEG shell of PNAs can bind drug and slow drug release. In addition,
drug-loaded 2PN displayed a longer half-life than either spiked or free drug. Figure 4.5
shows SFC measurements of spiked drug and spiked blank DMSO release. Because
PNAs are not present in the dialysis cassette for free CFZ release experiments, solvatofluorochromism could not be used to measure free CFZ release profiles. In contrast to
HPLC-based measurements which directly detected spiked drug by HPLC without
interference from DMSO, the spiked DMSO interfered with the SFC measurements of
drug release. Spiked drug slightly increased the initial PNA fluorescence from DMSOcorrected spiked drug SFC measurements, but the SFC signal was unaffected after 1
hour. Based on these observations, a mathematical model was developed to account for
drug binding to PNAs and diffusion through the dialysis membrane during drug release
measurements.
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Figure 4.4. HPLC-based measurements for the mechanistic modeling of drug release
from PNAs. Measurements were performed at 10 mg/ml (A) and 5 mg/ml (B) 2PN
concentration using carfilzomib as a model drug.
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Figure 4.5. SFC-based measurements for the mechanistic modeling of drug release from
PNAs. Measurements were performed at high (10 mg/ml) 2PN concentration (A-C) and
low (5 mg/ml) 2PN concentration (D-F).Released drug could not be easily detected at
high or low PNA concentrations (C,F).
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4.3.4

Mechanistic Modeling Indicates that Solvato-Fluorochromic Drug Release Rates

Are Insensitive to Free Drug
Figure 4.6 illustrates a mechanistic model of drug release kinetics from PNAs.
The released drug diffusion rate through the dialysis membrane (kD), the rate of
encapsulated drug leaving PNA core (kC), the rate of drug re-entering the PNA core (kR)
and the released drug water-PNA partition coefficient (KP) are determined by non-linear
regression as described in the methods section. It should be noted that a weighting value
of 2 reduced the standard error of modeling parameters compared to other weighting
values, but the weighting value did not significantly affect the mean values of each
parameter. Table 4.3 shows CFZ release kinetic parameters at high and low 2PN
concentrations from HPLC-based and SFC methods. The kinetic parameters from HPLCbased measurements were independent of PNA concentration, but it is possible that the
selection of a larger PNA concentration range for future experiments could increase the
differences between parameters. Since the 95% confidence interval of kR overlapped
zero, the re-entry of drugs into the PNA core was negligible under these experimental
conditions. Because the 95% confidence intervals of KP and kD were non-zero, weak drug
binding and slow diffusion affected HPLC-based drug release measurements. In contrast
to HPLC-based methods, kD and KP were not detectable by the SFC method. As a result,
these observations revealed that released drug would not directly affect SFC
measurements in comparison to HPLC-based methods using the experimental conditions
described for these drug release measurements.
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Figure 4.6. Graphical description of the mechanistic model for CFZ release from 2PN
during dialysis-based measurements. The model accounts for drug rebinding to PNAs
and diffusion through dialysis membrane.
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Table 4.3. Kinetic parameters from the mechanistic model of drug release from CFZloaded 2PN.
PNA Concentration
kC (h-1)
kR*105 (h-1)
Method
(mg/ml)
HPLC
10
0.170 (0.090-0.249)
0.3 (-4.3-5.0)
HPLC
5
0.116 (0.049-0.182)
8.1 (-32.2-39.6)
SFC
10
0.37 (0.31-0.43)
--SFC
5
0.39 (0.35-0.43)
--PNA Concentration
Method
KP (unitless)
kD (h-1)
(mg/ml)
HPLC
10
121.5 (60.5-182.5)
0.429 (0.361-0.497)
HPLC
5
95.7 (45.4-146.0)
0.421 (0.365-0.478)
SFC
10
----SFC
5
----Kinetic parameters are reported as mean with 95% CI in parentheses. Parameters were
compared by a Student’s T test. Statistical significance is indicated as described in the
methods section.
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4.3.5

Hydrophobic Excipients Alter Both the HPLC- and Solvato-Fluorochromic-Based

Drug Release Rates of PNAs
Figures 4.7 and 4.8 show HPLC-based and SFC drug release measurements from
DOC-loaded 2PN and 3PN that are stabilized by DOCA or PAL. Because the
mechanistic model could not be used for SFC measurements as described in the previous
section, HPLC- and SFC-based release rates were compared using a first order kinetic
model (equation 4.1). DOCA and PAL increased the initial fluorescence of PNAs during
SFC measurements, presumably due to increased dye-drug interactions within the core of
PNAs. Kinetic parameters of drug release from excipient-stabilized PNAs are
summarized in Table 4.4. The addition of hydrophobic excipients to PNAs decreased the
difference between drug release rates that were measured by HPLC-based and SFC
methods. In addition, both DOCA and PAL slightly decreased the drug release half-life
of PNAs that were determined by HPLC-based methods, possibly due to increased drug
loading in 2PN and 3PN.
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Figure 4.7. Docetaxel release measurements from excipient-stabilized 2PN containing
either DOCA (A/B) or PAL (C/D) using HPLC- and SFC-based methods (A/C). SFC
spectra of DOCA-stabilized 2PN (B) and PAL-stabilized 2PN (D).

143

Figure 4.8. Docetaxel release measurements from excipient-stabilized 3PN containing
either DOCA (A/B) or PAL (C/D) using HPLC- and SFC-based methods (A/C). SFC
spectra of DOCA-stabilized 3PN (B) and PAL-stabilized 3PN (D).
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Table 4.4. Parameters from a first order kinetic model for drug release for excipientstabilized PNAs from HPLC- and SFC-based methods.
PNA Excipient Method
t1/2 (h)
k (h-1)
kSFC/kHPLC
HPLC
2.25 (2.05-2.49)
0.31 (0.28-0.34)
2PN
None
1.39 (1.02-1.75)
SFC
1.62 (1.54-1.72)
0.43 (0.40-0.45)
HPLC
5.14 (4.64-5.76)
0.13 (0.12-0.15)
3PN
None
1.92 (1.27-2.58)
SFC
2.75 (2.49-3.08)
0.25 (0.23-0.28)
HPLC
2.12 (1.89-2.40)
0.33 (0.29-0.37)
2PN
DOCA
0.91 (0.47-1.34)
SFC
2.30 (2.07-2.59)
0.30 (0.27-0.34)
HPLC
2.27 (2.09-2.50)
0.30 (0.28-0.33)
3PN
DOCA
2.20 (1.62-2.78)
SFC
1.05 (0.96-1.15)
0.66 (0.60-0.72)
HPLC
2.24 (2.16-2.32)
0.31 (0.30-0.32)
2PN
PAL
0.77 (0.69-0.85)
SFC
2.93 (2.83-3.03)
0.24 (0.23-0.25)
HPLC
3.07 (2.73-3.51)
0.23 (0.20-0.25)
3PN
PAL
1.04 (0.61-1.48)
SFC
2.95 (2.56-3.32)
0.24 (0.20-0.28)
Data for PNAs without excipients is reproduced from Table 4.2. Kinetic parameters are
reported as mean with 95% CI in parenthesis. The error for kSFC/kHPLC is propagated
from individual rate measurements. The 95% CI of the drug release rate ratio is
compared to 1 to evaluate if drug release rates are statistically similar.
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4.3.6

Nile Blue Remains Chemically Stable during Solvato-Fluorochromic Drug

Release Measurements
Figure 4.9 shows the chemical stability and photostability of NB under the
experimental conditions of the SFC measurements. The absorbance spectra of NB
remained consistent up to 5 days post-storage. In addition, changes in the maximum
absorbance of NB (632 nm) over time were not statistically significant. In addition,
changes in the fluorescence intensity of NB were not statistically significant after 10
measurements of the same sample over 10 minutes.
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Figure 4.9. Chemical stability (A) and photostability (B) of NB in cell media or deionized
water, respectively.
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4.4

Discussion

4.4.1

Solvato-Fluorochromism Measures a Step of Drug Release
The measurement of drug release profiles is an important step for developing safe

and effective nanoparticle drug carriers for cancer chemotherapy (202, 203). Drug release
profiles indicate time-dependent changes in the amount of drugs that nanoparticles
release into the blood or the tumor. Nanoparticles are typically designed to minimize drug
release in the blood that can increase normal tissue exposure to drugs and cause organ
damage or other adverse effects (204). In contrast, drug release into the interstitial space
of tumors can facilitate the accumulation of active drugs in cancer cells (205).
Nanoparticles that accumulate selectively in tumors and release drugs at slow rates have
improved the therapeutic efficacy of anticancer drugs by maximizing drug delivery into
tumor cells (204).
Despite their significance to cancer treatment efficacy, in vivo drug release
profiles for nanoparticle drug carriers are often only estimated from in vitro
measurements of drug concentrations in nanoparticles, which are often completed using
HPLC-based methods that measure remaining drug during dialysis-based experiments.
As a result, the real-time determination of drug release in the blood and in tumors is
currently unavailable (167, 168, 174). Previous studies reported that HPLC-based
methods could inaccurately estimate in vivo drug release profiles for PNAs when drugs
bind to nanoparticles (206). Drug release profiles from HPLC-based methods may also be
inaccurate if drugs are chemically unstable or diffuse slowly through the dialysis
membrane (207). As an alternative method to determine drug release from the core of
PNAs and potentially other types of nanoparticles, the SFC method was investigated for
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the real-time, direct measurement of drug release from PNAs compared to HPLC-based
methods for measuring drug remaining in dialysis cassettes.
Differences between in vivo and in vitro drug release rates from nanoparticles are
often attributed to decreased in vivo nanoparticle concentrations following treatment
compared to in vitro measurement conditions. For example, some drug-loaded polymer
micelles sustain drug release in vitro, but they can release drug rapidly following dilution
after intravenous injection (208). Polymer nanoassemblies are made from covalently
tethered polymer chains that form unimolecular particles. These unimolecular particles
remain intact upon dilution in the blood following intravenous injection as opposed to
other multimolecular nanoparticles (209). Therefore, the in vivo dilution of PNAs is not
expected to alter drug release rates due to dissociation of the hydrophobic core.
Two poorly soluble model drugs, CFZ and DOC (5 μg/ml and 10 μg/ml
maximum solubility in water, respectively), were successfully entrapped in PNAs under
various conditions. Both CFZ and DOC showed first-order drug release kinetics,
although CFZ exhibited weak drug binding to 3PN based on tailing in drug release
profiles. However, other drug-loaded PNAs showed complete drug release. Interestingly,
2PN with an ionic core entrapped hydrophobic CFZ, possibly due to favorable
interactions between the tetrapeptide backbone of CFZ and cationic PEI backbone or
charged amines on NB. In comparison to the HPLC-based method which only provided
information about the time-dependent changes of drug concentrations in the dialysis
cassette, the SFC method indicated dynamic changes in the PNA core environment
during drug release by showing unique SFC spectra and intensities for each PNA
formulation.
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4.4.2

Mechanistic Modeling Compares HPLC- and Solvato-Fluorochromic-Based

Methods for Dialysis-Based Drug Release Measurements
To further investigate the effects of drug binding on HPLC-based and SFC
methods, spiked drug release experiments were performed. Drug release rates from the
HPLC-based method increased in order of drug-loaded 2PN, spiked drug, and free drug
for both high and low concentrations of 2PN. These data indicate that the diffusion of
free drug through the dialysis membrane slows apparent drug release rates, which is often
overlooked in HPLC-based methods. Unexpectedly, the SFC signals of PNAs increased
in the presence of DMSO used to dissolve CFZ during the spiked drug release
experiments. Spiked drug release data corrected for DMSO interference revealed that
weakly bound drugs and drugs in solution could not be detected. As a result, CFZ that is
weakly bound to 2PN or in solution would not affect SFC-based methods compared to
HPLC-based methods. These results indicate that the SFC method is less sensitive to drug
binding than HPLC-based methods under these experimental conditions, and that the SFC
method would provide more accurate information about drugs leaving the core of the
nanoparticle drug carriers than HPLC-based methods. However, additional work is
needed to verify if this conclusion is valid for PNAs with higher drug loadings or
increased substitution of fluorochromic dyes.
The unexpected increase in SFC signals from DMSO raised concerns about
potential interactions between PNAs and other hydrophobic molecules in solution. To
address these concerns, SFC drug release profiles for 3PN were compared to a physical
mixture of 2PN and hydrophobic excipients such as PAL. DOC was selected as a model
drug because it showed no tailing in drug release profiles. Drug release profiles revealed
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that DOCA and PAL increased drug entrapment in PNAs but also accelerated drug
release rates. In addition, hydrophobic excipients were confirmed to induce no change in
the SFC spectra of PNAs. PNAs with PAL, either covalently conjugated to the core or
physically mixed in the core, should have the same molecular components (i.e., 3PN
compared to 2PN and PAL), but they showed distinct SFC spectra. 2PN retained its SFC
spectra in the presence of PAL, although a physical mixture of 2PN and PAL exhibited
greater SFC intensity than 2PN. Hydrophobic excipients also increased the SFC intensity
for 3PN without affecting the shape of its SFC spectra.
It was initially hypothesized that SFC-based drug release rates would by equal to
HPLC-based drug release rates that were corrected for drug rebinding and diffusion.
However, kSFC values were significantly greater than kC, indicating that factors other than
drug rebinding and diffusion contribute to these differences. Factors other than drug
rebinding and diffusion could be decreasing apparent drug release rates measured by
HPLC compared to SFC, but the possible nature of these factors is unclear. In contrast,
SFC-based methods could be overestimating drug release compared to HPLC-based
methods. The fluorescence of NB-conjugated PNAs increased linearly in response to
drug loading, suggesting that increased apparent drug release rates from SFC-based
methods are not due to detection method limitations. PNAs could contain a
heterogeneous core environment, in which only the region of the core environment near
the scaffold is sensitive to drug loading. In this region, NB can interact with hydrophobic
drug molecules. The core environment closer to the PNA-water interface may not contain
NB, because the NB molecule is small and covalently conjugated to the polymer scaffold.
In this region, hydrophobic drugs do not interact with NB. In addition, water may enter
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the outside of the core, but fail to diffuse evenly throughout the core. If these statements
are valid, SFC-based drug release measurements would measure the diffusion of drugs
out of the NB-enriched region of the PNA core. Because drug molecules diffuse towards
the PNA-water interface, drug in the NB-enriched region of the PNA core could decrease
before the concentrations near the interface decrease. In this manner, SFC drug release
rates would measure a step of drug release, but not the rate-limiting step indicating
overall drug release rates. Unfortunately, experimental measurements of PNA core
heterogeneity remain challenging. Future studies may elucidate the relationship between
SFC drug release rates, HPLC-based drug release rates and physical processes occurring
during drug release.
4.4.3

Mechanistic Modeling Assesses the Thermodynamic Conditions of Dialysis-Based

Drug Release Measurements
Dialysis-based drug release measurements depend on a sink condition in the
dialysis solution in order to assure that in vitro drug release rates are accurate.
Researchers often assume that sink conditions are maintained if nanoparticle solutions are
dialyzed into a solution with a much greater volume than the nanoparticle solution (210).
The dialysis sink is expected to maintain an activity gradient between nanoparticles and
the solution that facilitates drug diffusion out of the nanoparticle core. However, a large
dialysis sink does not guarantee sink conditions for drug release, because the chemical
potential of the drug at the nanoparticle interface relative to the solution is often non-zero
(211). It is hypothesized that in vivo conditions such as reduced PNA concentrations and
blood flow promote the removal of released drugs from PNAs, allowing PNAs to
maintain sink conditions in vivo. By comparing HPLC-based drug release rates from the
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first order kinetic model to HPLC-based drug release rates from the mechanistic model,
the presence or absence of a sink condition can be assessed. Differences between these
release rates were not statistically significant, suggesting that HPLC-based drug release
measurements are occurring under sink conditions. However, due to the size of the 95%
confidence intervals, more precise methods of assessing sink conditions during dialysisbased drug release measurements may be needed.
The PNA-water partition coefficient (Kp) of carfilzomib allowed investigators to
measure the re-binding of hydrophobic drugs in solution to PNAs. For sink conditions to
be maintained during drug release, the dilution of hydrophobic drugs after they were
released into the dialysis solution would either prevent drugs from re-binding to the
surface of PNAs or make the process difficult to observe and quantify experimentally.
The mechanistic modeling of CFZ release from 2PN indicated that the PNA-water
partition coefficient of CFZ was non-zero. As a result, sink conditions cannot be assumed
for these drug release measurements. In order to allow for sink conditions during future
drug release studies, the rebinding of drugs to PNAs could be reduced by sequestering
released drug in the dialysis solution. For example, carfilzomib has been shown to form
cyclodextrin complexes (212). Determining the appropriate experimental conditions for
using cyclodextrins to sequester released CFZ is a future area of work.
The mechanistic model of drug release also allowed researchers to account for the
potential re-entry of drugs into the PNA core. The re-entry parameter (kR) allowed the
model to account for two potential experimental conditions: 1) a high released drug
concentration that causes the chemical potential of released drug and drug at the PNAwater interface to be equal, and 2) a high chemical potential of drug at the PNA-water
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interface relative to solution that slows drugs entry into solution but does not necessarily
affect drug leaving the core. The 95% confidence interval of the modeled kinetic
parameter for drug re-entry (kR) was not statistically different from zero. This observation
suggests that either the released drug is unlikely to interact with the PNA core due to a
small surface area of the core compared to the released drug binding area, or that PNAs
did not have a high enough initial drug concentration to detect the re-entry of drug into
the core of PNAs. Future experiments using a variety of model drugs at several drug
loading values may elucidate the necessary properties of both nanoparticles and drugs to
observe the re-entry of released drugs into the PNA core.
The addition of hydrophobic excipients to 3PN was expected to alter SFC signals
by controlling drug distribution in the core, but it also decreased the DOC release rate
measured by HPLC. Carboxylate anions at the interface of excipient-stabilized PNAs
could increase the apparent drug release rate by decreasing Kp. This phenomenon would
be difficult to measure experimentally, because excipients are not conjugated to the core
of PNAs and can diffuse into solution over time. As a result, the Kp value of excipientstabilized PNAs may change during the release measurement. In order to investigate the
effects of excipients on the PNA-water partition coefficient of drugs, investigators could
identify excipients that can be conjugated to the core of PNAs while introducing a
carboxylate anion to the surface of the PNA core, or they could chemically modify
DOCA or PAL so that they can be conjugated to PNAs without affecting the carboxylate
anion. Additionally, interactions between released drugs and excipients could decrease
kD. The effects of excipient-drug interactions on drug diffusivity should be investigated in
future work.
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4.4.4

Excipients Increase Drug Concentrations in the Nanoassembly Core
Hydrophobic excipients were expected to increase DOC encapsulation in order of

no excipient, DOCA, and PAL, because PAL (logP=7.2) is more lipophilic than DOCA
(logP=3.5) (213, 214). However, DOCA increased DOC loading by 2% more than PAL
in both 2PN and 3PN. Although PAL and DOCA increased the DOC release half-life for
2PN from SFC methods, the excipients unexpectedly accelerated DOC release from 3PN
from HPLC methods. Based on these results, it is speculated that the excipients mix with
PNAs during drug loading and increase core hydrophobicity and drug entrapment, while
NB detects the core environment changes and emits a stronger SFC intensity. However,
carboxyl groups on PAL and DOCA keep the excipients near the core-shell interface and
prevent direct contact between the excipients and NB, allowing PNAs to maintain their
distinct fluorescence spectra. Excipients may leave the core of excipient-stabilized PNAs
quickly along with drugs and accelerate drug release rates. Figure 4.10 illustrates this
potential mechanism.

155

Figure 4.10. Graphical description of the theoretical mechanism for the effects of
excipients on solvato-fluorochromism.
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4.4.5

Advantages of Solvato-Fluorochromic Drug Release Measurements
This study suggests that the SFC method has the potential to monitor drug release

from PNAs with a hydrophobic core. Although 2PN has a higher NB molar substitution
than 3PN, drug-loaded 3PN showed greater fluorescence intensity than drug-loaded 2PN,
suggesting that PAL kept drugs in the PNA core and forced water out of the core. As a
result, hydrophobic drugs could interact with NB more efficiently in the hydrophobic
3PN core than in the hydrophilic 2PN core. Importantly, drug loading did not alter the
maximum absorbance wavelengths for both PNAs. When DOCA was added to DOCloaded 2PN and PAL was added to DOC-loaded 3PN, the HPLC-based and SFC methods
showed statistically similar drug release rates. These observations suggest that the
excipients could help hydrophobic drug molecules stay in the PNA core and interact with
NB during drug release.
It should be noted that the HPLC-based method could not detect changes in the
PNA core environment. The HPLC-based method failed to distinguish between DOC
release profiles of 3PN and 2PN physically mixed with PAL, but the SFC method
detected distinct SFC spectra for each formulation. The SFC method also indicated that
hydrophobic excipients increased the initial dye-drug interactions in the core of PNAs,
but the drug-dye interactions decreased quicker than in PNAs without excipients. This
observation suggests that excipients may diffuse into solution over time, and the diffusion
of excipients accelerates drug diffusion out of the nanoassembly core. Therefore, in
comparison to HPLC-based methods, the SFC method provides more information
regarding changes in the physicochemical properties within the nanoassembly core
during drug delivery.
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In regard to future clinical applications, SFC-based drug release determination
may have two primary advantages over HPLC-based methods. First, SFC methods may
enable researchers to perform in situ drug release measurements. In this study, SFC
measurement timepoints and PNA concentrations were matched to HPLC timepoints and
PNA concentrations in order to directly compare the methods, but fluorescence signals
could be measured directly from tissues as well as dialysis cassettes without having to
sample the solutions for fluorescence measurements (215, 216). Second, the SFC method
may provide investigators with real-time drug release profiles that describe drug release
more accurately than mathematical models of drug release kinetics using HPLC-based
methods. Mathematical models of drug release from HPLC-based methods can
oversimplify drug release kinetics by assuming that drug release rates remain constant
over time. In addition, many HPLC-based methods sample high initial drug
concentrations more than low terminal drug concentrations, which can increase fitting
error by overweighting initial or terminal drug concentrations. However, SFC methods
can provide real-time information about drugs leaving the nanoparticle core, which may
overcome some of the limitations of mathematical modeling associated with HPLC-based
method analysis. Therefore, NB-conjugated PNAs are expected to allow clinicians to
address some of the limitations of HPLC-based methods and eventually perform in situ
real-time measurements of drug concentrations in nanoparticles circulating in the
bloodstream or accumulating in targeted tissues including tumors.
4.4.6

Limitations of Solvato-Fluorochromic Drug Release Measurements
Despite their previous applications described in chapter 2 and in the literature

(217), SFC dyes have several limitations for measuring drug release from various
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nanoparticle drug carriers. First, SFC dyes must remain in the nanoparticle core to detect
accurate chemical properties within the nanoparticle core environment. Physically
entrapped dyes in nanoparticles could diffuse into solution and reduce the SFC signal,
which would cause the SFC method to overestimate drug release rates. For this reason,
NB was covalently conjugated to PNAs with stable amide and imine bonds that prevent
NB from leaving the PNA core during SFC measurements. In addition, SFC dyes must
detect the entire nanoassembly core environment in order to accurately measure
nanoassembly core properties. Therefore, nanoparticles should be designed to allow
chemically conjugated SFC dyes to disperse throughout the entire nanoassembly core.
Future experiments should determine if the spatial distribution of SFC dyes in the core of
PNAs is homogeneous or heterogeneous.
SFC dyes in the nanoparticle core must remain intact during drug release
experiments in order to measure accurate drug release. Chemical degradation of SFC
dyes could decrease the fluorescence intensity of dye-loaded nanoparticles and increase
SFC drug release rates. Based on the optical characterization of NB, the dye is chemically
stable for up to 5 days in cell culture media at 37 °C. Therefore, NB in 2PN and 3PN
should be chemically stable under the described experimental conditions. The
photostability of NB was also confirmed for up to 10 fluorescence measurements under
the described experimental conditions. In addition, solvato-fluorochromism of dyes in the
nanoparticle core should be selective for encapsulated drugs in order to avoid interactions
with hydrophobic small molecules such as free lipids that could diffuse into the
hydrophobic core of nanoparticles and interfere with SFC signals (80, 218, 219). Based
on the negligible value of the measured rate of drug re-entry into the PNA core,
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hydrophobic small molecules are not expected to enter the PNA core and interact with
fluorochromic dyes.
The sensitivity of the SFC method to detect drug in the PNA core indicates the
potential of this method to measure accurate drug release rates. By measuring the
fluorescence of PNAs, 1.5% and 3% drug loading by weight could be detected in DOCloaded and CFZ-loaded 2PN. During SFC drug release measurements, 20% of the initial
drug loading could be detected in PNAs before reaching minimal fluorescence values.
Based on these values, minimum drug loading values of 0.3% DOC and 0.6% CFZ by
weight could be detected by measuring the fluorescence of NB-conjugated PNAs.
Estimations of the minimum detectable drug loading by solvato-fluorochromism are
higher than the minimum detection limit of the HPLC-based method used in study.
However, it should be noted that the minimum detectable drug loading was estimated
from drug release data, and that a direct measurement of the SFC detection limit could
indicate a higher sensitivity of the SFC method to detect drugs entrapped in the
nanoassembly core.
It should be noted that 1) the SFC method is intended to only detect drugs leaving
the nanoparticle core, 2) the SFC method cannot distinguish free drug in solution from
drug that is weakly bound to the surface of the carriers, and 3) the relationship between
SFC drug release measurements and the amount of biologically active drug in solution
needs to be further elucidated. As a result, SFC measurements may overestimate free
drug concentrations in tumor tissue. Mechanistic modeling showed that some released
drug binds to the surface of PNAs and slows drug release during HPLC-based
measurements, but previous research suggests that drug binding may not significantly
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affect drug release rates in vivo because of low PNA concentrations in the blood or
interstitial space compared to dialysis cassettes (220, 221). Determining the relationship
between SFC drug release rates and drug concentrations in tissues is a significant area of
future work.
4.5

Conclusions
A novel, SFC-based drug release measurement method was developed to

overcome the limitations of HPLC-based methods for dialysis-based drug release
measurements, such as unanticipated molecular interactions and complicated mass
transfer effects between drugs, PNAs, and dialysis membranes. The SFC method
demonstrated a facile and accurate determination of drug release rates compared to
HPLC-based methods. A comparisons of both methods revealed that HPLC-based
methods may be inaccurate at determining drug release involving interactions among
drug, drug carriers, and hydrophobic excipients. Mechanistic modeling confirmed that
drug rebinding and slow drug diffusion would influence HPLC-based but not the SFCbased method. These results indicate that the SFC method holds great promise to measure
drug release rates for PNAs and potentially other nanoparticle drug carriers with
improved convenience and accuracy compared to HPLC-based methods.

**Portions of Chapter 4 were previously published in (222). Reproduced with permission
from Springer: Pharmaceutical Research, Volume 34, Issue 2, 2017, Pages 394-407,
Figures 1, 4-10, and Text. Copyright 2016 is given to the publication in which the
material was originally published.
Copyright (C) Derek Reichel 2017
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CHAPTER FIVE
CHEMICAL MODIFICATIONS TO PNAs BASED ON A SOLVATOFLUOROCHROMIC CHARACTERIZATION OF THE NANOASSEMBLY CORE
ENVIRONMENT TO CONTROL DRUG RELEASE AND IMPROVE TEMPORAL
DRUG DISTRIBUTION
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5

CHEMICAL MODIFICATIONS TO PNAs BASED ON A SOLVATO-

FLUOROCHROMIC CHARACTERIZATION OF THE NANOASSEMBLY CORE
ENVIRONMENT TO CONTROL DRUG RELEASE AND IMPROVE TEMPORAL
DRUG DISTRIBUTION
5.1

Introduction
Drug release rates from nanoparticles are often used to predict the spatial and

temporal distribution of drugs in tumors, but modulating drug release rates in order to
improve cancer treatment efficacy remains challenging (223). Nanoparticles with small
diameters (10-100 nm) often accumulate in the leaky vasculature surrounding tumors at
3-12 hours post-injection and deliver anticancer drugs into the tumor interstitium (224,
225). Optimal drug release rates from nanoparticles can increase the accumulation of
anticancer drugs in tumors by maximizing drug release from nanoparticles accumulated
in the tumor vasculature (226). Rapid drug release rates can force nanoparticles to release
drugs in blood vessels before the nanoparticles can accumulate in tumors (227). Drugs
that are released in blood vessels may not reach tumors due to rapid renal clearance or
off-target accumulation in healthy organs causing dose-limiting toxicity. In addition, slow
drug release rates may decrease treatment efficacy by reducing peak anticancer drug
concentrations in cancer cells. Therefore, methods of modulating drug release rates from
nanoparticles are needed to increase anticancer drug accumulation in tumors and improve
treatment efficacy.
The core environment of drug-loaded nanoparticles controls drug release into
tumor tissue, but drug release rates remain difficult to modulate due to complicated
thermodynamic and mass transport effects between drugs and polymers in the
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nanoparticle core. For polymeric nanoparticles such as PNAs, diffusion out of the PNA
core and binding to hydrophobic polymers are two main factors governing drug release
(228, 229). Drugs must diffuse through the hydrophobic mesh-like core environment to
reach the interface between the core and the hydrophilic shell. Diffusion rates of drugs in
the hydrophobic core are influenced by both the chemical properties of the hydrophobic
groups in the core and the pore size of the hydrophobic mesh. The hydrophobic core
often contains water molecules that can interact with drugs or weakly hydrophobic
portions of the core and influence diffusion rates. After drugs diffuse to the core-shell
interface, they must cross the shell and partition into the surrounding solution.
Environmental factors such as the solution pH and the chemical potential of drug at the
interface in relation to the surrounding media can reduce drug release rates by decreasing
the amount of drug that can partition into the surrounding solution (230). Researchers
often control drug release rates from nanoparticles by altering the core environment
hydrophobicity, which can slow diffusion by increasing the affinity of the drug for the
core (231). Unfortunately, this approach is often ineffective at controlling drug release
rates, because the specific effects of hydrophobic interactions on drug release are difficult
to elucidate from drug release profiles. Experimental methods for determining the
thermodynamic and mass transport effects contributing to poor drug release rates may
identify rational approaches to modify the PNA core environment in order to control drug
release rates.
Solvato-fluorochromism was previously identified as a useful method to probe the
nanoparticle core environment and monitor its chemical properties during drug delivery.
Although PAL was attached to the core of PNAs to create a hydrophobic core
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environment capable of entrapping drugs, the quenched fluorescence of NB in the PNA
core indicated that some water remained in the core and decreased the nanoassembly core
hydrophobicity. The presence of water in the nanoassembly core was attributed to amines
on the polymer scaffold that can interact with water molecules entering the PNA core. In
addition, charged amine groups in the core can also repel cationic drugs or draw
counterions into the PNA core. Chemical modifications to the polymer scaffold in the
core of PNAs may remove these ionizable functional groups from the nanoassembly core.
For example, primary amines can be end-capped by chemical reactions that form stable,
unionizable amide bonds. In addition, secondary and tertiary amines can be removed
from the core by synthesizing PNAs with polymer scaffolds that lack ionizable secondary
or tertiary amines. Therefore, chemical modifications to PNAs to reduce the water
concentration in the hydrophobic core promise to sustain drug release and improve
temporal and spatial drug distribution in tumors.
This study addresses the drug delivery limitations of fluorochromic PNAs by
rationally modifying the chemical environment of the nanoassembly core based on
solvato-fluorochromism. These improved PNAs are synthesized similarly to
fluorochromic PNAs (Figure 5.1). However, the remaining ionizable groups on polymer
scaffolds were removed by replacing the PEI scaffold with a PLL scaffold, and by endcapping the remaining primary amines with either a chloroacetyl chloride (CAC) or
acetic anhydride (AA) reaction. The core environments of these PNAs are fine-tuned to
increase drug entrapment, avoid burst drug release and fine-tune drug release half-lives.
In order to determine the effects of drug properties such as pKa or functional groups on
drug loading and release, the entrapment and release of model drugs carfilzomib (CFZ)
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and docetaxel (DOC) were determined. CFZ and DOC were selected as model anticancer
drugs with distinct chemical structures (peptide vs. taxane), ionization potential (pKa of
5.1 for the morpholine group of CFZ vs. 11.0 for the carbamate group of DOC) and
lipophilicity (logP of 4.2 vs. 2.4), respectively. Drug release kinetics of end-capped PNAs
were evaluated using three models: a first order kinetic model, the Korsmeyer-Peppas
model and the unsteady state spherical diffusion model. A first order kinetic model
allowed the comparison of half-lives to determine the effects of polymer scaffold and
end-capping groups on drug release. The Korsmeyer-Peppas model was selected as a
semi-empirical model that indicates the mechanism of drug release from PNAs and
justifies the selection of mechanistic drug release models. The unsteady state spherical
diffusion model was selected as a mechanistic model that can measure the diffusivity of
drug molecules in the core of PNAs. By removing ionizable functional groups from the
nanoassembly core, this study evaluates the effects of ionizable groups on drug release
from PNAs and validates solvato-fluorochromism as a beneficial method for
characterizing the core environment of PNAs and potentially other nanoparticle drug
carriers.
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Figure 5.1. Graphical description of the end-capping approach to remove amines from
the core of PNAs (A). Six PNAs were synthesized by varying the polymer scaffold and
amine end-capping modification (B) to fine-tune drug release properties of PNAs (C).
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5.2

Materials and Methods

5.2.1

Materials
α-Succinimidyloxysuccinyl-ω-methoxy-poly(ethylene glycol) (NHS-activated

PEG, 5 kDa) was purchased from NOF America (White Plains, NY). Branched
poly(ethylene imine) (PEI, 25 kDa), poly(L-lysine) (PLL, 15-30 kDa), acetic anhydride
(AA), chloroacetyl chloride (CAC), HEPES sodium salt, palmitoyl chloride (PAL-Cl)
and fluorescamine were purchased from Sigma Aldrich (St. Louis, MO). Acetonitrile
(ACN), diethyl ether, dimethyl sulfoxide (DMSO), ethanol, pyridine, tetrahydrofuran
(THF), water, phosphate buffered saline (PBS), dialysis membranes with molecular
weight cut-off (MWCO) of 6-8 or 100 kDa, centrifugal filters (100 kDa MWCO) and
dialysis cups (20 kDa MWCO) were purchased from Fisher Scientific (Waltham, MA).
Carfilzomib (CFZ) and docetaxel (DOC) were purchased from LC Laboratories
(Woburn, MA). To remove low molecular weight impurities from PEI before reactions,
PEI was dialyzed in water overnight using a 100 kDa MWCO membrane. All other
chemicals were used without further purification.
5.2.2

Synthesis of Unmodified and End-Capped PNAs with Various Polymer Scaffolds
As shown in Figure 5.2, PNAs containing various scaffolds and end-capping

groups were synthesized by tethering NHS-activated PEG and PAL-Cl to PEI or PLL to
yield 3P (PEG-PEI-PAL) and 3P’ (PEG-PLL-PAL). 3P and 3P’ were further reacted with
either AA or CAC to yield 3PAA (PEG-PEI-PAL-AA), 3P’AA (PEG-PLL-PAL-AA),
3PCAC (PEG-PEI-PAL-CAC) and 3P’CAC (PEG-PLL-PAL-CAC). The synthesis of 3P
was described in chapter 2. NHS-activated PEG (1951.8 mg) was reacted with PLL
(100.0 mg) in a 4:1 mixed solution of HEPES buffer and DMSO for 3 days. The reaction
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yielded PEG-PLL, which was purified by dialysis and collected after freeze drying. A
portion of the PEG-PLL (1000.0 mg) was reacted with PAL-Cl (299 μl) at 40 °C for 2
hours in THF. To neutralize hydrochloric acid by-products formed during reactions,
pyridine was added to the reaction mixtures in equal volume ratios to the acyl chloride
reagents of all acyl chloride reactions 15 minutes after adding the reagent. The product
3P’ was purified by ether precipitation and dialysis, and then collected after freeze
drying. 3P and 3P’ (100.0 mg each) were separately reacted with either AA (19.3 μl for
each) at room temperature overnight in DMSO or with CAC (16.7 μl for each) at 40 °C
for 2 hours in THF. Each AA or CAC reaction products was purified by dialysis and
collected after freeze drying, yielding AA- and CAC-modified 3P and 3P’.
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Figure 5.2. Synthesis protocol for unmodified and end-capped PNAs. All PNAs are
shown to contain potentially unreacted primary amines.
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5.2.3

Physical Characterization of Unmodified and End-Capped PNAs
Primary amines remaining in the core of PNAs were directly quantified using the

amine-reactive fluorogenic dye fluorescamine. Because of potential fluorescence
interactions between amine-conjugated fluorescamine and NB in the core of PNAs,
primary amines in NB-conjugated PNAs were not quantified by fluorescamine in chapter
2. The PNAs 3P, 3PAA, 3PCAC, 3P’, 3P’AA and 3P’CAC were separately dispersed in
1:1 DMSO/water solutions at 1 mg/ml, and fluorescamine was dissolved in DMSO at 10
mg/ml. Ten microliters of fluorescamine solution was added to 100 μl of blank solution
and each PNA solution. The fluorescence of amine-conjugated fluorescamine (Ex 390
nm/Em 460 nm) in each solution was measured using a plate reader (Spectramax M5,
Sunnyvale, CA). The baseline signal was removed from each sample by subtracting the
fluorescence of the blank solution from the fluorescence of each sample. The baselinecorrected sample fluorescence was then normalized to the fluorescence of 3P (3PAA and
3PCAC) or 3P’ (3P’AA and 3P’CAC). The relative size and dispersity of PNAs was
determined by GPC as described in chapter 2 (Asahipak GF-7M, PBS, 0.5 ml/min, 40 °C,
calibrated using PEG standards). The chemical compositions of each PNA were
determined by proton NMR spectroscopy (Varian 400 MHz, DMSO-d6). The diameter
and surface charge of each PNA was also determined by DLS (Zetasizer Nano ZS,
Malvern, UK).
5.2.4

Hydrophobic Drug Loading of End-Capped PNAs
Stock solutions of PNAs (3P, 3PCAC, 3PAA, 3P’, 3P’CAC and 3P’AA; 100

mg/ml) and drugs (CFZ and DOC; 1 mg/ml) were prepared in ethanol. Each PNA
solution was mixed with either CFZ or DOC solution in a round-bottom flask, aiming for
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10% drug loading. The mixed solutions were evaporated under reduced pressure to
prepare thin films, which were rehydrated with deionized water and sonicated for 5
minutes. PNA solutions were then centrifuged for 1 minute at 1000 RPM to remove free
drug and other insoluble impurities. The supernatants were then collected and lyophilized
for storage. The drug loading efficiency, molar drug loading efficiency and encapsulation
efficiency of PNAs was determined from reconstituted samples using HPLC as described
in chapter 4.
5.2.5

Drug Release Measurements from Unmodified and End-Capped PNAs
Drug-loaded PNAs were dispersed in PBS (10 mg/ml). Each drug-loaded PNA

solution (500 μl) was added to dialysis cups and dialyzed at 37 °C in 1 l of PBS. Aliquots
of each sample (50 μl) from within the dialysis cups were collected at 0, 1, 3, 6, 24 and
48 hours. Drug remaining in these aliquots was quantified by HPLC, and the drug release
profiles for each drug-PNA combination were fitted to multiple kinetic models of drug
release using Prism (GraphPad, La Jolla, CA). Initially, drug release models were fit to
first order kinetic models (equation 4.1) as described in chapter 4.
In order to further elucidate the mechanism of drug release from PNAs, drug
release profiles were fit to the Korsmeyer-Peppas model of drug release in equation 5.1.
𝑀𝑀𝑡𝑡

𝑀𝑀∞

= 𝐾𝐾𝑡𝑡 𝑁𝑁

(5.1)

In equation 5.1, Mt is the mass of released drug at time t, M∞ is the mass of
released drug after an infinite amount of time, K is a kinetic constant with units of inverse
hours and N is a unitless constant determined experimentally. Equation 5.1 was
simplified to equation 5.2.
𝐶𝐶𝑡𝑡

𝐶𝐶0

= 𝐾𝐾𝑡𝑡 𝑁𝑁

(5.2)
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In equation 5.2, Ct/C0 is the concentration ratio of drug in the dialysis cup at time
t to the initial concentration as a percent. For drug release modeling, an N value with
standard error of mean equal to or below 0.45 was defined as Fickian diffusion-controlled
drug release, while N values between 0.45 and 0.85 were defined as non-Fickian
transport-based drug release.
An unsteady state spherical diffusion model of mass transfer was developed to
determine the diffusivity of drugs in the PNA core. The model was based on detailed
derivations by Arifin et al. (232). Initially, PNAs were assumed to be spherical and have
a constant diameter during drug release. The core-shell interface was also assumed to
have zero chemical potential for the drug (sink condition). Equation 5.3 below describes
diffusion-controlled drug release from a sphere obeying these assumptions.
𝑀𝑀𝑡𝑡

𝑀𝑀∞

6

1

= 1 − 𝜋𝜋2 ∗ ∑∞
𝑛𝑛=1 𝑛𝑛2 ∗ 𝑒𝑒

−𝐷𝐷∗𝑛𝑛2 ∗𝜋𝜋2 ∗𝑡𝑡
𝑎𝑎2

(5.3)

In equation 5.3, Mt is the mass of released drug at time t, M∞ is the mass of
released drug after an infinite time, D is the drug diffusivity with units of m2/s, and a is
the radius of the hydrophobic core with units of m (core radius measurement described
below). In order to simplify comparison, D is reported in units of cm2/s and a is reported
in units of nm. Equation 5.3 can be rearranged in terms of concentration in the form of
equation 5.4.
6

1

𝐶𝐶 = 𝐶𝐶0 ∗ 𝜋𝜋2 ∗ ∑∞
𝑛𝑛=1 𝑛𝑛2 ∗ 𝑒𝑒

−𝐷𝐷∗𝑛𝑛2 ∗𝜋𝜋2 ∗𝑡𝑡
𝑎𝑎2

(5.4)

In equation 5.4, C is the concentration of drug in the dialysis cup in micrograms
per milliliter. At the initial timepoint, the concentration of drug is equal to the total initial
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drug concentration C0 with units of micrograms per milliliter and the infinite sum is equal
to π2/6. Therefore, equation 5.4 can be further simplified into equation 5.5.
𝐶𝐶𝑡𝑡

𝐶𝐶0

6

= 𝜋𝜋2 ∗

1
∑∞
𝑛𝑛=1 𝑛𝑛2

∗ 𝑒𝑒

−𝐷𝐷∗𝑛𝑛2 ∗𝜋𝜋2 ∗𝑡𝑡
𝑎𝑎2

(5.5)

Drug release profiles were fit to equation 5.5. In order to assure the accurate
fitting of drug release profiles, weighting values were adjusted between 0 and 2. Because
the higher order terms in the infinite series converged to zero quickly, equation 5.5 was
approximated to ten terms in order to prevent overfitting of the data.
The radius of the hydrophobic core (a) of PNAs in equation 5.5 was estimated
using equation 5.6, which assumes the hydrodynamic diameter of a PNA is equal to two
times the sum of the radii of the hydrophobic core and PEG shell (233).
𝐷𝐷𝐻𝐻𝐻𝐻𝐻𝐻 = 2 ∗ 𝑅𝑅𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆 + 2 ∗ 𝑎𝑎

(5.6)

In equation 5.6, DHYD is the hydrodynamic diameter of nanoparticles measured by
DLS, a is the radius of the hydrophobic core and RSHELL is the radius of the PEG shell.
All diameters and radii have units of nm. RSHELL is determined using equation 5.7.
𝑅𝑅𝑠𝑠ℎ𝑒𝑒𝑒𝑒𝑒𝑒 = 2𝑅𝑅𝐺𝐺,𝑃𝑃𝑃𝑃𝑃𝑃 − 2 ∗ 0.215𝑀𝑀𝑊𝑊 0.583

(5.7)

In equation 5.7, RG,PEG and MW are the radius of gyration (nm) and molecular
weight of PEG (g/mol), respectively. For the methoxy-terminated 5 kDa PEG in the shell
of PNAs, RSHELL was determined to be 6.16 nm.
5.2.6

Statistics
All values are reported as mean±standard deviation of triplicate measurements,

while model parameters are described as mean±SEM unless indicated otherwise. Groups
of measurements were compared using one-way ANOVA with Bonferroni’s post hoc
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test, while pairs were compared with a Student’s t test. Statistical significance is indicated
by * (p<0.05), ** (p<0.01) or *** (p<0.001).
5.3

Results

5.3.1

End-Capping Groups Do Not Affect the Size or Surface Charge of PNAs
Proton NMR confirmed the successful synthesis of 3P [PEG (3.54 ppm, s, relative

area 1.000), PEI (2.32 ppm, s, relative area 0.017; 2.44 ppm, s; 2.55 ppm, s; 2.60 ppm, s;
2.66 ppm, s, relative area 0.019), and PAL (0.83 ppm, d, relative area 0.022; 1.20 ppm, s,
relative area 0.082)] and 3P’ [PEG (3.51 ppm, s, relative area 1.000), PLL (1.24 ppm, s,
relative area 0.043; 2.23 ppm, m, relative area 0.102; 2.60 ppm, s, relative area 0.007;
2.68 ppm, s, relative area 0.009; 2.97 ppm, s, relative area 0.009; 3.24 ppm, s, relative
area 0.118; 3.42 ppm, s, relative area 0.117; 3.68 ppm, s, relative area 0.012; 4.09 ppm, s,
relative area 0.007; 7.78 ppm, s, relative area 0.008), and PAL (0.83 ppm, d, relative area
0.006; 1.23 ppm, s, relative area 0.043; 1.46 ppm, s, relative area 0.021)]. Acetyl peaks
on 3PAA (1.90 ppm, s, relative area 0.017) and 3P’AA (1.78 ppm, s, relative area 0.011)
confirmed AA end-capping, while acetyl chloride peaks on 3PCAC (4.15 ppm, s, relative
area 0.018) and 3P’CAC (4.27 ppm, s, relative area 0.006) confirmed CAC end-capping.
The calculated molar substitutions (defined in chapter 2) of PEG, PAL, CAC, and AA on
the polymer scaffolds of PNAs are described in Table 5.1. Based on the molar
substitution of each component, 52 to 100 percent of primary amines on these PNAs were
end-capped. GPC confirmed that 3P, 3PCAC, 3PAA, 3P’, 3P’CAC and 3P’AA had
uniform molecular weight distribution and were free of small molecule impurities as
shown in Figure 5.3.
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Table 5.1. Molar substitution of unmodified and end-capped PNAs. PEG, PAL and endcapping group substitution were determined by NMR quantification.
Molar Substitution (mol/mol primary
Remaining Amines (mol/mol
amine on scaffold) (%)
primary amine on scaffold) (%)
PNA
PEG
PAL
CAC
AA
NH2
3P
10.0±0.3 55.0±1.4
----35.0±1.4
3PCAC 10.0±0.3 55.0±1.4 20.0±0.5
--15.0±1.5
3PAA 10.0±0.3 55.0±1.4
--23.0±0.6
12.0±1.6
3P’
5.0±0.1 47.0±1.2
----48.0±1.2
3P’CAC 5.0±0.1 47.0±1.2 33.0±0.8
--15.0±1.4
3P’AA 5.0±0.1 47.0±1.2
--48.0±1.2
0.0±1.7
PEG, PAL, CAC and AA substitution are reported as measurement±measurement error
for NMR (n=1). CAC and AA were not detectable on 3P or 3P’. CAC was not detectable
on 3PAA or 3P’AA, while AA was not detectable on 3PCAC or 3P’CAC. Error from
PEG, PAL, CAC and AA quantification were propagated into the remaining amine
quantification.
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Figure 5.3. Gel permeation chromatographs of unmodified and end-capped PNAs 3P (A),
3PCAC (B), 3PAA (C), 3P’ (D), 3P’CAC (E) and 3P’AA (F). Chromatographs were
measured by UV-visible absorbance detector at 220 nm.

177

The diameter and surface charge of the PNAs were measured by DLS. As
summarized in Table 5.2, all PNAs were between 15 and 40 nm in diameter. End-capping
reactions slightly decreased the diameter of 3P, but the reactions increased the diameter
of 3P’. However, the size changes of each PNA following end-capping reactions were not
statistically significant. All PEI-based PNAs had zeta potentials between -10 and 10 mV
indicating a neutral surface. The PEG in the shell of PEI-based PNAs shields any charged
groups remaining in the core and allows the PNAs to have a neutral surface charge.
3P’AA without core amines also had a neutral surface, but 3P’ and 3P’CAC with core
amines had large positive zeta potentials (>10 mV) indicating a positively charged
surface. These results suggest that the PEG in the shell of PLL-based PNAs may not
shield charged groups in the core from the surface. The differences in surface charge
between PEI-based PNAs are not statistically significant, but the differences in surface
charge between 3P’AA and 3P’ or 3P’CAC are statistically significant. The diameter and
zeta potential of drug-loaded PNAs could not be directly determined by DLS due to the
turbidity of the samples which prevented the accurate detection of scattered light.
Increased turbidity of PNA colloidal solutions after drug loading could be due to two
factors: 1) increased diameter of drug-loaded PNAs increasing light scattering by the
Tyndall effect (234), or 2) disruption of the palmitate in the nanoassembly core leading
to the formation of a cloudy emusion near the PNA core due to undesired interactions
between water and palmitate groups. Further studies are needed to elucidate the causes
for cloudiness of drug-loaded PNAs.
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Table 5.2. Physicochemical properties of unmodified and end-capped PNAs.
PDI (unitless)
Nanoparticle
Diameter (nm)
Zeta Potential (mV)
0.38±0.04
3P
35.2±5.5
-5.2±0.8
0.37±0.01
3PCAC
32.6±7.8
-1.3±0.6
0.42±0.08
3PAA
29.5±4.6
-4.1±0.7
0.56±0.02
3P’
16.3±3.0
29.5±1.6
0.54±0.01
3P’CAC
22.4±3.4
26.0±3.5
0.62±0.09
3P’AA
22.4±2.8
-6.0±0.6***
Diameter, zeta potential and PDI are reported as mean±SD (n=3). Statistical
significance is determined by a one-way ANOVA with Bonferroni’s post-test correction
for each group as described in the methods section.
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5.3.2

End-Capping Group Bulkiness and Scaffold Amine Steric Hindrance Control

End-Capping Reaction Yields
A fluorescamine assay was used to quantify the remaining primary amines in
PNAs after end-capping reactions with AA or CAC. Figure 5.4 shows the normalized
fluorescence of fluorescamine-modified PEI- and PLL-based PNAs. All PNAs were in
the linear range of a fluorescamine calibration curve. The AA reaction decreased the
fluorescence of 3PAA by 65% compared to 3P, and the reaction decreased the
fluorescence of 3P’AA by greater than 99% compared to 3P’. The decreases in
fluorescence correspond to a 65% and greater than 99% molar substitution yield for AA
on 3PAA and 3P’AA, respectively. By comparing the changes in fluorescence to the
remaining primary amines on 3P or 3P’ before the reaction, the molar substitution of AA
on PNAs could be determined. These decreases in fluorescence correspond to 23% and
48% AA molar substitution of 3PAA and 3P’AA, respectively, which is in agreement
with NMR quantification. In contrast, the CAC modification showed false positive
signals during the fluorescamine assay which were not in agreement with NMR
quantification. The CAC reaction increased the fluorescence of 3PCAC by 54%
compared to 3P, and it increased the fluorescence of 3P’CAC by 68% compared to 3P’.
The decreases in fluorescence correspond to a 54% and 68% increase in primary amines
on 3PCAC and 3PCAC following the reaction with CAC. These increases correspond to
a 19% and 33% increase in primary amines on 3P and 3P’, respectively. False positives
from the fluorescamine assay may be due to three causes: 1) physical interactions
between amine-conjugated fluorescamine and CAC groups in the core of PNAs that alter
the electronic environment of the dye, 2) an unexpected reaction between fluorescamine
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and CAC that produces a highly fluorescent side product, or 3) fluorescence of CAC
groups in the same wavelength range as amine-conjugated fluorescamine. It should be
noted that fluorescamine reacts with primary amines by nucleophilic addition of the
amine (235), and that chloride groups are unlikely to undergo the same addition. In
addition, both 3PCAC and 3P’CAC were non-fluorescent under fluorescamine
measurement conditions. Although physical reactions between CAC groups and reacted
fluorescamine in the core of PNAs are hypothesized to increase fluorescence signals,
further studies are needed to elucidate a detailed mechanism of the increased fluorescence
signals. Other amine-reactive fluorogenic dyes such as ninhydrin were considered as an
alternative method of directly quantifying the remaining primary amines in the core of
CAC-reacted PNAs, but the elevated temperature often required for these reactions may
degrade the peptide scaffold of 3P’ PNAs and generate primary amines that increase the
fluorescence signal following the assay (236, 237). Because NMR quantification was
verified as an accurate method to determine the AA end-capping yield of PNAs, the
NMR quantification was used exclusively to determine the end-capping reaction yield of
CAC-modified PNAs.
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Figure 5.4. Fluorescamine quantification of primary amines in unmodified and endcapped PNAs. Primary amines were quantified in PEI-based (A) and PLL-based (B)
PNAs and normalized to unmodified PNAs for each group.
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5.3.3

Removal of Amines from the PNA Core Increases Drug Loading and

Encapsulation Efficiency
The drug loading and encapsulation efficiencies of PNAs are summarized in
Table 5.3. End-capped PNAs increased CFZ loading compared to unmodified PNAs, and
end-capping reactions allowed PNAs to stably entrap DOC. In addition, PLL-based
PNAs had higher CFZ and DOC loading efficiencies than PEI-based PNAs. These
differences in drug loading efficiencies between PNAs are statistically significant. Both
3P and 3P’were unable to stably entrap DOC, and thus DOC-loaded 3P and 3P’ were not
tested further. For both PEI- and PLL-based PNAs, drug loading and encapsulation
efficiency were highest with the AA modification. Statistical trends of the drug loading
and encapsulation efficiencies of PNAs are summarized in Figure 5.5.
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Table 5.3. Drug loading of unmodified and end-capped PNAs.
Molar Drug
Encapsulation
Drug Loading
Loading Efficiency
Efficiency (w/w
Drug
PNAs
Efficiency (w/w
(mol Drug/mol
%)
%)
PNA)
9.7±0.5
3P
4.3±0.2
44.5±1.8
CFZ
15.4±1.1
3PCAC
6.7±0.5
71.8±5.7
15.5±0.5
3PAA
6.8±0.2
73.5±2.1
4.4±0.4
3P’
5.3±0.5
55.8±5.2
CFZ
7.2±0.9
3P’CAC
8.3±1.0
90.1±10.4
7.5±0.6
3P’AA
8.8±0.7
96.2±7.2
3P
------DOC
3PCAC
3.3±0.1
6.8±0.2
34.2±2.0
9.6±0.2
3PAA
4.7±0.1
49.3±1.1
3P’
------DOC
3P’CAC
6.2±1.0
4.8±0.8
66.4±10.8
5.8±0.5
3P’AA
7.6±0.7
81.9±7.9
Drug loading efficiency, molar drug loading efficiency and encapsulation efficiency are
reported as mean±SD (n=3). Statistical significance is indicated in Figure 5.5.
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Figure 5.5. Drug loading efficiency of unmodified and end-capped PNAs. Drug loading
was determined using the model drugs carfilzomib (A,C) and docetaxel (B,D).

185

5.3.4

Amine End-Capping Groups Sustain Drug Release from PNAs
Figures 5.6 and 5.7 show drug release profiles from CFZ- and DOC-loaded

PNAs, respectively. The first order kinetic model was a good approximation for the
release of CFZ and DOC from drug-loaded PNAs. Drug release rates were consistent
over 48 hours, and burst release was not observed for the PNAs used in this study. This
model failed to provide any mechanistic information about drug release mechanisms
from PNAs, but it did provide a facile method of comparing drug release between
formulations. End-capping modifications increased the half-life of CFZ release from
PNAs in order of no, CAC, and AA modifications for both PEI- and PLL-based PNAs,
with the exception of CFZ-loaded 3P’CAC which decreased its drug release half-life
(Table 5.4 and Figure 5.8). In addition, the AA modification increased the half-life of
DOC release compared to CAC modification for both PEI- and PLL-based PNAs. PLLbased PNAs increased drug release half-life compared to PEI-based PNAs with the
exception of CFZ-loaded 3P’CAC. These results suggest that the chemical modification
of PNAs to remove charged groups from the core can increase drug release half-life and
sustain drug release over time.
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Figure 5.6. Carfilzomib release profiles from unmodified and end-capped PNAs 3P (A),
3PCAC (B), 3PAA (C), 3P’ (D), 3P’CAC (E) and 3P’AA (F).
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Figure 5.7. Docetaxel release profiles from unmodified and end-capped PNAs 3P (A),
3PCAC (B), 3PAA (C), 3P’ (D), 3P’CAC (E) and 3P’AA (F). Due to poor drug loading of
3P (A) and 3P’ (D), drug release was not measured from these PNAs.
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Table 5.4. Parameters from a first order kinetic model for drug release from unmodified
and end-capped PNAs.
Drug
PNAs
t1/2 (h)
k (h-1)
3P
4.1 (3.0-6.6)
0.169 (0.106-0.233)
CFZ
3PCAC
17.5 (14.9-21.1)
0.040 (0.033-0.046)
3PAA
23.1 (17.8-33.2)
0.030 (0.020-0.039)
3P’
6.5 (4.9-9.6)
0.107 (0.072-0.142)
CFZ
3P’CAC
3.6 (2.7-5.5)
0.190 (0.127-0.253)
3P’AA
28.2 (24.5-33.1)
0.024 (0.020-0.028)
3P
----DOC
3PCAC
4.8 (3.6-7.1)
0.146 (0.097-0.194)
3PAA
5.3 (3.7-9.5)
0.130 (0.072-0.187)
3P’
----DOC
3P’CAC
22.3 (18.8-27.5)
0.031 (0.025-0.037)
3P’AA
26.6 (22.3-33.1)
0.026 (0.021-0.031)
Kinetic parameters are reported as mean with 95% CI in parentheses. Differences in
kinetic parameters between each model were compared by an extra sum of squares F
test. Statistical significance is reported in figure 5.8.
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Figure 5.8. Drug release half-lives from unmodified and end-capped PNAs. Drug release
half-lives were determined using the model drugs carfilzomib (A,C) and docetaxel (B,D).
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5.3.5

Drug Diffusion through the Hydrophobic Core of PNAs Controls Drug Release
Figure 5.9 shows drug release profiles of PNAs that were modeled with the

Korsmeyer-Peppas model. The Korsmeyer-Peppas model fit the drug release profiles
well for all PNAs except for DOC-loaded 3P’CAC, which underestimated terminal drug
release for weighting values of 0, 1 and 2. Table 5.5 shows kinetic parameters from the
Korsmeyer-Peppas model. End-capping reactions decreased the kinetic constant K
compared to unmodified PNAs, which confirms the results from the first-order kinetic
models. In all cases, AA-modified PNAs had lower K than CAC-modified PNAs. PLLbased PNAs decreased K for DOC compared to PEI-based PNAs, but the scaffold had a
minimal effect on K for CFZ-loaded PNAs. Figure 5.10 compares N values of drug
release from end-capped PNAs. The 95% confidence intervals of the N values for most
PNAs contained 0.45, indicating that drug release was diffusion-controlled. The 95%
confidence intervals of the N values for CFZ-loaded 3PCAC and 3PAA were between
0.45 and 0.65, indicating that other transport processes in addition to diffusion may
control drug release. The 95% confidence intervals of the N values for PNAs was not
greater than 0.85, suggesting that a receding boundary of the hydrophobic core did not
contribute to drug release. Based on these findings, drug release profiles were further
modeled using a diffusion-based drug release model.
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Figure 5.9. Drug release profiles of unmodified and end-capped PNAs using the
Korsmeyer-Peppas drug release model. Drug release profiles were measured using
model drugs CFZ (A-F) and DOC (G-L). Due to poor DOC loading of 3P (G) and 3P’
(J), drug release was not measured from these PNAs.
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Table 5.5. Kinetic parameters for drug release from unmodified and end-capped PNAs
using the Korsmeyer-Peppas model. N values indicate a Fickian diffusion-controlled
(N=0.45), a non-Fickian transport-controlled (0.45<N<0.85), or an anomalous
transport-controlled drug release mechanism (N>0.85).
Drug
Release Mechanism
PNA
K (h-1)
N (unitless)
Fickian Diffusion
3P
24.0 (16.5-31.5)
0.46 (0.34-0.57)
CFZ 3PCAC
Non-Fickian Transport
8.5 (5.9-11.1)
0.61 (0.53-0.70)
Non-Fickian Transport
3PAA
7.3 (4.3-10.2)
0.55 (0.46-0.65)
Fickian Diffusion
3P’
18.3 (11.5-25.1)
0.50 (0.36-0.63)
CFZ 3P’CAC 25.1 (15.2-35.0)
Fickian Diffusion
0.44 (0.30-0.58)
Fickian Diffusion
3P’AA
8.7 (6.3-11.1)
0.52 (0.45-0.60)
3P
DOC 3PCAC
Fickian Diffusion
24.1 (17.7-30.5)
0.38 (0.30-0.46)
Fickian Diffusion
3PAA
21.1 (15.2-27.1)
0.41 (0.32-0.49)
3P’
DOC 3P’CAC
Fickian Diffusion
10.2 (5.6-14.9)
0.49 (0.40-0.60)
Fickian Diffusion
3P’AA
11.2 (7.0-15.4)
0.46 (0.37-0.55)
Kinetic parameters are reported as mean with 95% CI in parentheses. The 95%
confidence intervals of N values were compared to 0.45 to determine the drug release
mechanism.
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Figure 5.10. N values from the Korsmeyer-Peppas drug release model for unmodified
and end-capped PNAs.
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5.3.6

Amine End-Capping Groups Decrease Drug Diffusivity in the Core of PNAs
Figure 5.11 shows drug release profiles for CFZ and DOC using an unsteady state

spherical diffusion model. Semi-log plots of concentration vs. time were slightly curved,
but the model fit the data well up to 90% of drug released. Table 5.6 summarizes the drug
diffusivities and hydrophobic core diameters of various PNAs. In comparison to the
estimated diffusivity of free CFZ or DOC at 37 °C in water from the Stokes-Einstein
equation, PNAs reduced drug diffusivity by 4- to 5-fold, perhaps due to increased density
and interactions with the PNA core. Amine end-capping reactions decreased the radius of
the hydrophobic core for PEI-based PNAs, but they increased the hydrophobic core
radius of PLL-based PNAs. PLL-based PNAs had smaller core radii than PEI-based
PNAs for each end-capping modification, possibly due to the compact secondary
structure of unmodified PLL compared to PEI. Figure 5.12 compares drug diffusivities in
the core of end-capped PNAs. AA modifications decreased the diffusivity of both CFZ
and DOC in PNAs, but CAC modifications increased the diffusivity of CFZ in 3P’CAC.
These results suggest that end-capping modifications to PNAs can sustain drug release
from the core of PEI-based PNAs by decreasing the diffusivity of drugs in the PNA core,
but that end-capping modifications of PLL-based PNAs sustain drug release by
increasing the diameter of the hydrophobic core.
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Figure 5.11. Drug release profiles of unmodified and end-capped PNAs using the
unsteady state spherical diffusion model. Drug release profiles were measured using the
model drugs CFZ (A-F) and DOC (G-L). Due to poor DOC loading of 3P (G) and 3P’
(J), drug release was not measured from these PNAs.
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Table 5.6. Diffusion parameters for PNA-encapsulated drugs from the unsteady state
spherical diffusion model (equation 5.5). Diffusion parameters for free drugs were
estimated using the Stokes-Einstein equation and are included for comparison.
Drug
PNA
a (nm)
D (cm2/s) *1018
CFZ
None
--53,400
3P
11.4±2.8
3.90 (2.70-5.10)
CFZ
3PCAC
10.1±3.9
0.89 (0.73-1.05)
3PAA
8.6±2.3
0.27 (0.22-0.33)
3P’
2.0±1.5
0.07 (0.06-0.08)
CFZ
3P’CAC
5.0±1.7
0.93 (0.81-1.05)
3P’AA
5.0±1.4
0.10 (0.08-0.11)
DOC
None
--53,000
3P
11.4±2.8
--DOC
3PCAC
10.1±3.9
1.50 (1.08-1.93)
3PAA
8.6±2.3
0.95 (0.63-1.22)
3P’
2.0±1.5
--DOC
3P’CAC
5.0±1.7
0.13 (0.11-0.15)
3P’AA
5.0±1.4
0.11 (0.08-0.13)
Hydrophobic radius is reported as mean±SD. The error is propagated from equation 5.7
into equation 5.6. The diffusivity is reported as the mean with 95% CI in parentheses.
Statistical significance is determined in Figure 5.12.
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Figure 5.12. Drug diffusivities in the core of unmodified and end-capped PNAs from the
unsteady state spherical diffusion model.
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5.4

Discussion

5.4.1

PNAs with an Uncharged Core are Effective Carriers for Hydrophobic Drugs
PNAs forming globular, micellar and vesicular structures have drawn attention as

multifunctional drug carriers over the past several decades (238-240). Unfortunately, the
therapeutic efficacy of PNAs is often disappointing due to particle instability, low drug
entrapment, and rapid drug release in the blood (241-243). Polymer micelles are used as
FDA-approved drug delivery vehicles (244, 245), but micelles often demonstrate initial
burst drug release followed by sustained long-term drug release. This two-step drug
release pattern reduces drug accumulation in tumors, which can limit the efficacy of
cancer chemotherapy (246). Drugs that are released from drug carriers that are away from
the tumor may accumulate in healthy tissues and cause undesired side effects (247). Twostep drug release profiles are often attributed to drugs that remain weakly bound to the
polymer shell of nanoassemblies, even after extensive purification (248, 249). Unlike free
drugs that often co-exist as impurities along with drug-loaded carriers, weakly bound
drugs cannot be easily separated from drug-loaded nanoassemblies without removing
entrapped drugs. Therefore, despite the critical need to fine-tune drug release from
nanoparticles, preventing burst drug release from PNAs remains difficult.
A simplified form of PNA with a charged scaffold (PEI or PLL), hydrophobic
groups (PAL), and amine end-capping pendant groups (CAC and AA) was synthesized.
By following this process, a family of polymer nanoassemblies was synthesized for
entrapping CFZ and DOC. The data demonstrated that all six PNAs were small enough to
maintain sufficient PEG shell density in order to minimize weak binding of drugs or other
molecules to the surface of PNAs (250). Amine end-capping modifications to the core of
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PNAs did not significantly affect their particle size, suggesting that chemical
modifications to the nanoparticle core do not prevent PNAs from permeating throughout
small blood vessels in the body. PNAs were also uniform in molecular weight
distribution, which maintains the intermolecular consistency of nanoassemblies and
minimizes changes in dispersity among the formulations after core modifications.
The fluorescamine characterization and NMR quantification of PNAs showed that
NHS-activated PEG and palmitoyl chloride reactions could not remove all remaining
primary amines from the core of PNAs, but amine end-capping reagents further removed
some of the remaining primary amines. This suggests that the steric hindrance of the
remaining primary amines on PNAs increases following PEG and PAL reactions, which
limits the molar substitution of larger hydrophilic polymers or hydrophobic groups on
polymer scaffolds (251). Both AA and CAC modifications removed more remaining
primary amines from 3P’ than from 3P, indicating that the primary amines on PLL are
less hindered than the primary amines on PEI (252). AA modification of 3P’ removed all
remaining primary amines in the PNA core, verifying that the use of small pendant
groups and less sterically hindered scaffolds allows for the complete removal of
remaining primary amines from PNAs. These results also indicate that the selection of
polymer scaffolds with less sterically hindered amines or lower amine density may allow
for higher substitution yields of PEG and PAL on PNAs.
5.4.2

End-Capping Modifications Modulate Drug Encapsulation and Release
Experimental results show that amine end-capping groups increased the drug

loading and encapsulation efficiency of PNAs. Charged amines in the PNA core may
prevent drugs from entering nanoassemblies during loading. In addition, these results
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demonstrated that PLL, a polymer scaffold with minimal ionic effects resulting in a
distinct pKa value, could increase drug loading compared to PEI, a polymer scaffold with
significant ionic effects and a broad pKa value (253, 254). Therefore, removing ionic
groups to increase the hydrophobicity of the PNA core is an effective approach to
increase drug loading and ultimately improve the delivery of anticancer drugs to tumors.
Drug release profiles of CFZ-loaded PNAs demonstrated that this experimental
approach helped to prevent the burst release of CFZ from PNAs compared to previously
developed CFZ-loaded polymer micelles (255). Drug release studies also indicated that
PNAs could fine-tune drug release as a function of scaffold and pendant group
modifications to the core. The drug release half-lives of PNAs ranged from 4 to 28 hours
as amines were removed from the core by changing scaffold from PEI to PLL and by
increasing the end-capping group substitution from no modification to AA modification.
Although some primary amines of 3P were reacted during the conjugation of PEG and
PAL to the scaffold, the remaining primary, secondary and tertiary amines make the core
of 3P charged (256). Because of this core charge, drugs could be weakly bound in the 3P
core and release quickly compared to 3P’ with only primary amines.
5.4.3

Mechanistic Modeling Elucidates a Mechanism for Controlling Drug Release

from PNAs
In order to determine the mechanism for the changes in drug release profiles of
PNAs following end-capping reactions, drug release profiles were fit to several
mathematical models. Initially, a first order kinetic model was used to determine the
effects of end-capping modifications on overall drug release rates. Although this model
indicated that end-capping modifications increase the drug release half-lives of PNAs, it
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fails to provide detailed information about drug release mechanisms from PNAs (257). It
was hypothesized that the rate-determining step of drug release from PNAs was the
diffusion of drug out of the PNA core, and that end-capping modifications decreased drug
diffusivity in the PNA core. In order to elucidate the rate-determining step for drug
release from PNAs, the drug release profiles were then fit to the Korsmeyer-Peppas
model of drug release. By comparing the N values from fitted drug release profiles to
literature, a rate-determining step could be determined (258). For N values equal to 0.45,
the drug release is controlled by the Fickian diffusion of drug molecules out of the
hydrophobic core. Fickian diffusion indicates that the diffusivity value of drug in the
nanoparticle core is independent of both time and drug concentration. The 95%
confidence intervals for the N values of most drug-PNA combinations overlapped 0.45,
indicating that drug release from these PNAs occurred because of Fickian diffusion
(259). N values between 0.45 and 0.85 indicate that non-Fickian transport processes
control drug release. Non-Fickian transport processes refer to a combination of Fickian
diffusion and a time- or drug concentration-dependent change in nanoparticle core
environment during drug release such as a glass transition for polymers (260). The 95%
confidence intervals for the N values of CFZ-loaded 3PCAC and 3PAA were between
0.45 and 0.85, indicating that CFZ loading may alter the rigidity of the PNA core or alter
diffusion rates in the core of these PNAs (261). N values above 0.85 indicate that
processes other than diffusion control the release of drug from the nanoparticle core.
None of the 95% confidence intervals of the N values for PNAs were greater than 0.85.
Because the Korsmeyer-Peppas model indicated that the rate-determining step for
drug release was diffusion, an unsteady state spherical diffusion model was used to
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measure drug diffusivity in the PNA core. End-capping modifications to 3P decreased
CFZ diffusivity, suggesting that end-capping modifications reduce the pore sizes for drug
diffusion in the PNA core. In contrast, end-capping modifications increased the
hydrophobic core diameter of PLL-based PNAs but had a minimal effect on drug
diffusivity, suggesting that end-capping modifications of PLL-based PNAs do not affect
the pore sizes in the core of these PNAs.
5.4.4

PNAs with a Positive Core Charge Release Carfilzomib Quickly Compared to

Similar PNAs with a Neutral Core
The CFZ release half-life of 3P’CAC was shorter than initially expected.
Although drug release rate trends suggest that the CFZ release half-life of 3P’CAC would
be 22 hours, the observed CFZ release half-life of 3P’CAC was 4 hours. One explanation
for the relatively short CFZ release half-life of 3P’CAC is that the positive core charge of
3P’CAC drew charged molecules into the PNA core. In this highly charged core
environment, CFZ may become positively charged and repel from the cationic core
environment. In contrast, DOC is not easily ionizable and hydroxyl groups on DOC may
favorably interact with charged molecules in the PNA core. Therefore, pendant groups
that do not increase core charge of PNAs would achieve stable entrapment and sustained
release of hydrophobic anticancer drugs.
5.5

Conclusions
In this study, a novel delivery system was developed for CFZ and DOC by using

polymer nanoassemblies (PNAs). Six PNAs were synthesized with various polymer
scaffolds and end-capping modifications to determine the effects of ionizable groups in
the PNA core on drug delivery. Removing charged groups from the core of PNAs
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increased their drug loading and encapsulation efficiency, while also sustaining drug
release and increasing their drug release half-life. In addition, mechanistic modeling
showed that drug release from PNAs was controlled by decreasing drug diffusivity in the
nanoassembly core. In summary, this study has demonstrated a mechanism-based, facile
engineering method for the development of PNA drug carriers that can entrap drugs at
high yields and enhance their therapeutic efficacy by suppressing initial burst drug
release.

**Portions of Chapter 5 were previously published in (262). Reproduced with permission
from Future Science Group: Therapeutic Delivery, Volume 7, Issue 10, Pages 665-681,
Figures 1-7 and Text. Copyright 2016 is given to the publication in which the material
was originally published.
Copyright (C) Derek Reichel 2017
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CHAPTER SIX
PNAs WITH CONTROLLED DRUG RELEASE PROFILES IMPROVE
CARFILZOMIB EFFICACY BY PREVENTING RAPID DRUG METABOLISM AND
SUSTAINING PROTEASOME INHIBITION IN CELLS
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6

PNAs WITH CONTROLLED DRUG RELEASE PROFILES IMPROVE

CARFILZOMIB EFFICACY BY PREVENTING RAPID DRUG METABOLISM AND
SUSTAINING PROTEASOME INHIBITION IN CELLS
6.1

Introduction
The inhibition of novel biological targets such as the proteasome has emerged as a

promising approach to improve cancer treatment. The proteasome is a multi-protease
enzyme complex that plays an essential role in the regulation of cellular processes by
degrading the proteins involved in cell proliferation and signaling (263). Small molecule
inhibitors of proteasomes can increase the accumulation of misfolded proteins in cells.
The accumulation of misfolded proteins in cancer cells following sustained proteasome
inhibition causes cell stress leading to apoptosis. Because of the essential role that the
proteasome plays in the survival of all living cells, the selectivity of proteasome
inhibitors towards cancer cells was initially questioned (264). However, several studies
have validated proteasome inhibition as a selective method for killing rapidly
proliferating cancer cells compared to normal cells (265). In particular, cancer cells that
are resistant to other conventional and targeted chemotherapies have shown sensitivity to
proteasome inhibitors (266, 267). Three proteasome inhibitors (bortezomib, carfilzomib
and ixazomib) have received FDA approval for cancer treatment (268-270).
Carfilzomib (CFZ) is a second-generation proteasome inhibitor with the potential
to treat solid tumors, but its clinical applications have been limited to blood cancers such
as multiple myeloma (271). CFZ showed efficacy at treating a variety of solid cancers in
animal models (272, 273). While many clinical studies have proposed the use of CFZ in
solid tumors, clinical trials in breast, lung, and colon cancers were unsuccessful (274).
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The limited clinical applications of CFZ are often attributed to its poor biopharmaceutical
properties such as its rapid clearance that limits the accumulation of active drug in tumors
and prevents the sustained inhibition of proteasomes in cancer cells (275). Therefore,
there is a need to improve the biopharmaceutical properties of CFZ in order to increase
drug accumulation in solid tumors and improve treatment efficacy.
CFZ is clinically available as an intravenous cyclodextrin formulation
(Kyprolis®), but this formulation fails to increase the metabolic stability of CFZ (276).
Although cyclodextrin complexation increased the solubility of CFZ, the half-life of CFZ
in blood after intravenous injection of Kyprolis is less than 30 minutes (277, 278). The
poor half-life of CFZ in blood is typically attributed to the rapid extrahepatic metabolism
of free drug. As free CFZ is degraded in the blood, the cyclodextrin complex rapidly
dissociates to maintain thermodynamic equilibrium between the free CFZ, the unbound
cyclodextrin and the CFZ-cyclodextrin complex. As a result, cyclodextrin formulations of
CFZ fail to increase the accumulation of CFZ in solid tumors. Therefore, there is a
growing need to develop novel formulations of CFZ to expand the therapeutic benefits of
proteasome inhibition therapy to a variety of human cancers.
Previously, polymer micelle (PM) carriers for CFZ were developed using FDAapproved materials, but these formulations had poor pharmacokinetic properties that
limited their in vivo efficacy (160). Several drug-loaded PMs are either used clinically
(e.g., Genexol, Nanoxel) or are undergoing clinical trials (e.g., NK012, NK105,
SP1049C, NC-6004) for the controlled delivery of anticancer drugs to solid tumors (279281). These formulations reduced the systemic, cardiac, hepatic, and renal toxicities of
anticancer drugs (282). In a previous study, CFZ-loaded PMs protected the drug from
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enzymatic degradation in the presence of mouse liver homogenate (255). However, the
antitumor efficacy of CFZ-loaded PMs was similar to cyclodextrin-complexed CFZ. This
unexpected result was attributed to the poor drug release properties of CFZ-loaded PMs
such as burst release and rapid drug release rates (160). In addition, the dilution of PMs
after intravenous injection can destabilize the micelles and increase drug release into the
blood. Stable PNA formulations of CFZ with improved drug release properties may
increase the in vivo treatment efficacy of CFZ by protecting the drug from extrahepatic
metabolism and sustaining drug release into solid tumors.
In this study, the treatment efficacy of CFZ-loaded PNAs was compared to free
CFZ using cell-based assays mimicking in vivo drug delivery conditions. 3P’AA was
selected as a model PNA with the highest CFZ loading and release half-life of the
previously tested formulations in chapter 5. The metabolic stability, cytotoxicity and
proteasome inhibition profile of CFZ formulations were identified as three key factors
controlling the in vivo treatment efficacy of CFZ. HT29 colon cancer cells were used as a
model cell line for CRC tumors, while H23 lung cancer cells were selected as a model
cell line with well-characterized proteasome activity profiles following treatment with
proteasome inhibitors. The results from this study will indicate the potential of
nanoparticle drug carriers with sustained CFZ release to improve the treatment of solid
tumors and justify further in vivo experiments.
6.2

Materials and Methods

6.2.1

Materials and Cells
3P’AA was synthesized and loaded with CFZ as described in chapter 5.

Epoxomicin, ethylenediaminetetraacetic acid (EDTA), resazurin sodium salt, sodium
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dodecyl sulfate (SDS), and Tris-HCl were purchased from Sigma Aldrich (St. Louis,
MO). A fluorogenic peptide substrate Succinate-Leu-Leu-Val-Tyr-(7-amino-4methylcoumarin) (Suc-LLMY-AMC) was purchased from Biovision (Milpitas, CA).
Acetonitrile (ACN), dimethyl sulfoxide (DMSO), phosphate buffered saline (PBS), water
and Hanks’ balanced salt solution (HBSS) were purchased from Fisher Scientific
(Waltham, MA). Passive lysis buffer solution was purchased from Promega (Madison,
WI). 20S proteasome assay buffer (20 mM Tris-HCl, 0.5 mM EDTA, 0.035% SDS, pH
8.0) was prepared by dissolving components in water and adjusting the pH with sodium
hydroxide. Carfilzomib (CFZ) was purchased from LC Laboratories (Woburn, MA).
McCoy’s 5A media (M5A), RPMI-1640 media and 0.05% trypsin/EDTA were purchased
from GE Healthcare (Logan, UT). Fetal bovine serum (FBS) was purchased from Atlanta
Biologicals (Flowery Branch, GA). The human lung cancer cell line H23 and human
colon cancer cell line HT29 were purchased from American Type Culture Collection
(ATCC, Manassas, VA). H23 cells were cultured in RPMI-1640 media with 10% FBS,
while HT29 cells were cultured in M5A with 10% FBS. All ATCC recommendations
were followed for both cell lines. Cells were cultured in a humidified environment with
5% CO2 at 37 °C.
6.2.2

Screening of Carfilzomib Degradation Conditions
A stock solution of CFZ was prepared (DMSO, 10 mg/ml). Ten microliters of

CFZ stock solution was added to 990 microliters of acetonitrile, M5A containing 25%
inactivated FBS (iFBS), M5A containing 25% active FBS (aFBS) and M5A without
FBS. The CFZ-spiked solutions were stored at 37 °C while gently mixing. Aliquots (50
μl) of each solution were removed after 0, 30 and 60 minutes. Each aliquot was diluted in
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50 μl of acetonitrile to quench the degradation reactions. The quenched aliquots were
then centrifuged at 14,500 RPM for 20 minutes to remove serum proteins and other
insoluble impurities. Drug concentrations in each sample were quantified using HPLC as
described in chapter 2. Drug concentration measurements were normalized to the initial
sample concentration for each condition. To determine if any drug concentration changes
in the samples were due to drug precipitation during centrifugation, 10 μl of CFZ stock
solution was added to 990 μl of deionized water and the solution was immediately
centrifuged at 1000 RPM for 1 minute. Sample aliquots before and after centrifugation
were diluted in acetonitrile (1:1 v/v) to prevent any potential further drug precipitation.
Changes in drug concentration following centrifugation were measured by HPLC and
normalized to the initial sample concentration.
6.2.3

Cytotoxicity of Carfilzomib-Loaded PNAs and Free Carfilzomib With and Without

Pre-Incubation in Cell Media
HT29 cells were seeded in 96 well plates at 3,000 cells per well. Cells were
treated with either fresh or pre-incubated CFZ. Pre-incubation of CFZ in FBS for 1 hour
at 37 °C was selected as an experimental condition to mimic the expected extrahepatic
metabolism of CFZ in the blood following intravenous administration. Briefly, serial
dilutions of free CFZ and CFZ-loaded PNAs were prepared in DMSO and PBS,
respectively, and added to M5A to create 2X stock solutions of free CFZ and CFZ-loaded
PNAs. Half of each solution was immediately diluted with M5A containing 20% FBS to
yield 1X solutions in M5A containing 10% FBS (fresh), while the other half was stored at
37 °C for 1 hour with mixing before dilution (pre-incubated). Cells were treated with
fresh or pre-incubated CFZ (free or PNAs) for 72 hours. Cell viability was measured by
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adding 10 μl of 1 mM resazurin solution to each well and measuring the fluorescence of
the oxidized product resorufin (Ex 560 nm/Em 590 nm) after 3 hours of incubation. Cell
viability was calculated from equation 6.1.
(𝐹𝐹𝐹𝐹𝐹𝐹 −𝐹𝐹𝐹𝐹𝐹𝐹 )

𝐶𝐶𝐶𝐶 = (𝐹𝐹𝐹𝐹𝐹𝐹𝑆𝑆 −𝐹𝐹𝐹𝐹𝐹𝐹𝑀𝑀 ) ∗ 100%
𝑉𝑉

(6.1)

𝑀𝑀

In equation 6.1, CV is the percent cell viability, FLUS is the fluorescence of CFZtreated samples, FLUM is the average fluorescence of media-only samples, and FLUV is
the fluorescence of vehicle-treated cells. All fluorescence measurements have units of
relative fluorescence units. The half maximal inhibitory concentration (IC50) of each
formulation was calculated from a sigmoidal fit of the cell viability vs. the logarithm of
drug concentration using Prism 5.0 (Graphpad, La Jolla, Ca). The IC50 value has units of
nM.
6.2.4

Carfilzomib Treatment of Cells and Proteasome Collection
H23 cells were seeded in 12 well plates at 150,000 cells per well. Cells were

treated with 7 nM of either free CFZ or CFZ-loaded PNAs for 0, 6, 24, 48 or 72 hours.
The media was removed after treatment and the cells were washed twice with HBSS.
Cells were lysed in passive lysis buffer for 15 minutes, and soluble proteins were
collected after centrifuging the cell lysate at 14,000 RPM for 20 minutes and collecting
the supernatant.
6.2.5

Proteasome Activity Measurement in the Cell Lysates of Carfilzomib-Treated

Cells
Total protein concentrations in the supernatants of cell lysates were quantified
using a Bradford assay, which was calibrated using protein standards. The supernatants of
the cell lysates were diluted in 20S proteasome assay buffer to create a 55.6 μg total
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protein/ml stock solution. Ninety microliters of cell lysate stock solution for each sample
was added to a 96 well plate and incubated at room temperature for 60 minutes. Ten
microliters of 1 mM Suc-LLMY-AMC substrate solution was added to each well. The
fluorescence of the wells was measured (Ex 360 nm/Em 460 nm) every minute for 1 hour
at 37 °C using a plate reader. To account for non-proteasomal proteolytic activity in cell
lysate solutions, cell lysate solutions were treated with the 20S proteasome-inhibitor
epoxomicin (10 μM) and the proteasome activity of these solutions was subtracted from
the activity of CFZ-treated sample measurements. The proteasome activities of H23 cells
treated with either free CFZ or CFZ-loaded PNAs were reported as a percentage of the
proteasome activity of untreated H23 cells.
6.2.6

Statistics
All values are reported as mean±standard deviation of three measurements unless

described otherwise. Groups of measurements were compared to each other using a oneway analysis of variance (ANOVA) with Bonferroni’s post hoc test. Pairs of
measurements are compared with Student’s t test. Statistical significance is indicated by *
(p<0.05), ** (p<0.01) or *** (p<0.001).
6.3

Results

6.3.1

Serum Minimizes Carfilzomib Degradation in Cell Media
Stability profiles of CFZ are shown in Figure 6.1. CFZ concentrations remain

consistent in acetonitrile or M5A containing FBS. However, the CFZ concentration
decreases by 62% after 1 hour in M5A without FBS. As CFZ peaks on the HPLC
decreased, a peak with a shorter retention time (1.6 min vs. 2.0 min) appeared. It should
be noted that CFZ degrades rapidly in human blood containing serum proteins, and that
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differences between FBS-containing media and whole blood may contribute to this
discrepancy. A full discussion of these differences is postponed until the discussion
section. Centrifugation did not decrease the measured CFZ concentration in control
samples, indicating that any decreases in CFZ concentrations during experiments are not
attributed to drug precipitation.
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Figure 6.1. Stability of free CFZ at 37 °C in various solvent conditions. CFZ was stored
in acetonitrile (ACN), McCoy’s 5A with 25% inactive FBS (M5A+iFBS), McCoy’s 5A
with 25% active FBS (M5A+aFBS) or pure McCoy’s 5A (M5A) following 0, 30 or 60
minutes of incubation.
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6.3.2

Carfilzomib-Loaded PNAs Maintain Drug Cytotoxicity after Pre-Incubation
The cytotoxicity of fresh and pre-incubated CFZ in HT29 colon cancer cells are

shown in Figure 6.2 and Table 6.1. The differences in IC50 values between fresh and preincubated free CFZ are statistically significant, but the differences between fresh and preincubated CFZ-loaded PNAs are not statistically significant. Differences between the
IC50 ratios of free CFZ and CFZ-loaded PNAs are statistically significant. Figure 6.3
compares the predicted changes in CFZ cytotoxicity based on drug concentrations to the
measured cytotoxicity changes in cancer cells. For CFZ-loaded PNAs, released drug was
assumed to degrade, while encapsulated drug was assumed to remain stable. Based on
changes in drug concentrations from the HPLC quantification of free CFZ following preincubation, the free CFZ and CFZ-loaded PNA IC50 ratio are predicted to be 2.61 and
1.02, respectively. The differences between predicted and measured treatment efficacy
were not statistically significant, but the differences between each formulation were
significant. These results suggest that PNAs with sustained drug release can prevent drug
degradation and deliver active drug to cancer cells.
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Figure 6.2. Cytotoxicity of fresh and pre-incubated free CFZ (A) and carfilzomib-loaded
PNAs (B). Zoomed-in graphs of free CFZ (C) and PNAs (D).
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Table 6.1. Cytotoxicity parameters of fresh and pre-incubated free CFZ and CFZ-loaded
PNAs.
Treatment
IC50 (nM)
IC50 Ratio
Formulation
Condition
Free CFZ
Fresh
28.6 (23.1-35.3)*
--Free CFZ
Pre-Incubated
85.5 (76.2-96.1)*
2.99 (2.08-3.89)*
CFZ-Loaded PNAs
Fresh
42.1 (37.4-47.3)
--CFZ-Loaded PNAs
Pre-Incubated
44.7 (41.6-48.0)
1.06 (0.83-1.29)*
Pharmacological parameters are presented as mean with 95% CI in parentheses. Error
in the IC50 ratio is propagated from each IC50 value. IC50 values for each formulation and
IC50 ratios were compared by a Student’s t-test. Statistical significance is indicated as
described in the methods section.
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Figure 6.3. Predicted and measured changes in the cytotoxicity of free CFZ and CFZloaded PNAs.
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6.3.3

Carfilzomib-Loaded PNAs Sustain Long-Term Proteasome Inhibition in Cancer

Cells
Proteasome inhibition profiles of H23 lung cancer cells treated with either free
CFZ or CFZ-loaded PNAs are shown in Figure 6.4. The proteasome activity of H23 cells
decreased at 6 hours compared to untreated samples. Some proteasome activity was
recovered up to 48 hours post-treatment for both formulations compared to 6 hours posttreatment. Free CFZ-treated cells continued to recover proteasome activity at 72 hours
post-treatment compared to 48 hours, but PNA-treated cells decreased proteasome
activity. Free CFZ-treated cells had reduced proteasome activity compared to PNAtreated cells at initial times post-treatment, but PNA-treated cells had reduced proteasome
activity compared to free CFZ-treated cells at 72 hours post-treatment.
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Figure 6.4. Proteasome activity of H23 cancer cells treated with free CFZ or CFZ-loaded
PNAs. Proteasome activity was measured at 6, 24, 48 and 72 hours post-treatment and
normalized to the activity of proteasomes from untreated cells (A). The AUC of
proteasome activity from each sample was also compared (B).
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6.4

Discussion

6.4.1

PNAs Reduce the Degradation of Carfilzomib
CFZ is promising for the effective treatment of a variety of human cancers, but it

has been ineffective in clinical trials for solid tumors (267). These discouraging results
are often attributed to extrahepatic metabolism that prevents the necessary accumulation
of active drug in solid tumors. As a result, misfolded proteins fail to accumulate in cancer
cells and cause cell stress leading to apoptosis (283). PMs were previously reported as a
promising formulation to solubilize hydrophobic anticancer drugs and prevent drug
metabolism, but PMs had similar treatment efficacy to clinically available cyclodextrin
formulations (160). In contrast to PMs that can dissociate after injection and release CFZ
into the blood, unimolecular PNAs may remain stable and sustain drug release.
Therefore, this study compares free CFZ to CFZ-loaded PNAs using in vitro models to
determine the effects of sustained release on proteasome inhibition and cytotoxicity.
Physiologically relevant models of in vivo drug metabolism are difficult to
develop, because the factors contributing to metabolic stability profiles such as in vitro
exposure time, enzyme concentrations and buffer conditions must be carefully optimized
for each drug (284, 285). One common in vitro metabolism model is the liver
homogenate model, in which drugs are exposed to proteins collected from liver tissue
(286). Changes in drug concentrations over time are correlated to in vivo metabolic drug
stability, but previous studies suggest that the accuracy of these models at predicting in
vivo metabolism are limited for drugs undergoing extrahepatic metabolism (287). As an
alternative to liver homogenate experiments, a facile method was developed to mimic the
extrahepatic metabolism of CFZ and predict the metabolic stability of CFZ. Although
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M5A does not contain all of the enzymes present in whole blood, 60% of the free CFZ in
M5A was found to degrade within one hour. In contrast, over 95% of CFZ degraded
within 5 minutes following exposure to liver homogenate, which significantly
overestimates CFZ degradation rates in vivo (60). These results suggest that the storage of
free CFZ in cell media without FBS may be advantageous compared to compared to liver
homogenate studies at predicting extrahepatic metabolism due to drug hydrolysis (288).
Although CFZ can rapidly metabolize in whole blood and other tissue
homogenates (60), CFZ remained stable in active FBS-containing media mimicking
whole blood. This surprising result suggests that FBS-containing cell media fails to
mimic the enzymatic properties of whole human blood, and that the chemical
components of M5A contribute to observed CFZ degradation profiles. Two potential
factors could contribute to these differences: 1) the manufacturing steps for FBS
preparation such as coagulation and centrifugation may not collect the specific proteases
from whole blood that cause CFZ degradation, and 2) the peptide bonds in carfilzomib
may not be substrates for bovine serum proteases. Further work is needed to determine
enzymatic activity of proteases in FBS compared to human serum. CFZ remains
relatively stable under neutral and slightly acidic conditions in water, but recent
publications suggest that the formation of chloride adducts increases the in vitro
hydrolysis of the epoxyketone group on CFZ (289, 290). This observation suggests that
the high chloride concentrations in M5A (>110 mM) may contribute to epoxyketone ring
opening, but that interactions between CFZ and serum proteins protect CFZ from
degradation in serum-containing samples. However, significant experimental work is
needed to test this hypothesis.
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6.4.2

Controlled Release of Carfilzomib from PNAs Sustains Proteasome Inhibition
CFZ-loaded PNAs can increase proteasome inhibition in cancer cells compared to

free CFZ at 72 h post-treatment. Sustained proteasome inhibition in cancer cells may
increase the efficacy of CFZ in MM or solid tumors by increasing the accumulation of
misfolded proteins in cancer cells (291). However, it should be noted that IC50 values are
lower for free CFZ than for CFZ-loaded PNAs, and that initial proteasome inhibition is
greater with free CFZ than with CFZ-loaded 3P’AA. In addition, the area under the curve
(AUC) up to 72 hours post-treatment indicating overall proteasome activity is slightly
greater for CFZ-loaded PNAs than for free CFZ (1888 vs 1551 normalized activity/h,
respectively, p>0.05). Taken together, these results suggest that short-term proteasome
inhibition controls in vitro CFZ cytotoxicity, and that in vitro cytotoxicity measurements
of proteasome inhibitors may not mimic the long-term proteasome inhibition necessary
for solid tumor treatment. Determining the relationship between in vitro proteasome
inhibition profiles and the in vivo effects of sustained proteasome inhibition in solid
tumors is an important area of future work.
6.4.3

PNAs May Increase the Accumulation of Active Carfilzomib in Solid Tumors
By extending the drug release half-life of CFZ, PNAs can increase the

accumulation of active drug in solid tumors compared to free drugs. Nanoassemblies
such as PNAs can passively accumulate in the porous vasculature of solid tumors and
increase the concentration of nanoparticles in tumor tissue compared to healthy tissue
(282). The maximum accumulation of nanoassemblies in the vasculature surrounding
solid tumors typically occurs between 3 to 6 hours after intravenous injection (292, 293).
Based on drug release measurements in chapter 5, 3P’AA will release less than 15% of
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drug before accumulating in solid tumors, which decreases the amount of free drug
released into the blood before PNAs can reach solid tumors. Therefore, PNAs are
expected to increase the amount of active anticancer drugs delivered to tumors and
potentially enhance anticancer efficacy (294, 295). Future studies will focus on
elucidating the benefits of PNA drug delivery in animal models of solid tumors.
6.5

Conclusions
In this study, the treatment efficacies of free CFZ and CFZ-loaded PNAs were

compared using in vitro drug metabolism, cytotoxicity and proteasome activity models.
The sustained release of CFZ from PNAs maintained drug efficacy after pre-incubation
compared to free CFZ. Changes in the efficacy of free CFZ following pre-incubation
corresponded to predictions based on HPLC quantification of active drug, suggesting that
drug activity controls cytotoxicity. In addition, PNAs with a longer drug release half-life
sustained proteasome inhibition in model cancer cell lines compared to free drug,
suggesting that CFZ delivery using PNAs can modulate proteasome activity in various
types of cancer cells. Overall, this study has demonstrated the advantages of PNAs to
protect CFZ from metabolic degradation, maintain cytotoxicity and extend proteasome
inhibition in cancer cells to potentially improve the efficacy of CFZ in solid tumors.

**Portions of Chapter 6 were previously published in (262). Reproduced with permission
from Future Science Group: Therapeutic Delivery, Volume 7, Issue 10, Pages 665-681,
Figures 8-10 and Text. Copyright 2016 is given to the publication in which the material
was originally published.
Copyright (C) Derek Reichel 2017
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7

CONCLUSIONS AND FUTURE DIRECTIONS

7.1

Conclusions

7.1.1

Dye Entrapment in Polymer Nanoassemblies Enable Fluorochromism for

Theranostics
In this work, dyes were entrapped in the core of polymer nanoassemblies in order
to create PNAs for cancer theranostics. The conjugation of non-fluorochromic dyes such
as IR820 and Alexa Fluor® 546 to the polymer scaffold created PNAs without
fluorochromism. Non-fluorochromic PNAs such as 3P’IR820 and 3P’A546 had
consistent fluorescence properties in various solvent and core environments. The
consistent fluorescence properties of non-fluorochromic PNAs allowed for the accurate
quantification of PNAs in agarose gels, organs and sectioned tissue samples. In contrast,
the conjugation of the model fluorochromic dye NB to the nanoassembly core yielded
PNAs with fluorochromism. While the fluorescence of free NB was quenched in water,
NB in the core of the PEI-based PNAs fluoresced strongly. Fluorochromic PNAs
detected environmental properties such as acidity and nanoparticle core environment
properties such as drug loading. Therefore, the entrapment of fluorochromic dyes in
PNAs enabled fluorochromism in comparison to PNAs entrapping traditional fluorescent
dyes.
In order to investigate the effects of the PNA core environment on
fluorochromism, NB was attached to the polymer scaffold of PNAs with either an ionic
or a hydrophobic core environment. PNAs with a hydrophobic core environment (3PN)
fluoresced strongly in comparison to PNAs with an ionic core environment (2PN),
suggesting that increasing the PNA core hydrophobicity prevents fluorescence quenching
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of NB by forcing water out of the PNA core. 3PN fluoresced at lower excitation and
emission wavelengths than 2PN, indicating that interactions between hydrophobic groups
and dyes increase the energy of their fluorescence emission spectra. 2PN had decreased
fluorescence in acidic solution while 3PN had increased fluorescence, suggesting that
shifts in fluorescence spectra contribute to the halo-fluorochromic properties of PNAs.
Taken together, these results suggest that the core environment of PNAs must be
carefully considered to maximize the fluorochromism of entrapped dyes.
The effects of polymer scaffold composition on dye fluorochromism were also
evaluated using PNAs with fewer (3P’N) or no amines in core (3P’NAA). Amines were
removed from the PNA core by replacing the PEI scaffold with a PLL scaffold (3P’N)
lacking secondary and tertiary amines, and by further end-capping and remaining primary
amines on the scaffold (3P’NAA). The fluorescence of 3P’N could not be detected,
suggesting that the PLL scaffold draws water into the PNA core compared to the PEI
scaffold and quenches NB fluorescence. The further removal of remaining primary
amines restored the fluorescence of PNAs but interfered with their fluorochromism.
Therefore, interactions between amines on the polymer scaffold and fluorochromic dyes
in the core of PNAs contribute to the fluorochromism of PNAs entrapping fluorochromic
dyes.
7.1.2

Halo- and Solvato-Fluorochromism are Useful Theranostic Properties
The halo-fluorochromism of PNAs allowed for the sensitive and accurate

detection of metastatic tumors compared to PNAs without fluorochromism. 3PN diffused
into agarose gels and fluoresced strongly in tumor microenvironment conditions
(pH<7.0) compared to healthy tissue (pH=7.4). In addition, PNAs failed to interact with

227

ions or proteins that could cause false positive fluorescence signals in healthy tissue by
altering the acidity of nanoassembly core. Although PNAs without fluorochromism
fluoresced throughout healthy organs, healthy liver and metastatic tumors in the liver,
3PN minimized background fluorescence signals in healthy tissues and identified the
acidic perimeter of liver metastatic tumors. As a result, halo-fluorochromic PNAs are
promising tools for the early and accurate detection of tumor metastasis, which can allow
for effective cancer treatment and potentially reduce cancer mortality.
The solvato-fluorochromism of PNAs allowed for the detection of drug release
from the PNA core. A fluorescence-based method of measuring drug release from PNAs
was developed and compared to HPLC-based methods for measuring drug release during
dialysis-based drug release measurements. Although HPLC-based methods measure
encapsulated and released drug, solvato-fluorochromism only detected drug release from
the PNA core. Solvato-fluorochromism indicated that PNAs released drug very quickly in
comparison to HPLC-based methods, but molecular modeling of HPLC-based
measurements indicated that drug rebinding and slow diffusion did not cause these
differences. Based on this observation, it was hypothesized that PNAs contain a NBenhanced region by the polymer scaffold in the PNA core, and that solvatofluorochromism is only sensitive to drug diffusion out of this region and towards the
interface. As a result, solvato-fluorochromism may detect one step of drug release, but
drug release rates determined by solvato-fluorochromism may not represent the ratelimiting step of in vivo drug release. Hydrophobic excipients forced drug into the PNA
core and increased the solvato-fluorochromism of PNAs, suggesting that interactions
between drugs and dyes control the SFC intensity and spectra of dyes. Based on this
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information, solvato-fluorochromism may be a beneficial method for investigating drug
release processes in the core of PNAs without interference from drug rebinding or
diffusion.
7.1.3

Theranostics Overcomes Some Limitations of Cancer Nanotechnology
PNAs with controlled drug release profiles can increase drug accumulation in

tumors and improve treatment efficacy, but many nanoparticles have rapid drug release
rates that limit their treatment efficacy. The solvato-fluorochromism of PNAs indicated
that the polymer scaffolds draw water into the nanoassembly core and decreases the core
hydrophobicity, which weakens the interactions between hydrophobic drugs and PNAs.
Based on this observation, ionizable amines were removed from the polymer scaffolds of
PNAs in order to increase core hydrophobicity and sustain drug release. The removal of
amines increased both the drug encapsulation and drug release half-life of model drugs
CFZ and DOC. This result suggests that chemical modifications based on solvatofluorochromism can improve the drug delivery properties of PNAs for cancer
chemotherapy.
Controlled drug release from PNAs can increase the metabolic stability of drugs
and increase drug accumulation in solid tumors in comparison to free drugs. Free CFZ
remained stable in organic solvents and in cell media containing FBS, but CFZ degraded
in cell media without serum. CFZ lost therapeutic efficacy following pre-incubation in
cell media, but CFZ-loaded PNAs maintained their efficacy for up to one hour. CFZloaded PNAs decreased proteasome activity in H23 lung cancer cells compared to free
carfilzomib after 72 hours, suggesting that the sustained release of carfilzomib from
PNAs can modulate proteasome activity and sustain treatment efficacy. Based on these
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observations, PNAs may improve CFZ treatment efficacy by delivering active drug to
solid tumors and increasing drug accumulation in cancer cells.
7.2

Future Directions

7.2.1

Increase the Tumor Penetration and Halo-Fluorochromism of PNAs for the

Improved Detection of Metastatic Tumors
Halo-fluorochromic PNAs accumulated at the perimeter of liver metastatic tumors
and detected the acidic interstitium of tumors. Although PNAs identified metastatic CRC
tumors on the livers of mice, the GFP signals from metastatic tumors were not in perfect
agreement with the fluorescence signals from halo-fluorochromic PNAs. Increasing the
penetration of halo-fluorochromic PNAs into metastatic tumors would increase the
accumulation of PNAs in the hypoxic and acidic regions of tumor tissue, which would
increase the accuracy of liver MCRC detection. One method to achieve this goal is to
decrease their diameter of nanoparticles entrapping halo-fluorochromic dyes, so that
nanoparticles diffuse further into tumors (296). A second method is to increase the
porosity of metastatic tumors such as by co-administration of tissue-penetrating peptides
with PNAs (297, 298). In addition, increasing the halo-fluorochromism of dyes in PNAs
can maximize the fluorescence signal of PNAs that are accumulating in the hypoxic
region of metastatic tumors.
7.2.2

Predict the Treatment Efficacy of Drug-Loaded PNAs in Tumors from Solvato-

Fluorochromic Drug Release Profiles
Solvato-fluorochromic PNAs indicated real-time drug release profiles in a noninvasive manner. Because fluorescence imaging can measure the fluorescence of organs,
solvato-fluorochromic drug release profiles hold promise to predict treatment efficacy
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based on measured drug delivery into tumors. In order to accomplish this, several
characteristics of PNAs must be determined. First, the relationship between active drug
concentrations in organs and drug release from PNAs must be evaluated. Next, the effects
of tissue penetration on solvato-fluorochromic measurements of drug release in organs
should be determined. Then, by treating animals with drug-loaded solvato-fluorochromic
PNAs and measuring both fluorescence changes and drug concentrations in tumors over
time, the relationship between solvato-fluorochromic drug release profiles, drug
concentrations in tumors and treatment efficacy can be determined.
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